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Abstract
The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available),
plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise
Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time
record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full. G protein-coupled receptors are one of the eight
major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic
receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for
further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2017, and supersedes data presented in the 2015/16
and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature Committee of the Union of Basic and Clinical Pharmacology
(NC-IUPHAR), therefore, providing ofﬁcial IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
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Overview: G protein-coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome. The term "7TM receptor" is commonly used interchangeably with "GPCR", although
there are some receptors with seven transmembrane domains that do not signal through G proteins. GPCRs share a common architecture, each consisting of a single polypeptide with an extracellular
N-terminus, an intracellular C-terminus and seven hydrophobic transmembrane domains (TM1-TM7) linked by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). About 800
GPCRs have been identiﬁed in man, of which about half have sensory functions, mediating olfaction (∼400), taste (33), light perception (10) and pheromone signalling (5) [1362]. The remaining ∼350
non-sensory GPCRs mediate signalling by ligands that range in size from small molecules to peptides to large proteins; they are the targets for the majority of drugs in clinical usage [1519, 1631], although
only a minority of these receptors are exploited therapeutically. The ﬁrst classiﬁcation scheme to be proposed for GPCRs [1030] divided them, on the basic of sequence homology, into six classes. These
classes and their prototype members were as follows: Class A (rhodopsin-like), Class B (secretin receptor family), Class C (metabotropic glutamate), Class D (fungal mating pheromone receptors), Class
E (cyclic AMP receptors) and Class F (frizzled/smoothened). Of these, classes D and E are not found in vertebrates. An alternative classiﬁcation scheme "GRAFS" [1737] divides vertebrate GPCRs into ﬁve
classes, overlapping with the A-F nomenclature, viz:
Searchable database: http://www.guidetopharmacology.org/index.jsp G protein-coupled receptors S17
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129
Glutamate family (class C), which includes metabotropic glutamate receptors, a calcium-sensing receptor and GABAB receptors, as well as three taste type 1 receptors and a family of pheromone
receptors (V2 receptors) that are abundant in rodents but absent in man [1362].
Rhodopsin family (class A), which includes receptors for a wide variety of small molecules, neurotransmitters, peptides and hormones, together with olfactory receptors, visual pigments, taste type 2
receptors and ﬁve pheromone receptors (V1 receptors).
Adhesion family GPCRs are phylogenetically related to class B receptors, from which they differ by possessing large extracellular N-termini that are autoproteolytically cleaved from their 7TM domains
at a conserved "GPCR proteolysis site" (GPS) which lies within a much larger (˜320 residue) "GPCR autoproteolysis-inducing" (GAIN) domain, an evolutionary ancient moﬁf also found in polycystic kidney
disease 1 (PKD1)-like proteins, which has been suggested to be both required and sufﬁcient for autoproteolysis [1609].
Frizzled family consists of 10 Frizzled proteins (FZD(1-10)) and Smoothened (SMO). The FZDs are activated by secreted lipoglycoproteins of the WNT family, whereas SMO is indirectly activated by the
Hedgehog (HH) family of proteins acting on the transmembrane protein Patched (PTCH).
Secretin family (class B), encoded by 15 genes in humans. The ligands for receptors in this family are polypeptide hormones of 27-141 amino acid residues; nine of the mammalian receptors respond
to ligands that are structurally related to one another (glucagon, glucagon-like peptides (GLP-1, GLP-2), glucose-dependent insulinotropic polypeptide (GIP), secretin, vasoactive intestinal peptide (VIP),
pituitary adenylate cyclase-activating polypeptide (PACAP) and growth-hormone-releasing hormone (GHRH)) [738].
GPCR families
Family Class A Class B (Secretin) Class C (Glutamate) Adhesion Frizzled
Receptors with known ligands 197 15 12 0 11
Orphans 87 (54)a - 8 (1)a 26 (6)a 0
Sensory (olfaction) 390b,c - - - -
Sensory (vision) 10d opsins - - - -
Sensory (taste) 30c taste 2 - 3c taste 1 - -
Sensory (pheromone) 5c vomeronasal 1 - - - -
Total 719 15 22 33 11
aNumbers in brackets refer to orphan receptors for which an endogenous ligand has been proposed in at least one publication, see [414]; b[1511]; c[1362]; d[1941].
Much of our current understanding of the structure and function of GPCRs is the result of pioneering work on the visual pigment rhodopsin and on the β2 adrenoceptor, the latter culminating in the
award of the 2012 Nobel Prize in chemistry to Robert Lefkowitz and Brian Kobilka [1021, 1137].
Family structure
S19 Orphan and other 7TM receptors
S19 Class A Orphans
– Class B Orphans
S28 Class C Orphans
S28 Taste 1 receptors
S29 Taste 2 receptors
S30 Other 7TM proteins
S30 5-Hydroxytryptamine receptors
S34 Acetylcholine receptors (muscarinic)
S36 Adenosine receptors
S37 Adhesion Class GPCRs
S39 Adrenoceptors
S43 Angiotensin receptors
S44 Apelin receptor
S45 Bile acid receptor
S45 Bombesin receptors
S47 Bradykinin receptors
S48 Calcitonin receptors
S50 Calcium-sensing receptor
S51 Cannabinoid receptors
S52 Chemerin receptor
S52 Chemokine receptors
S57 Cholecystokinin receptors
S58 Class Frizzled GPCRs
S59 Complement peptide receptors
S60 Corticotropin-releasing factor receptors
S61 Dopamine receptors
S63 Endothelin receptors
S64 G protein-coupled estrogen receptor
S65 Formylpeptide receptors
S66 Free fatty acid receptors
S67 GABAB receptors
S69 Galanin receptors
S70 Ghrelin receptor
S71 Glucagon receptor family
S72 Glycoprotein hormone receptors
S73 Gonadotrophin-releasing hormone receptors
S74 GPR18, GPR55 and GPR119
S76 Histamine receptors
S77 Hydroxycarboxylic acid receptors
S78 Kisspeptin receptor
S79 Leukotriene receptors
S80 Lysophospholipid (LPA) receptors
S82 Lysophospholipid (S1P) receptors
S83 Melanin-concentrating hormone receptors
S84 Melanocortin receptors
S85 Melatonin receptors
S86 Metabotropic glutamate receptors
S88 Motilin receptor
S89 Neuromedin U receptors
S90 Neuropeptide FF/neuropeptide AF receptors
S91 Neuropeptide S receptor
S91 Neuropeptide W/neuropeptide B receptors
S92 Neuropeptide Y receptors
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S94 Neurotensin receptors
S95 Opioid receptors
S97 Orexin receptors
S98 Oxoglutarate receptor
S98 P2Y receptors
S100 Parathyroid hormone receptors
S101 Platelet-activating factor receptor
S102 Prokineticin receptors
S103 Prolactin-releasing peptide receptor
S104 Prostanoid receptors
S106 Proteinase-activated receptors
S107 QRFP receptor
S108 Relaxin family peptide receptors
S110 Somatostatin receptors
S110 Succinate receptor
S111 Tachykinin receptors
S112 Thyrotropin-releasing hormone receptors
S113 Trace amine receptor
S114 Urotensin receptor
S115 Vasopressin and oxytocin receptors
S116 VIP and PACAP receptors
Orphan and other 7TM receptors
G protein-coupled receptors → Orphan and other 7TM receptors
Class A Orphans
G protein-coupled receptors → Orphan and other 7TM receptors → Class A Orphans
Overview: Table 1 lists a number of putative GPCRs identiﬁed by NC-IUPHAR [557], for which preliminary evidence for an endogenous ligand has been published, or for which there exists a potential
link to a disease, or disorder. These GPCRs have recently been reviewed in detail [414]. The GPCRs in Table 1 are all Class A, rhodopsin-like GPCRs. Class A orphan GPCRs not listed in Table 1 are putative
GPCRs with as-yet unidentiﬁed endogenous ligands.
Table 1: Class A orphan GPCRs with putative endogenous ligands
GPR1 GPR3 GPR4 GPR6 GPR12 GPR15 GPR17 GPR20
GPR22 GPR26 GPR31 GPR34 GPR35 GPR37 GPR39 GPR50
GPR63 GRP65 GPR68 GPR75 GPR84 GPR87 GPR88 GPR132
GPR149 GPR161 GPR183 LGR4 LGR5 LGR6 MAS1 MRGPRD
MRGPRX1 MRGPRX2 P2RY10 TAAR2
In addition the orphan receptors GPR18, GPR55 and GPR119 which are reported to respond to endogenous agents analogous to the endogenous cannabinoid ligands have been grouped together
(GPR18, GPR55 and GPR119).
Nomenclature GPR1 GPR3
HGNC, UniProt GPR1, P46091 GPR3, P46089
Endogenous agonists chemerin (RARRES2, Q99969) [101] –
Agonists – diphenyleneiodonium chloride [2179]
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(continued)
Nomenclature GPR1 GPR3
Comments Reported to act as a co-receptor for HIV
[1791]. See review [414] for discussion of
pairing with chemerin.
sphingosine 1-phosphate was reported to be an endogenous agonist [1997], but this ﬁnding was not replicated in subsequent studies
[2182]. Reported to activate adenylyl cyclase constitutively through Gs [494]. Gene disruption results in premature ovarian ageing
[1128], reduced β-amyloid deposition [1943] and hypersensitivity to thermal pain [1689] in mice. First small molecule inverse agonist
[903] and agonists identiﬁed [2179].
Nomenclature GPR4 GPR6 GPR42
HGNC, UniProt GPR4, P46093 GPR6, P46095 GPR42, O15529
Endogenous ligands Protons – –
Comments An initial report suggesting activation by lysophosphatidylcholine and
sphingosylphosphorylcholine [2225] has been retracted [1470]. GPR4,
GPR65, GPR68 and GPR132 are now thought to function as
proton-sensing receptors detecting acidic pH [414, 1775]. Gene
disruption is associated with increased perinatal mortality and impaired
vascular proliferation [2173]. Negative allosteric modulators of GPR4 have
been reported [1967].
An initial report that sphingosine 1-phosphate (S1P) was a high-afﬁnity
ligand (EC50 value of 39nM) [855, 1997] was not repeated in arrestin-based
assays [1854, 2182]. Reported to activate adenylyl cyclase constitutively
through Gs and to be located intracellularly [1521]. GPR6-deﬁcient mice
showed reduced striatal cyclic AMP production in vitro and selected
alterations in instrumental conditioning in vivo. [1200].
–
Nomenclature GPR12 GPR15 GPR17
HGNC, UniProt GPR12, P47775 GPR15, P49685 GPR17, Q13304
Endogenous agonists – – UDP-glucose [134, 359], LTC4 [359], UDP-galactose [134, 359],
uridine diphosphate [134, 359], LTD4 [359]
Comments Reports that sphingosine 1-phosphate is a ligand
of GPR12 [854, 1997] have not been replicated in
arrestin-based assays [1854, 2182]. Gene
disruption results in dyslipidemia and obesity
[158].
Reported to act as a co-receptor for HIV [490]. In
an infection-induced colitis model, Gpr15
knockout mice were more prone to tissue damage
and inﬂammatory cytokine expression [991].
Reported to be a dual leukotriene and uridine diphosphate receptor [359].
Another group instead proposed that GPR17 functions as a negative
regulator of the CysLT1 receptor response to leukotriene D4 (LTD4). For
further discussion, see [414]. Reported to antagonize CysLT1 receptor
signalling in vivo and in vitro [1239]. See reviews [258] and [414].
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Nomenclature GPR19 GPR20 GPR21 GPR22 GPR25 GPR26 GPR27
HGNC, UniProt GPR19,
Q15760
GPR20, Q99678 GPR21, Q99679 GPR22, Q99680 GPR25,
O00155
GPR26, Q8NDV2 GPR27, Q9NS67
Comments – Reported to inhibit adenylyl
cyclase constitutively through
Gi/o [743]. GPR20 deﬁcient
mice exhibit hyperactivity
characterised by increased
total distance travelled in an
open ﬁeld test [213].
Gpr21 knockout mice were
resistant to diet-induced
obesity, exhibiting an
increase in glucose tolerance
and insulin sensitivity, as well
as a modest lean phenotype
[1516].
Gene disruption results in
increased severity of functional
decompensation following aortic
banding [10]. Identiﬁed as a
susceptibility locus for
osteoarthritis [520, 975, 2011].
– Has been reported to activate
adenylyl cyclase constitutively
through Gs [923]. Gpr26
knockout mice show
increased levels of anxiety
and depression-like
behaviours [2209].
Knockdown of Gpr27
reduces endogenous
mouse insulin promotor
activity and
glucose-stimulated
insulin secretion [1059].
Nomenclature GPR31 GPR32 GPR33 GPR34
HGNC, UniProt GPR31, O00270 GPR32, O75388 GPR33, Q49SQ1 GPR34, Q9UPC5
Potency order of endogenous ligands – resolvin D1 > LXA4 – –
Endogenous agonists 12S-HETE [700] – Mouse resolvin D1 [1052], LXA4 [1052] – lysophosphatidylserine [1008, 1891]
Labelled ligands – [3H]resolvin D1 (Agonist) [1052] – –
Comments See [414] for discussion
of pairing.
resolvin D1 has been demonstrated to
activate GPR32 in two publications [331,
1052]. The pairing was not replicated in a
recent study based on arrestin recruitment
[1854]. GPR32 is a pseudogene in mice
and rats. See reviews [258] and [414].
GPR33 is a pseudogene in most
individuals, containing a
premature stop codon within
the coding sequence of the
second intracellular loop [1696].
Lysophosphatidylserine has been reported to be a
ligand of GPR34 in several publications, but the pairing
was not replicated in a recent study based on arrestin
recruitment [1854]. Fails to respond to a variety of
lipid-derived agents [2182]. Gene disruption results in
an enhanced immune response [1168].
Characterization of agonists at this receptor is
discussed in [859] and [414].
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Nomenclature GPR35 GPR37
HGNC, UniProt GPR35, Q9HC97 GPR37, O15354
Endogenous agonists 2-oleoyl-LPA [1503], kynurenic acid [1854, 2066] –
Agonists – neuropeptide head activator [1652]
Comments Several studies have shown that kynurenic acid is an agonist of GPR35 but it remains controversial whether
the proposed endogenous ligand reaches sufﬁcient tissue concentrations to activate the receptor [1061].
2-oleoyl-LPA has also been proposed as an endogenous ligand [1503] but these results were not replicated
in an arrestin assay [1854]. The phosphodiesterase inhibitor zaprinast [1937] has become widely used as a
surrogate agonist to investigate GPR35 pharmacology and signalling [1937]. GPR35 is also activated by the
pharmaceutical adjunct pamoic acid [2218]. See reviews [414] and [453].
Reported to associate and regulate the dopamine transporter
[1269] and to be a substrate for parkin [1267]. Gene disruption
results in altered striatal signalling [1268]. The peptides
prosaptide and prosaposin are proposed as endogenous
ligands for GPR37 and GPR37L1 [1324].
Nomenclature GPR37L1 GPR39 GPR45 GPR50
HGNC, UniProt GPR37L1, O60883 GPR39, O43194 GPR45, Q9Y5Y3 GPR50, Q13585
Endogenous agonists – Zn2+ [813] – –
Comments The peptides prosaptide and
prosaposin are proposed as
endogenous ligands for GPR37
and GPR37L1 [1324].
Zn2+ has been reported to be a potent and efﬁcacious agonist of
human, mouse and rat GPR39 [2176]. obestatin (GHRL, Q9UBU3),
a fragment from the ghrelin precursor, was reported initially as an
endogenous ligand, but subsequent studies failed to reproduce
these ﬁndings. GPR39 has been reported to be down-regulated in
adipose tissue in obesity-related diabetes [285]. Gene disruption
results in obesity and altered adipocyte metabolism [1567].
Reviewed in [414].
– GPR50 is structurally related to MT1 and MT2
melatonin receptors, with which it
heterodimerises constitutively and speciﬁcally
[1155]. Gpr50 knockout mice display abnormal
thermoregulation and are much more likely than
wild-type mice to enter fasting-induced torpor
[117].
Nomenclature GPR52 GPR61 GPR62 GPR63 GPR65
HGNC, UniProt GPR52, Q9Y2T5 GPR61, Q9BZJ8 GPR62, Q9BZJ7 GPR63, Q9BZJ6 GPR65, Q8IYL9
Endogenous ligands – – – – Protons
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(continued)
Nomenclature GPR52 GPR61 GPR62 GPR63 GPR65
Comments First small molecule agonist
reported [1774].
GPR61 deﬁcient mice exhibit obesity
associated with hyperphagia [1422].
Although no endogenous ligands
have been identiﬁed,
5-(nonyloxy)tryptamine has been
reported to be a low afﬁnity inverse
agonist [1925].
– sphingosine 1-phosphate and
dioleoylphosphatidic acid have been
reported to be low afﬁnity agonists for
GPR63 [1459] but this ﬁnding was not
replicated in an arrestin-based assay
[2182].
GPR4, GPR65, GPR68 and GPR132 are
now thought to function as
proton-sensing receptors detecting
acidic pH [414, 1775]. Reported to
activate adenylyl cyclase; gene
disruption leads to reduced
eosinophilia in models of allergic
airway disease [1044].
Nomenclature GPR68 GPR75 GPR78 GPR79 GPR82
HGNC, UniProt GPR68, Q15743 GPR75, O95800 GPR78, Q96P69 GPR79, – GPR82, Q96P67
Endogenous ligands Protons – – – –
Allosteric modulators lorazepam (Positive) [838] – – – –
Comments GPR68 was previously identiﬁed as a receptor for
sphingosylphosphorylcholine (SPC) [2157], but the
original publication has been retracted [2156]. GPR4,
GPR65, GPR68 and GPR132 are now thought to
function as proton-sensing receptors detecting acidic
pH [414, 1775]. A family of 3,5-disubstituted
isoxazoles were identiﬁed as agonists of GPR68
[1691].
CCL5 (CCL5, P13501) was
reported to be an agonist of
GPR75 [856], but the pairing
could not be repeated in an
arrestin assay [1854].
GPR78 has been reported to
be constitutively active,
coupled to elevated cAMP
production [923].
– Mice with Gpr82 knockout have a lower
body weight and body fat content
associated with reduced food intake,
decreased serum triglyceride levels, as well
as higher insulin sensitivity and glucose
tolerance [507].
Nomenclature GPR83 GPR84 GPR85 GPR87 GPR88 GPR101
HGNC, UniProt GPR83, Q9NYM4 GPR84, Q9NQS5 GPR85, P60893 GPR87, Q9BY21 GPR88, Q9GZN0 GPR101, Q96P66
Endogenous agonists – – – LPA [1401, 1911] – –
Agonists PEN {Mouse} [655] – Mouse,
Zn2+ [1409] – Mouse
decanoic acid [1854, 2067],
undecanoic acid [2067], lauric acid
[2067]
– – –
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Nomenclature GPR83 GPR84 GPR85 GPR87 GPR88 GPR101
Comments One isoform has been implicated
in the induction of CD4(+)
CD25(+) regulatory T cells
(Tregs) during inﬂammatory
immune responses [731]. The
extracellular N-terminal domain
is reported as an intramolecular
inverse agonist [1410].
Medium chain free fatty acids with
carbon chain lengths of 9-14 activate
GPR84 [1901, 2067]. A surrogate
ligand for GPR84,
6-n-octylaminouracil has also been
proposed [1901]. See review [414] for
discussion of classiﬁcation. Mutational
analysis and molecular modelling of
GPR84 has been reported [1463].
Proposed to regulate
hippocampal neurogenesis
in the adult, as well as
neurogenesis-dependent
learning and memory
[319].
– Gene disruption results in
altered striatal signalling
[1203]. Small molecule
agonists have been
reported [151].
Mutations in GPR101
have been linked to
gigantism and
acromegaly [1982].
Nomenclature GPR132 GPR135 GPR139 GPR141 GPR142 GPR146
HGNC, UniProt GPR132, Q9UNW8 GPR135,
Q8IZ08
GPR139, Q6DWJ6 GPR141,
Q7Z602
GPR142, Q7Z601 GPR146, Q96CH1
Endogenous ligands Protons – – – – –
Comments GPR4, GPR65, GPR68 and GPR132
are now thought to function as
proton-sensing receptors detecting
acidic pH [414, 1775]. Reported to
respond to lysophosphatidylcholine
[934], but later retracted [2126].
– Peptide agonists have been
reported [867].
– Small molecule agonists
have been reported
[1968, 2196].
Yosten et al. demonstrated inhibition
of proinsulin C-peptide (INS,
P01308)-induced stimulation of cFos
expression folllowing knockdown of
GPR146 in KATO III cells, suggesting
proinsulin C-peptide as an
endogenous ligand of the receptor
[2193].
Nomenclature GPR148 GPR149 GPR150 GPR151 GPR152 GPR153 GPR160
HGNC, UniProt GPR148,
Q8TDV2
GPR149, Q86SP6 GPR150,
Q8NGU9
GPR151, Q8TDV0 GPR152,
Q8TDT2
GPR153,
Q6NV75
GPR160,
Q9UJ42
Comments – Gpr149 knockout mice displayed increased
fertility and enhanced ovulation, with increased
levels of FSH receptor and cyclin D2 mRNA
levels [491].
– GPR151 responded to galanin with an EC50 value
of 2 μM, suggesting that the endogenous ligand
shares structural features with galanin (GAL,
P22466) [853].
– – –
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Nomenclature GPR161 GPR162 GPR171 GPR173 GPR174 GPR176 GPR182
HGNC, UniProt GPR161, Q8N6U8 GPR162,
Q16538
GPR171, O14626 GPR173,
Q9NS66
GPR174, Q9BXC1 GPR176,
Q14439
GPR182, O15218
Endogenous agonists – – – – lysophosphatidylserine
[864]
– –
Comments A C-terminal truncation (deletion)
mutation in Gpr161 causes congenital
cataracts and neural tube defects in
the vacuolated lens (vl) mouse mutant
[1289]. The mutated receptor is
associated with cataract, spina biﬁda
and white belly spot phenotypes in
mice [1039]. Gene disruption is
associated with a failure of asymmetric
embryonic development in zebraﬁsh
[1151].
– GPR171 has been shown to
be activated by the
endogenous peptide BigLEN
{Mouse}. This
receptor-peptide interaction is
believed to be involved in
regulating feeding and
metabolism responses [654].
– See [859] which
discusses
characterization of
agonists at this
receptor.
– Rat GPR182 was ﬁrst proposed as
the adrenomedullin receptor
[947]. However, it was later
reported that rat and human
GPR182 did not respond to
adrenomedullin [973] and
GPR182 is not currently
considered to be a genuine
adrenomedullin receptor [756].
Nomenclature GPR183 LGR4
HGNC, UniProt GPR183, P32249 LGR4, Q9BXB1
Endogenous agonists 7α,25-dihydroxycholesterol [729, 1191], 7α,27-dihydroxycholesterol [1191],
7β, 25-dihydroxycholesterol [1191], 7β, 27-dihydroxycholesterol [1191]
R-spondin-2 (RSPO2, Q6UXX9) [277], R-spondin-1 (RSPO1, Q2MKA7) [277], R-spondin-3
(RSPO3, Q9BXY4) [277], R-spondin-4 (RSPO4, Q2I0M5) [277]
Comments Two independent publications have shown that 7α,25-dihydroxycholesterol is an
agonist of GPR183 and have demonstrated by mass spectrometry that this oxysterol is
present endogenously in tissues [729, 1191]. Gpr183-deﬁcient mice show a reduction in
the early antibody response to a T-dependent antigen. GPR183-deﬁcient B cells fail to
migrate to the outer follicle and instead stay in the follicle centre [966, 1557].
LGR4 does not couple to heterotrimeric G proteins or recruit arrestins when stimulated by
the R-spondins, indicating a unique mechanism of action. R-spondins bind to LGR4,
which speciﬁcally associates with Frizzled and LDL receptor-related proteins (LRPs) that are
activated by the extracellular Wnt molecules and then trigger canonical Wnt signalling to
increase gene expression [277, 426, 1686]. Gene disruption leads to multiple
developmental disorders [911, 1219, 1849, 2092].
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Nomenclature LGR5 LGR6 MAS1 MAS1L
HGNC, UniProt LGR5, O75473 LGR6, Q9HBX8 MAS1, P04201 MAS1L, P35410
Endogenous agonists R-spondin-2 (RSPO2, Q6UXX9) [277], R-spondin-1 (RSPO1,
Q2MKA7) [277], R-spondin-3 (RSPO3, Q9BXY4) [277], R-spondin-4
(RSPO4, Q2I0M5) [277]
R-spondin-1 (RSPO1, Q2MKA7) [277, 426],
R-spondin-2 (RSPO2, Q6UXX9) [277, 426],
R-spondin-3 (RSPO3, Q9BXY4) [277, 426],
R-spondin-4 (RSPO4, Q2I0M5) [277, 426]
– –
Agonists – – angiotensin-(1-7) (AGT,
P01019) [645] – Mouse
–
Comments The four R-spondins can bind to LGR4, LGR5, and LGR6, which
speciﬁcally associate with Frizzled and LDL receptor-related proteins
(LRPs), proteins that are activated by extracellular Wnt molecules
and which then trigger canonical Wnt signalling to increase gene
expression [277, 426].
– – –
Nomenclature MRGPRD MRGPRE MRGPRF MRGPRG
HGNC, UniProt MRGPRD, Q8TDS7 MRGPRE, Q86SM8 MRGPRF, Q96AM1 MRGPRG, Q86SM5
Endogenous agonists β-alanine [1797, 1854] – – –
Comments An endogenous peptide with a high degree of sequence similarity to
angiotensin-(1-7) (AGT, P01019), alamandine (AGT), was shown to promote
NO release in MRGPRD-transfected cells. The binding of alamandine to
MRGPRD to was shown to be blocked by D-Pro7-angiotensin-(1-7), β-alanine
and PD123319 [1102]. Genetic ablation of MRGPRD+ neurons of adult mice
decreased behavioural sensitivity to mechanical stimuli but not to thermal
stimuli [292]. See reviews [414] and [1847].
See reviews [414] and [1847]. MRGPRF has been reported to
respond to stimulation by
angiotensin metabolites [620].
See reviews [414] and [1847].
See reviews [414] and
[1847].
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Nomenclature MRGPRX1 MRGPRX2 MRGPRX3 MRGPRX4 OPN3 OPN4 OPN5
HGNC, UniProt MRGPRX1, Q96LB2 MRGPRX2, Q96LB1 MRGPRX3,
Q96LB0
MRGPRX4,
Q96LA9
OPN3, Q9H1Y3 OPN4, Q9UHM6 OPN5, Q6U736
Endogenous agonists bovine adrenal medulla peptide 8-22
(PENK, P01210) [315, 1144, 1854]
PAMP-20 (ADM, P35318) [942] – – – – –
Agonists – cortistatin-14 {Mouse, Rat} [942,
1667, 1854]
– – – – –
Selective agonists – PAMP-12 (human) [942] – – – – –
Comments Reported to mediate the sensation of
itch [1196, 1808]. Reports that
bovine adrenal medulla peptide 8-22
(PENK, P01210) was the most potent
of a series of proenkephalin A-derived
peptides as an agonist of MRGPRX1 in
assays of calcium mobilisation and
radioligand binding [1144] were
replicated in an independent study
using an arrestin recruitment assay
[1854]. See reviews [414] and [1847].
A diverse range of substances has
been reported to be agonists of
MRGPRX2, with cortistatin 14
the highest potency agonist in
assays of calcium mobilisation
[1667], also conﬁrmed in an
independent study using an
arrestin recruitment assay [1854].
See reviews [414] and [1847].
– See reviews [414]
and [1847].
– – Evidence indicates
OPN5 triggers a
UV-sensitive
Gi-mediated signalling
pathway in
mammalian tissues
[1028].
Nomenclature P2RY8 P2RY10 TAAR2 TAAR3 TAAR4P
HGNC, UniProt P2RY8, Q86VZ1 P2RY10, O00398 TAAR2, Q9P1P5 TAAR3P, Q9P1P4 TAAR4P, –
Potency order of endogenous
ligands
– – β-phenylethylamine > tryptamine [189] – –
Endogenous agonists – sphingosine 1-phosphate
[1401], LPA [1401]
– – –
Comments – – Probable pseudogene in 10–15% of Asians due
to a polymorphism (rs8192646) producing a
premature stop codon at amino acid 168
[414].
TAAR3 is thought to be a pseudogene in
man though functional in rodents [414].
Pseudogene in man but
functional in rodents
[414].
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Nomenclature TAAR5 TAAR6 TAAR8 TAAR9
HGNC, UniProt TAAR5, O14804 TAAR6, Q96RI8 TAAR8, Q969N4 TAAR9, Q96RI9
Comments Trimethylamine is reported as an agonist [2058] and
3-iodothyronamine an inverse agonist [450].
– – TAAR9 appears to be functional in most individuals but has a polymorphic
premature stop codon at amino acid 61 (rs2842899) with an allele frequency
of 10–30% in different populations [2023].
Class C Orphans
G protein-coupled receptors → Orphan and other 7TM receptors → Class C Orphans
Nomenclature GPR156 GPR158 GPR179 GPRC5A GPRC5B GPRC5C GPRC5D GPRC6 receptor
HGNC, UniProt GPR156, Q8NFN8 GPR158, Q5T848 GPR179, Q6PRD1 GPRC5A, Q8NFJ5 GPRC5B, Q9NZH0 GPRC5C, Q9NQ84 GPRC5D, Q9NZD1 GPRC6A, Q5T6X5
Comments – – – – – – – GPRC6 is a related
Gq-coupled receptor
which responds to basic
amino acids [2090].
Taste 1 receptors
G protein-coupled receptors → Orphan and other 7TM receptors → Taste 1 receptors
Overview: Whilst the taste of acid and salty foods appear to
be sensed by regulation of ion channel activity, bitter, sweet
and umami tastes are sensed by specialised GPCR. Two classes
of taste GPCR have been identiﬁed, T1R and T2R, which are
similar in sequence and structure to Class C and Class A GPCR,
respectively. Activation of taste receptors appears to involve
gustducin- (Gαt3) and Gα14-mediated signalling, although the
precise mechanisms remain obscure. Gene disruption studies
suggest the involvement of PLCβ2 [2215], TRPM5 [2215] and
IP3 [802] receptors in post-receptor signalling of taste recep-
tors. Although predominantly associated with the oral cav-
ity, taste receptors are also located elsewhere, including further
down the gastrointestinal system, in the lungs and in the brain.
Sweet/Umami
T1R3 acts as an obligate partner in T1R1/T1R3 and T1R2/T1R3 het-
erodimers, which sense umami or sweet, respectively. T1R1/T1R3
heterodimers respond to L-glutamic acid andmay be positively al-
losterically modulated by 5’-nucleoside monophosphates, such as
5’-GMP [1162]. T1R2/T1R3 heterodimers respond to sugars, such
as sucrose, and artiﬁcial sweeteners, such as saccharin [1440].
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Nomenclature TAS1R1 TAS1R2 TAS1R3
HGNC, UniProt TAS1R1, Q7RTX1 TAS1R2, Q8TE23 TAS1R3, Q7RTX0
Taste 2 receptors
G protein-coupled receptors → Orphan and other 7TM receptors → Taste 2 receptors
Overview: The composition and stoichiometry of bitter taste receptors is not yet established. Bitter receptors appear to separate into two groups, with very restricted ligand speciﬁcity or much broader
responsiveness. For example, T2R5 responded to cycloheximide, but not 10 other bitter compounds [302], while T2R14 responded to at least eight different bitter tastants, including (-)-α-thujone and
picrotoxinin [124].
Specialist database BitterDB contains additional information on bitter compounds and receptors [2113].
Nomenclature TAS2R1 TAS2R3 TAS2R4 TAS2R5 TAS2R7 TAS2R8 TAS2R9
HGNC, UniProt TAS2R1, Q9NYW7 TAS2R3, Q9NYW6 TAS2R4, Q9NYW5 TAS2R5, Q9NYW4 TAS2R7, Q9NYW3 TAS2R8, Q9NYW2 TAS2R9, Q9NYW1
Nomenclature TAS2R10 TAS2R13 TAS2R14 TAS2R16 TAS2R19 TAS2R20 TAS2R30
HGNC, UniProt TAS2R10, Q9NYW0 TAS2R13, Q9NYV9 TAS2R14, Q9NYV8 TAS2R16, Q9NYV7 TAS2R19, P59542 TAS2R20, P59543 TAS2R30, P59541
Nomenclature TAS2R31 TAS2R38 TAS2R39 TAS2R40
HGNC, UniProt TAS2R31, P59538 TAS2R38, P59533 TAS2R39, P59534 TAS2R40, P59535
Antagonists 6-methoxysakuranetin (pIC50 5.6) [1000], GIV3727 (pIC50 5.1–5.2) [1823] – – –
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Nomenclature TAS2R41 TAS2R42 TAS2R43 TAS2R45 TAS2R46 TAS2R50 TAS2R60
HGNC, UniProt TAS2R41, P59536 TAS2R42, Q7RTR8 TAS2R43, P59537 TAS2R45, P59539 TAS2R46, P59540 TAS2R50, P59544 TAS2R60, P59551
Other 7TM proteins
G protein-coupled receptors → Orphan and other 7TM receptors → Other 7TM proteins
Nomenclature GPR107 GPR137 OR51E1 TPRA1 GPR143 GPR157
HGNC, UniProt GPR107, Q5VW38 GPR137, Q96N19 OR51E1, Q8TCB6 TPRA1, Q86W33 GPR143, P51810 GPR157, Q5UAW9
Endogenous agonists – – – – levodopa [1207] –
Comments GPR107 is a member of the LUSTR
family of proteins found in both
plants and animals, having similar
topology to G protein-coupled
receptors [489]
– OR51E1 is a putative
olfactory receptor.
TPRA1 shows no
homology to known G
protein-coupled
receptors.
Loss-of-function
mutations underlie
ocular albinism type 1
[109].
GPR157 has ambiguous sequence
similarities to several different GPCR
families (class A, class B and the slime
mould cyclic AMP receptor). Because of
its distant relationship to other GPCRs, it
cannot be readily classiﬁed.
Further reading on Orphan and other 7TM receptors
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5-Hydroxytryptamine receptors
G protein-coupled receptors → 5-Hydroxytryptamine receptors
Overview: 5-HT receptors (nomenclature as agreed by the
NC-IUPHAR Subcommittee on 5-HT receptors [828] and
subsequently revised [742]) are, with the exception of the
ionotropic 5-HT3 class, GPCRs where the endogenous agonist is
5-hydroxytryptamine. The diversity of metabotropic 5-HT recep-
tors is increased by alternative splicing that produces isoforms of
the 5-HT2A (non-functional), 5-HT2C (non-functional), 5-HT4, 5-
HT6 (non-functional) and 5-HT7 receptors. Unique amongst the
GPCRs, RNA editing produces 5-HT2C receptor isoforms that dif-
fer in function, such as efﬁciency and speciﬁcity of coupling to
Gq/11 and also pharmacology [167, 2098]. Most 5-HT receptors
(except 5-ht1e and 5-ht5b) play speciﬁc roles mediating functional
responses in different tissues (reviewed by [1625, 2037]).
Nomenclature 5-HT1A receptor 5-HT1B receptor
HGNC, UniProt HTR1A, P08908 HTR1B, P28222
Agonists U92016A [1302], vilazodone (Partial agonist) [421], vortioxetine (Partial agonist) [96] L-694,247 [671], naratriptan (Partial agonist) [1425], eletriptan [1425], frovatriptan [2158],
zolmitriptan (Partial agonist) [1425], vortioxetine (Partial agonist) [96], rizatriptan (Partial
agonist) [1425]
Selective agonists 8-OH-DPAT [431, 720, 939, 1143, 1338, 1451, 1453, 1454], NLX-101 [1452] CP94253 [1022]
Antagonists (S)-UH 301 (pKi 7.9) [1451] –
Selective antagonists WAY-100635 (pKi 7.9–9.2) [1451, 1453], robalzotan (pKi 9.2) [915] SB 224289 (Inverse agonist) (pKi 8.2–8.6) [614, 1449, 1768], SB236057 (Inverse agonist)
(pKi 8.2) [1331], GR-55562 (pKB 7.4) [830]
Labelled ligands [3H]robalzotan (Antagonist) (pKd 9.8) [904], [
3H]WAY100635 (Antagonist) (pKd 9.5)
[978], [3H]8-OH-DPAT (Agonist) [160, 939, 1450, 1453], [3H]NLX-112 (Agonist)
[785], [11C]WAY100635 (Antagonist) [1991], p-[18F]MPPF (Antagonist) [382]
[3H]N-methyl-AZ10419369 (Agonist, Partial agonist) [1245], [3H]GR 125,743 (Selective
Antagonist) (pKd 8.6–9.2) [671, 2150], [
3H]alniditan (Agonist) [1150], [125I]GTI (Agonist)
[197, 237] – Rat, [3H]eletriptan (Agonist, Partial agonist) [1425], [3H]sumatriptan (Agonist,
Partial agonist) [1425], [11C]AZ10419369 (Agonist, Partial agonist) [2029]
Nomenclature 5-HT1D receptor 5-ht1e receptor 5-HT1F receptor
HGNC, UniProt HTR1D, P28221 HTR1E, P28566 HTR1F, P30939
Agonists dihydroergotamine [719, 1150, 1157], ergotamine [648], L-694,247 [2140],
naratriptan [457, 1425, 1651], zolmitriptan [1425], frovatriptan [2158], rizatriptan
[1425]
BRL-54443 [232] BRL-54443 [232], eletriptan [1425], sumatriptan [12, 13,
1425, 2052]
Selective agonists PNU109291 [511] – Gorilla, eletriptan [1425] – lasmiditan [1439], LY334370 [2052], 5-BODMT [1014],
LY344864 [1572]
Selective antagonists SB 714786 (pKi 9.1) [2074] – –
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(continued)
Nomenclature 5-HT1D receptor 5-ht1e receptor 5-HT1F receptor
Labelled ligands [3H]eletriptan (Agonist) [1425], [3H]alniditan (Agonist) [1150], [125I]GTI (Selective
Agonist) [197, 237] – Rat, [3H]GR 125,743 (Selective Antagonist) (pKd 8.6) [2150],
[3H]sumatriptan (Agonist) [1425]
[3H]5-HT (Agonist) [1299, 1532] [3H]LY334370 (Agonist) [2052], [125I]LSD (Agonist) [45] –
Mouse
Nomenclature 5-HT2A receptor 5-HT2B receptor
HGNC, UniProt HTR2A, P28223 HTR2B, P41595
Agonists DOI [210, 1438, 1825] methysergide (Partial agonist) [1018, 1679, 2053], DOI
[1077, 1438, 1730]
Selective agonists – BW723C86 [115, 1018, 1730], Ro 60-0175 [1018]
Antagonists risperidone (Inverse agonist) (pKi 9.3–10) [1032, 1055, 1746], mianserin (pKi 7.7–9.6) [1018, 1045, 1338], ziprasidone
(pKi 8.8–9.5) [1032, 1055, 1746, 1782], volinanserin (pIC50 6.5–9.3) [1018, 1208, 1640], blonanserin (pKi 9.1)
[1487], clozapine (Inverse agonist) (pKi 7.6–9) [1018, 1055, 1335, 1746, 2022]
mianserin (pKi 7.9–8.8) [184, 1018, 2053]
Selective antagonists ketanserin (pKi 8.1–9.7) [241, 1018, 1630], pimavanserin (Inverse agonist) (pKi 9.3) [603, 2022] BF-1 (pKi 10.1) [1742], RS-127445 (pKi 9–9.5) [184,
1018], EGIS-7625 (pKi 9) [1045]
Labelled ligands [3H]fananserin (Antagonist) (pKd 9.9) [1251] – Rat, [
3H]ketanserin (Antagonist) (pKd 8.6–9.7) [1018, 1630],
[11C]volinanserin (Antagonist) [712], [18F]altanserin (Antagonist) [1675]
[3H]LSD (Agonist) [1630], [3H]5-HT (Agonist) [2051] – Rat,
[3H]mesulergine (Antagonist, Inverse agonist) (pKd 7.9)
[1018], [125I]DOI (Agonist)
Nomenclature 5-HT2C receptor 5-HT4 receptor
HGNC, UniProt HTR2C, P28335 HTR4, Q13639
Agonists DOI [493, 1438, 1730], Ro 60-0175 [999, 1018] cisapride (Partial agonist) [80, 132, 631, 1326, 1327, 2013]
Selective agonists WAY-163909 [482], lorcaserin [1955] TD-8954 [1312], ML 10302 (Partial agonist) [140, 164, 1326, 1327, 1328],
RS67506 [765] – Rat, relenopride (Partial agonist) [641], velusetrag [1205, 1832],
BIMU 8 [362]
Antagonists mianserin (Inverse agonist) (pKi 8.3–9.2) [551, 1018, 1338], methysergide (pKi 8.6–9.1) [493,
1018], ziprasidone (Inverse agonist) (pKi 7.9–9) [779, 1055, 1782], olanzapine (Inverse
agonist) (pKi 8.1–8.4) [779, 1055, 1782], loxapine (Inverse agonist) (pKi 7.8–8) [779, 1055]
–
Selective antagonists FR260010 (pKi 9) [735], SB 242084 (pKi 8.2–9) [974, 1018], RS-102221 (pKi 8.3–8.4) [185,
1018]
RS 100235 (pKi 8.7–12.2) [362, 1663], SB 204070 (pKi 9.8–10.4) [132, 1326,
1327, 2013], GR 113808 (pKi 9.3–10.3) [80, 132, 164, 362, 1327, 1663, 2013]
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Nomenclature 5-HT2C receptor 5-HT4 receptor
Labelled ligands [3H]mesulergine (Antagonist, Inverse agonist) (pKd 8.7–9.3) [551, 1630], [
125I]DOI (Agonist)
[551], [3H]LSD (Agonist)
[3H]GR 113808 (Antagonist) (pKd 9.7–10.3) [80, 132, 1328, 2013],
[123I]SB 207710 (Antagonist) (pKd 10.1) [233] – Pig, [
3H]RS 57639 (Selective
Antagonist) (pKd 9.7) [183] – Guinea pig, [
11C]SB207145 (Antagonist) (pKd 8.6)
[1233]
Nomenclature 5-HT5A receptor 5-ht5b receptor 5-HT6 receptor 5-HT7 receptor
HGNC, UniProt HTR5A, P47898 HTR5BP, – HTR6, P50406 HTR7, P34969
Selective agonists – – WAY-181187 [1734], E6801 (Partial agonist) [808], WAY-208466
[139], EMD-386088 [1291]
LP-12 [1148], LP-44 [1148], LP-211 [1149] –
Rat, AS-19 [993], E55888 [212]
Antagonists – – – lurasidone (pKi 9.3) [868], pimozide (pKi 9.3)
[1678] – Rat, vortioxetine (pKi 6.3) [96]
Selective antagonists SB 699551 (pKi 8.2)
[380]
– SB399885 (pKi 9) [801], SB 271046 (pKi 8.9) [229], cerlapirdine
(pKi 8.9) [371], SB357134 (pKi 8.5) [230], Ro 63-0563 (pKi
7.9–8.4) [170, 1824]
SB269970 (pKi 8.6–8.9) [1949], SB656104
(pKi 8.7) [558], DR-4004 (pKi 8.7) [647, 985],
JNJ-18038683 (pKi 8.2) [181], SB 258719
(Inverse agonist) (pKi 7.5) [1950]
Labelled ligands [125I]LSD (Agonist) [670],
[3H]5-CT (Agonist) [670]
[125I]LSD (Agonist) [1290] –
Mouse, [3H]5-CT (Agonist)
[2049] – Mouse
[11C]GSK215083 (Antagonist) (pKi 9.8) [1531], [
125I]SB258585
(Selective Antagonist) (pKd 9) [801], [
3H]LSD (Agonist) [169],
[3H]Ro 63-0563 (Antagonist) (pKd 8.3) [170], [
3H]5-CT (Agonist)
[3H]5-CT (Agonist) [1949], [3H]5-HT (Agonist)
[99, 1864], [3H]SB269970 (Selective
Antagonist) (pKd 8.9) [1949], [
3H]LSD
(Agonist) [1864]
Comments: Tabulated pKi and KD values refer to binding to hu-
man 5-HT receptors unless indicated otherwise. The nomencla-
ture of 5-HT1B/5-HT1D receptors has been revised [742]. Only
the non-rodent form of the receptor was previously called 5-
HT1D: the human 5-HT1B receptor (tabulated) displays a differ-
ent pharmacology to the rodent forms of the receptor due to
Thr335 of the human sequence being replaced by Asn in rodent
receptors. Wang et al. (2013) report X-ray structures which re-
veal the binding modality of ergotamine and dihydroergotamine
to the 5-HT1B receptor in comparison with the structure of the
5-HT2B receptor [2064]. NAS181 is a selective antagonist of the
rodent 5-HT1B receptor. Fananserin and ketanserin bindwith high
afﬁnity to dopamine D4 and histamine H1 receptors respectively,
and ketanserin is a potent α1 adrenoceptor antagonist, in addition
to blocking 5-HT2A receptors. Lysergic acid (LSD) and ergotamine
show a strong preference for arrestin recruitment over G protein
coupling at the 5-HT2B receptor, with no such preference evident
at 5-HT1B receptors, and they also antagonise 5-HT7A receptors
[2047]. DHE (dihydroergocryptine), pergolide and cabergoline
also show signiﬁcant preference for arrestin recruitment over
G protein coupling at 5-HT2B receptors [2047]. The serotonin
antagonist mesulergine was key to the discovery of the 5-HT2C
receptor [1546]. The human 5-HT5A receptor has been claimed
to couple to several signal transduction pathways when stably
expressed in C6 glioma cells [1472] and electrophysiological
recordings from mice and rat prefrontal cortex (layer V pyrami-
dal neurons) demonstrate 5-HT-elicited outward currents medi-
ated via the 5-HT5A receptor [660]. The human orthologue of the
mouse 5-ht5b receptor is non-functional due to interruption of the
gene by stop codons. The 5-ht1e receptor appears not to have been
cloned from mouse, or rat, impeding deﬁnition of its function. In
addition to the receptors listed in the table, an ’orphan’ receptor,
unofﬁcially termed 5-HT1P, has been described [635]. .
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Further reading on 5-Hydroxytryptamine receptors
Bockaert J et al. (2011) 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 11: 87-93
[PMID:21342787]
Hayes DJ et al. (2011) 5-HT receptors and reward-related behaviour: a review. Neurosci Biobehav Rev
35: 1419-49 [PMID:21402098]
Hoyer D et al. (1994) International Union of Pharmacology classiﬁcation of receptors for
5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46: 157-203 [PMID:7938165]
Leopoldo M et al. (2011) Serotonin 5-HT7 receptor agents: Structure-activity relationships and po-
tential therapeutic applications in central nervous system disorders. Pharmacol. Ther. 129:
120-48 [PMID:20923682]
Meltzer HY et al. (2011) The role of serotonin receptors in the action of atypical antipsychotic drugs.
Curr Opin Pharmacol 11: 59-67 [PMID:21420906]
Roberts AJ et al. (2012) The 5-HT(7) receptor in learning and memory. Hippocampus 22: 762-71
[PMID:21484935]
Acetylcholine receptors (muscarinic)
G protein-coupled receptors → Acetylcholine receptors (muscarinic)
Overview: Muscarinic acetylcholine receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on Mus-
carinic Acetylcholine Receptors [288]) are GPCRs of the
Class A, rhodopsin-like family where the endogenous agonist
is acetylcholine. In addition to the agents listed in the ta-
ble, AC-42, its structural analogues AC-260584 and 77-LH-28-1,
N-desmethylclozapine, TBPB and LuAE51090 have been described
as functionally selective agonists of the M1 receptor subtype via
binding in a mode distinct from that utilized by non-selective ag-
onists [74, 921, 1096, 1097, 1294, 1708, 1857, 1858, 1898]. There
are two pharmacologically characterised allosteric sites on mus-
carinic receptors, one deﬁned by it binding gallamine, strychnine
and brucine, and the other deﬁned by the binding of KT 5720,
WIN 62,577, WIN 51,708 and staurosporine [1110, 1111].
Nomenclature M1 receptor M2 receptor
HGNC, UniProt CHRM1, P11229 CHRM2, P08172
Agonists carbachol [350, 888, 2129], pilocarpine (Partial agonist) [888], bethanechol [888] bethanechol [888]
Antagonists glycopyrrolate (pIC50 9.9) [1874], umeclidinium (pKi 9.8) [1090, 1705], AE9C90CB (pKi
9.7) [1818], propantheline (pKi 9.7) [837], atropine (pKi 8.5–9.6) [350, 582, 797, 837,
1555, 1831], tiotropium (pKi 9.6) [452], 4-DAMP (pKi 9.2) [486]
tiotropium (pKi 9.9) [452], umeclidinium (pKi 9.8) [1090, 1705], propantheline (pKi 9.5)
[837], glycopyrrolate (Full agonist) (pIC50 9.3) [1874], atropine (pKi 7.8–9.2) [245, 325,
797, 837, 1046, 1437, 1555], AE9C90CB (pKi 8.6) [1818], tolterodine (Inverse agonist)
(pKi 8.4–8.6) [642, 1437, 1818]
Selective antagonists biperiden (pKd 9.3) [175], VU0255035 (pKi 7.8) [1786], guanylpirenzepine (pKi 7.3–7.6)
[23, 2050] – Rat
tripitramine (pKi 9.6) [1240]
Allosteric modulators muscarinic toxin 7 (Negative) (pKi 11–11.1) [1480], benzoquinazolinone 12 (Positive)
(pKB 6.6) [4], KT 5720 (Positive) (pKd 6.4) [1110], brucine (Positive) (pKd 4.5–5.8) [888,
1109], BQCA (Positive) (pKB 4–4.8) [4, 5, 271, 1225], VU0029767 (Positive) [1270],
VU0090157 (Positive) [1270]
W-84 (Negative) (pKd 6–7.5) [1353, 1983], C7/3-phth (Negative) (pKd 7.1) [351],
alcuronium (Negative) (pKd 6.1–6.9) [888, 1983], gallamine (Negative) (pKd 5.9–6.3)
[363, 1107], LY2119620 (Positive) (pKd 5.7) [399, 1057], LY2033298 (Positive) (pKd 4.4)
[2009]
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Nomenclature M1 receptor M2 receptor
Labelled ligands [3H]QNB (Antagonist) (pKd 10.6–10.8) [352, 1555], Cy3B-telenzepine (Antagonist) (pKd
10.5) [777], [3H]N-methyl scopolamine (Antagonist) (pKd 9.4–10.3) [294, 350, 352,
797, 888, 889, 918, 977, 1107], [3H](+)telenzepine (Antagonist) (pKi 9.4) [526] – Rat,
Alexa-488-telenzepine (Antagonist) (pKd 9.3) [777], [
3H]pirenzepine (Antagonist) (pKd
7.9) [2083], BODIPY-pirenzepine (Antagonist) (pKi 7) [860], [
11C]butylthio-TZTP
(Agonist) [530], [11C]xanomeline (Agonist) [530],
[18F](R,R)-quinuclidinyl-4-ﬂuoromethyl-benzilate (Antagonist) [982] – Rat
[3H]QNB (Antagonist) (pKd 10.1–10.6) [1555], Cy3B-telenzepine (Antagonist) (pKi 10.4)
[1444], [3H]tiotropium (Antagonist) (pKd 10.3) [1705], [
3H]N-methyl scopolamine
(Antagonist) (pKd 9.3–9.9) [294, 325, 797, 888, 889, 918, 977, 1107, 2072],
Alexa-488-telenzepine (Antagonist) (pKi 8.8) [1444], [
3H]acetylcholine (Agonist) [1108],
[3H]oxotremorine-M (Agonist) [141], [3H]dimethyl-W84 (Allosteric modulator, Positive)
(pKd 8.5) [1983], [
18F]FP-TZTP (Agonist) [887] – Mouse
Nomenclature M3 receptor M4 receptor M5 receptor
HGNC, UniProt CHRM3, P20309 CHRM4, P08173 CHRM5, P08912
Agonists pilocarpine (Partial agonist) [888], carbachol [325, 888,
2129], bethanechol [888]
pilocarpine (Partial agonist) [888], carbachol [888,
2129], bethanechol [888]
pilocarpine (Partial agonist) [673], carbachol [2129]
Antagonists tiotropium (pKi 9.5–11.1) [452, 469], umeclidinium
(pKi 10.2) [1090, 1705], propantheline (pKi 10) [837],
AE9C90CB (pKi 9.9) [1818], atropine (pKi 8.9–9.8)
[245, 469, 797, 837, 1555, 1831], ipratropium (pKi
9.3–9.8) [469, 797], aclidinium (pIC50 9.8) [1601]
umeclidinium (pKi 10.3) [1705], glycopyrrolate (pIC50
9.8) [1874], AE9C90CB (pKi 9.5) [1818], 4-DAMP (pKi
8.9) [486], oxybutynin (pKi 8.7) [1818], biperiden
(pKd 8.6) [175], UH-AH 37 (pKi 8.3–8.4) [642, 2099]
umeclidinium (pKi 9.9) [1705], glycopyrrolate (pIC50
9.7) [1874], AE9C90CB (pKi 9.5) [1818], 4-DAMP (pKi
9) [486], tolterodine (pKi 8.5–8.8) [642, 1818],
darifenacin (pKi 7.9–8.6) [642, 764, 797, 1818]
Selective antagonists – – ML381 (pKi 6.3) [625]
Allosteric modulators WIN 62,577 (Positive) (pKd 5.1) [1111],
N-chloromethyl-brucine (Positive) (pKd 3.3) [1109]
muscarinic toxin 3 (Negative) (pKi 8.7) [918, 1512],
VU0152100 (Positive) (pEC50 6.4) [207] – Rat,
VU0152099 (Positive) (pEC50 6.4) [207] – Rat,
LY2119620 (Positive) (pKd 5.7) [399], thiochrome
(Positive) (pKd 4) [1108], LY2033298 (Positive) [301]
ML380 (Positive) (pEC50 6.7) [627]
Selective allosteric modulators – – ML375 (Negative) (pIC50 6.5) [626]
Labelled ligands [3H]tiotropium (Antagonist) (pKd 10.7) [1705],
[3H]QNB (Antagonist) (pKd 10.4) [1555],
[3H]N-methyl scopolamine (Antagonist) (pKd
9.7–10.2) [294, 325, 797, 837, 888, 918, 977, 1107],
[3H]darifenacin (Antagonist) (pKd 9.5) [1831]
[3H]QNB (Antagonist) (pKd 9.7–10.5) [352, 1555],
[3H]N-methyl scopolamine (Antagonist) (pKd
9.9–10.2) [294, 325, 352, 797, 888, 918, 977, 1107,
1512, 2072], [3H]acetylcholine (Agonist) [1108]
[3H]QNB (Antagonist) (pKd 10.2–10.7),
[3H]N-methyl scopolamine (Antagonist) (pKd 9.3–9.7)
[294, 325, 797, 918, 977, 2072]
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Comments: LY2033298 and BQCA have also been shown to
directly activate the M4 and M1 receptors, respectively, via an
allosteric site [1119, 1121, 1427, 1428]. The allosteric site for
gallamine and strychnine on M2 receptors can be labelled by
[3H]dimethyl-W84 [1983]. McN-A-343 is a functionally selective
partial agonist that appears to interact in a bitopicmode with both
the orthosteric and an allosteric site on the M2 muscarinic recep-
tor [2010]. THRX160209, hybrid 1 and hybrid 2, are multivalent
(bitopic) ligands that also achieve selectivity for M2 receptors by
binding both to the orthosteric and a nearby allosteric site [55,
1866].
Although numerous ligands for muscarinic acetylcholine recep-
tors have been described, relatively few selective antagonists have
been described, so it is common to assess the rank order of afﬁn-
ity of a number of antagonists of limited selectivity (e.g. 4-DAMP,
darifenacin, pirenzepine) in order to identify the involvement of
particular subtypes. It should be noted that the measured afﬁni-
ties of antagonists (and agonists) in radioligand binding studies
are sensitive to ionic strength and can increase over 10-fold at
low ionic strength compared to their values at physiological ionic
strengths [155].
Further reading on Acetylcholine receptors (muscarinic)
Caulﬁeld MP et al. (1998) International Union of Pharmacology. XVII. Classiﬁcation of muscarinic
acetylcholine receptors. Pharmacol. Rev. 50: 279-290 [PMID:9647869]
Eglen RM. (2012) Overview of muscarinic receptor subtypes. Handb Exp Pharmacol 3-28
[PMID:22222692]
Gregory KJ et al. (2007) Allosteric modulation of muscarinic acetylcholine receptors. Curr Neu-
ropharmacol 5: 157-67 [PMID:19305798]
Kruse AC et al. (2014) Muscarinic acetylcholine receptors: novel opportunities for drug develop-
ment. Nat Rev Drug Discov 13: 549-60 [PMID:24903776]
Leach K et al. (2012) Structure-function studies of muscarinic acetylcholine receptors. Handb Exp
Pharmacol 29-48 [PMID:22222693]
Valant C et al. (2012) The best of both worlds? Bitopic orthosteric/allosteric ligands of g protein-
coupled receptors. Annu. Rev. Pharmacol. Toxicol. 52: 153-78 [PMID:21910627]
Adenosine receptors
G protein-coupled receptors → Adenosine receptors
Overview: Adenosine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Adenosine Receptors [569]) are activated by the endogenous ligand adenosine (potentially
inosine also at A3 receptors). Crystal structures for the antagonist-bound [374, 876, 1198, 1765], agonist-bound [1126, 1127, 2154] and G protein-bound A2A adenosine receptors [278] have been described.
Nomenclature A1 receptor A2A receptor A2B receptor A3 receptor
HGNC, UniProt ADORA1, P30542 ADORA2A, P29274 ADORA2B, P29275 ADORA3, P0DMS8
Sub/family-selective agonists NECA [602, 913, 1665, 1980, 2166] NECA [193, 451, 602, 990, 1071,
2166]
NECA [148, 193, 905, 1179, 1870,
2024, 2166]
NECA [193, 602, 883, 1707, 2025,
2166]
Selective agonists cyclopentyladenosine [404, 428, 602, 771,
880, 913, 1665], 5-Cl-5-deoxy-(±)-ENBA
[565], TCPA [150], CCPA [880, 1485]
apadenoson [1548], UK-432,097
[2154], compound 4g [374],
CGS 21680 [193, 451, 602, 880, 990,
1016, 1071, 1485], regadenoson [880]
BAY 60-6583 [488] piclidenoson [537, 592, 1016, 2025],
Cl-IB-MECA [208, 883, 987], MRS5698
[1977]
Sub/family-selective
antagonists
CGS 15943 (pKi 8.5) [1513],
xanthine amine congener (pKd 7.5) [565]
CGS 15943 (pKi 7.7–9.4) [451, 990,
1016, 1513],
xanthine amine congener (pKi 8.4–9)
[451, 1016]
xanthine amine congener (pKi 6.9–8.8)
[148, 905, 906, 1016, 1179, 1870],
CGS 15943 (pKi 6–8.1) [68, 905, 906,
1016, 1513, 1870]
CGS 15943 (pKi 7–7.9) [995, 1016,
1513, 2025], xanthine amine congener
(pKi 7–7.4) [1016, 1707, 2025]
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Nomenclature A1 receptor A2A receptor A2B receptor A3 receptor
Selective antagonists PSB36 (pKi 9.9) [6] – Rat, DPCPX (pKi
7.4–9.2) [428, 865, 1485, 1665, 2102],
derenofylline (pKi 9) [939], WRC-0571 (pKi
8.8) [1272], DU172 (pKi 7.4) [649]
SCH442416 (pKi 8.4–10.3) [1796,
1969], ZM-241385 (pKi 8.8–9.1)
[1513]
PSB-0788 (pKi 9.4) [192], PSB603 (pKi
9.3) [192], MRS1754 (pKi 8.8) [905,
994], PSB1115 (pKi 7.3) [757]
MRS1220 (pKi 8.2–9.2) [883, 995,
1892, 2177], VUF5574 (pKi 8.4) [2016],
MRS1523 (pKi 7.7) [1158], MRS1191
(pKi 7.5) [883, 909, 1163]
Allosteric modulators PD81723 (Positive) [239] – – LUF6000 (Positive) [701], LUF6096
(Positive) [770]
Labelled ligands [3H]CCPA (Agonist) [1016, 1665],
[3H]DPCPX (Antagonist) (pKd 8.4–9.2)
[404, 537, 1016, 1513, 1665, 1980]
[3H]ZM 241385 (Antagonist) (pKd
8.7–9.1) [36, 600], [3H]CGS 21680
(Agonist) [894, 2062]
[3H]MRS1754 (Antagonist) (pKd 9.8)
[905]
[125I]AB-MECA (Agonist) [1513, 2025]
Comments: Adenosine inhibits many intracellular ATP-utilising
enzymes, including adenylyl cyclase (P-site). A pseudogene exists
for the A2B adenosine receptor (ADORA2BP1) with 79% identity
to the A2B adenosine receptor cDNA coding sequence, but which
is unable to encode a functional receptor [884]. DPCPX also ex-
hibits antagonism at A2B receptors (pKi ca. 7,[34, 1016]). An-
tagonists at A3 receptors exhibit marked species differences, such
that only MRS1523 and MRS1191 are selective at the rat A3 re-
ceptor. In the absence of other adenosine receptors, [3H]DPCPX
and [3H]ZM 241385 can also be used to label A2B receptors (KD
ca. 30 and 60 nM respectively). [125I]AB-MECA also binds to A1
receptors [1016]. [3H]CGS 21680 is relatively selective for A2A re-
ceptors, but may also bind to other sites in cerebral cortex [400,
914]. [3H]NECA binds to other non-receptor elements, which also
recognise adenosine [1209]. XAC-BY630 has been described as a
ﬂuorescent antagonist for labelling A1 adenosine receptors in liv-
ing cells, although activity at other adenosine receptors was not
examined [217].
Further reading on Adenosine receptors
Fredholm BB et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXI.
Nomenclature and classiﬁcation of adenosine receptors–an update. Pharmacol. Rev. 63: 1-34
[PMID:21303899]
Guo D et al. (2017) Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Re-
ceptor: The Case of the Adenosine Receptors. Chem. Rev. 117: 38-66 [PMID:27088232]
Göblyös A et al. (2011) Allosteric modulation of adenosine receptors. Biochim. Biophys. Acta 1808:
1309-18 [PMID:20599682]
Headrick JP et al. (2011) Adenosine and its receptors in the heart: regulation, retaliation and adap-
tation. Biochim. Biophys. Acta 1808: 1413-28 [PMID:21094127]
Lasley RD. (2011) Adenosine receptors and membrane microdomains. Biochim. Biophys. Acta 1808:
1284-9 [PMID:20888790]
Mundell S et al. (2011) Adenosine receptor desensitization and trafﬁcking. Biochim. Biophys. Acta
1808: 1319-28 [PMID:20550943]
Wei CJ et al. (2011) Normal and abnormal functions of adenosine receptors in the central ner-
vous system revealed by genetic knockout studies. Biochim. Biophys. Acta 1808: 1358-79
[PMID:21185258]
Adhesion Class GPCRs
G protein-coupled receptors → Adhesion Class GPCRs
Overview: Adhesion GPCRs are structurally identiﬁed on the basis of a large extracellular region, similar to the Class B GPCR, but which is linked to the 7TM region by a GPCR autoproteolysis-inducing
(GAIN) domain [56] containing a GPCR proteolytic site. The N-terminus often shares structural homology with proteins such as lectins and immunoglobulins, leading to the term adhesion GPCR [571,
2187]. The nomenclature of these receptors was revised in 2015 as recommended by NC-IUPHAR and the Adhesion GPCR Consortium [718].
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Nomenclature ADGRA1 ADGRA2 ADGRA3 ADGRB1 ADGRB2 ADGRB3 CELSR1
HGNC, UniProt ADGRA1, Q86SQ6 ADGRA2, Q96PE1 ADGRA3, Q8IWK6 ADGRB1, O14514 ADGRB2, O60241 ADGRB3, O60242 CELSR1, Q9NYQ6
Endogenous agonists – – – phosphatidylserine [1530] – – –
Comments – – – ADGRB1 is reported to
respond to
phosphatidylserine [1530].
– – –
Nomenclature CELSR2 CELSR3 ADGRD1 ADGRD2 ADGRE1 ADGRE2 ADGRE3
HGNC, UniProt CELSR2, Q9HCU4 CELSR3, Q9NYQ7 ADGRD1, Q6QNK2 ADGRD2, Q7Z7M1 ADGRE1, Q14246 ADGRE2, Q9UHX3 ADGRE3, Q9BY15
Comments – – – – – A mutation destabilizing the GAIN domain
sensitizes mast cells to IgE-independent
vibration-induced degranulation [202].
–
Nomenclature ADGRE4P ADGRE5 ADGRF1 ADGRF2 ADGRF3 ADGRF4 ADGRF5
HGNC, UniProt ADGRE4P, Q86SQ3 ADGRE5, P48960 ADGRF1, Q5T601 ADGRF2, Q8IZF7 ADGRF3, Q8IZF5 ADGRF4, Q8IZF3 ADGRF5, Q8IZF2
Nomenclature ADGRG1 ADGRG2 ADGRG3 ADGRG4 ADGRG5
HGNC, UniProt ADGRG1, Q9Y653 ADGRG2, Q8IZP9 ADGRG3, Q86Y34 ADGRG4, Q8IZF6 ADGRG5, Q8IZF4
Comments Reported to bind tissue transglutaminase 2 [2155] and collagen,
which activates the G12/13 pathway [1220].
– – – –
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Nomenclature ADGRG6 ADGRG7 ADGRL1 ADGRL2 ADGRL3 ADGRL4 ADGRV1
HGNC, UniProt ADGRG6, Q86SQ4 ADGRG7, Q96K78 ADGRL1, O94910 ADGRL2, O95490 ADGRL3, Q9HAR2 ADGRL4, Q9HBW9 ADGRV1, Q8WXG9
Comments – – – – – – Loss-of-function mutations are
associated with Usher syndrome,
a sensory deﬁcit disorder [885].
Further reading on Adhesion Class GPCRs
Hamann J et al. (2015) International Union of Basic and Clinical Pharmacology. XCIV. Adhesion G
protein-coupled receptors. Pharmacol. Rev. 67: 338-67 [PMID:25713288]
Yona S et al. (2008) Adhesion-GPCRs: emerging roles for novel receptors. Trends Biochem. Sci. 33:
491-500 [PMID:18789697]
Adrenoceptors
G protein-coupled receptors → Adrenoceptors
Overview: The nomenclature of the Adrenoceptors has been agreed by the NC-IUPHAR Subcommittee on Adrenoceptors [256], see also [789].
Adrenoceptors, α1
α1-Adrenoceptors are activated by the endogenous agonists
(-)-adrenaline and (-)-noradrenaline. Phenylephrine, methoxa-
mine and cirazoline are agonists and prazosin and cirazoline an-
tagonists considered selective for α1- relative to α2-adrenoceptors.
[3H]prazosin and [125I]HEAT (BE2254) are relatively selec-
tive radioligands. S(+)-niguldipine also has high afﬁnity for
L-type Ca2+ channels. Fluorescent derivatives of prazosin (Bod-
ipy PLprazosin- QAPB) are used to examine cellular localisa-
tion of α1-adrenoceptors. Selective α1-adrenoceptor agonists are
used as nasal decongestants; antagonists to treat hypertension
(doxazosin, prazosin) and benign prostatic hyperplasia (alfuzosin,
tamsulosin). The α1- and β2-adrenoceptor antagonist carvedilol
is used to treat congestive heart failure, although the contri-
bution of α1-adrenoceptor blockade to the therapeutic effect is
unclear. Several anti-depressants and anti-psychotic drugs are
α1-adrenoceptor antagonists contributing to side effects such as
orthostatic hypotension and extrapyramidal effects.
Nomenclature α1A-adrenoceptor α1B-adrenoceptor α1D-adrenoceptor
HGNC, UniProt ADRA1A, P35348 ADRA1B, P35368 ADRA1D, P25100
Endogenous agonists (-)-adrenaline [819, 1789], (-)-noradrenaline [819, 1789, 1936] – (-)-noradrenaline [819, 1789], (-)-adrenaline [819, 1789]
Agonists oxymetazoline [819, 1486, 1789, 1936], phenylephrine [1936],
methoxamine [1789, 1936]
phenylephrine [559, 1345] –
Selective agonists A61603 [559, 1017], dabuzalgron [165] – –
Antagonists prazosin (Inverse agonist) (pKi 9–9.9) [303, 405, 559, 1789,
2118], doxazosin (pKi 9.3) [724], terazosin (pKi 8.7) [1323],
phentolamine (pKi 8.6) [1789], alfuzosin (pKi 8.1) [787]
prazosin (Inverse agonist) (pKi 9.6–9.9)
[559, 1789, 2118], tamsulosin (Inverse
agonist) (pKi 9.5–9.7) [559, 1789, 2118],
doxazosin (pKi 9.1) [724], alfuzosin (pKi
8.6) [788], terazosin (pKi 8.6) [1323],
phentolamine (pKi 7.5) [1789]
prazosin (Inverse agonist) (pKi 9.5–10.2) [559, 1789, 2118],
tamsulosin (pKi 9.8–10.2) [559, 1789, 2118], doxazosin (pKi 9.1)
[724], terazosin (pKi 9.1) [1323], alfuzosin (pKi 8.4) [787],
dapiprazole (pKi 8.4) [71], phentolamine (Inverse agonist) (pKi
8.2) [1789], RS-100329 (pKi 7.9) [2118], labetalol (pKi 6.6) [71]
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(continued)
Nomenclature α1A-adrenoceptor α1B-adrenoceptor α1D-adrenoceptor
Selective antagonists tamsulosin (pKi 10–10.7) [303, 405, 559, 1789, 2118], silodosin
(pKi 10.4) [1789], S(+)-niguldipine (pKi 9.1–10) [559, 1789],
RS-100329 (pKi 9.6) [2118], SNAP5089 (pKi 8.8–9.4) [787, 1147,
2101], ρ-Da1a (pKi 9.2–9.3) [1298, 1619], RS-17053 (pKi
9.2–9.3) [303, 405, 556, 559]
Rec 15/2615 (pKi 9.5) [1942], L-765314
(pKi 7.7) [1537], AH 11110 (pKi 7.5)
[1724]
BMY-7378 (pKi 8.7–9.1) [280, 2192]
Adrenoceptors, α2
α2-Adrenoceptors are activated by (-)-adrenaline and with lower
potency by (-)-noradrenaline. Brimonidine and talipexole are
agonists and rauwolscine and yohimbine antagonists selective
for α2- relative to α1-adrenoceptors. [3H]rauwolscine, [3H]
brimonidine and [3H]RX821002 are relatively selective radioli-
gands. There is species variation in the pharmacology of the
α2A-adrenoceptor. Multiple mutations of α2-adrenoceptors have
been described, some associated with alterations in function.
Presynaptic α2-adrenoceptors regulate many functions in the ner-
vous system. The α2-adrenoceptor agonists clonidine, guanabenz
and brimonidine affect central baroreﬂex control (hypotension
and bradycardia), induce hypnotic effects and analgesia, and
modulate seizure activity and platelet aggregation. Clonidine
is an anti-hypertensive and counteracts opioid withdrawal.
Dexmedetomidine (also xylazine) is used as a sedative and anal-
gesic in human and veterinary medicine with sympatholytic and
anxiolytic properties. The α2-adrenoceptor antagonist yohimbine
has been used to treat erectile dysfunction and mirtazapine as
an anti-depressant. The α2B subtype appears to be involved in
neurotransmission in the spinal cord and α2C in regulating cate-
cholamine release from adrenal chromafﬁn cells.
Nomenclature α2A-adrenoceptor α2B-adrenoceptor α2C-adrenoceptor
HGNC, UniProt ADRA2A, P08913 ADRA2B, P18089 ADRA2C, P18825
Endogenous agonists (-)-adrenaline [896, 1573], (-)-noradrenaline [896, 1573] (-)-noradrenaline (Partial agonist) [896, 1573],
(-)-adrenaline [896]
(-)-noradrenaline [896, 1573], (-)-adrenaline [896]
Agonists dexmedetomidine (Partial agonist) [896, 1228, 1552, 1573],
clonidine (Partial agonist) [896, 1552, 1573], brimonidine [896,
1228, 1552, 1573], apraclonidine [1399], guanabenz [71],
guanfacine (Partial agonist) [896, 1231]
dexmedetomidine [896, 1228, 1552, 1573], clonidine
(Partial agonist) [896, 1552, 1573], brimonidine
(Partial agonist) [896, 1552, 1573], guanabenz [71],
guanfacine [896]
dexmedetomidine [896, 1552, 1573], brimonidine
(Partial agonist) [896, 1228, 1552, 1573],
apraclonidine [1399], guanfacine (Partial agonist)
[896], guanabenz [71]
Selective agonists oxymetazoline (Partial agonist) [896, 1228, 1998] – –
Antagonists yohimbine (pKi 8.4–9.2) [255, 440, 1998] yohimbine (pKi 7.9–8.9) [255, 440, 1998],
phenoxybenzamine (pKi 8.5) [2088], tolazoline (pKi
5.5) [896]
yohimbine (pKi 8.5–9.5) [255, 440, 1998], WB 4101
(pKi 8.4–9.4) [255, 440, 1998], spiroxatrine (pKi 9)
[1998], mirtazapine (pKi 7.7) [539], tolazoline (pKi
5.4) [896]
Selective antagonists BRL 44408 (pKi 8.2–8.8) [1998, 2194] imiloxan (pKi 7.3) [1329] – Rat JP1302 (pKB 7.8) [1704]
Labelled ligands – – [3H]MK-912 (Antagonist) (pKd 10.1) [1998]
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Adrenoceptors, β
β-Adrenoceptors are activated by the endogenous agonists
(-)-adrenaline and (-)-noradrenaline. Isoprenaline is selective
for β-adrenoceptors relative to α1- and α2-adrenoceptors, while
propranolol (pKi 8.2-9.2) and cyanopindolol (pKi 10.0-11.0)
are relatively β1 and β2 adrenoceptor-selective antagonists.
(-)-noradrenaline, xamoterol and (-)-Ro 363 show selectivity for
β1- relative to β2-adrenoceptors. Pharmacological differences ex-
ist between human and mouse β3-adrenoceptors, and the ’rodent
selective’ agonists BRL 37344 and CL316243 have low efﬁcacy at
the human β3-adrenoceptor whereas CGP 12177 and L 755507
activate human β3-adrenoceptors [88]. β3-Adrenoceptors are re-
sistant to blockade by propranolol, but can be blocked by high
concentrations of bupranolol. SR59230A has reasonably high
afﬁnity at β3-adrenoceptors, but does not discriminate well be-
tween the three β- subtypes whereas L 755507 is more selective.
[125I]-cyanopindolol, [125I]-hydroxy benzylpindolol and [3H]-
alprenolol are high afﬁnity radioligands that label β1- and β2-
adrenoceptors and β3-adrenoceptors can be labelled with higher
concentrations (nM) of [125I]-cyanopindolol together with β1-
and β2-adrenoceptor antagonists. [3H]-L-748337 is a β3-selective
radioligand [2020]. Fluorescent ligands such as BODIPY-TMR-
CGP12177 can be used to track β-adrenoceptors at the cel-
lular level [8]. Somewhat selective β1-adrenoceptor agonists
(denopamine, dobutamine) are used short term to treat cardio-
genic shock but, chronically, reduce survival. β1-Adrenoceptor-
preferring antagonists are used to treat hypertension (atenolol,
betaxolol, bisoprolol, metoprolol and nebivolol), cardiac ar-
rhythmias (atenolol, bisoprolol, esmolol) and cardiac failure
(metoprolol, nebivolol). Cardiac failure is also treated with
carvedilol that blocks β1- and β2-adrenoceptors, as well as
α1-adrenoceptors. Short (salbutamol, terbutaline) and long
(formoterol, salmeterol) acting β2-adrenoceptor-selective agonists
are powerful bronchodilators used to treat respiratory disorders.
Many ﬁrst generation β-adrenoceptor antagonists (propranolol)
block both β1- and β2-adrenoceptors and there are no β2-
adrenoceptor-selective antagonists used therapeutically. The β3-
adrenoceptor agonist mirabegron is used to control overactive
bladder syndrome.
Nomenclature β1-adrenoceptor β2-adrenoceptor β3-adrenoceptor
HGNC, UniProt ADRB1, P08588 ADRB2, P07550 ADRB3, P13945
Potency order of endogenous ligands (-)-noradrenaline > (-)-adrenaline (-)-adrenaline > (-)-noradrenaline (-)-noradrenaline = (-)-adrenaline
Endogenous agonists (-)-adrenaline [579, 806], (-)-noradrenaline [579, 806],
noradrenaline [579]
(-)-adrenaline [579, 806, 893], (-)-noradrenaline [579, 806] (-)-noradrenaline [806, 1589,
1880], (-)-adrenaline [806]
Agonists pindolol (Partial agonist) [1058], isoprenaline [579, 1723],
dobutamine (Partial agonist) [870]
pindolol (Partial agonist) [1058], arformoterol [37],
isoprenaline [1723], dobutamine (Partial agonist) [1166],
ephedrine (Partial agonist) [893]
carazolol [1318]
Selective agonists (-)-Ro 363 [1355], xamoterol (Partial agonist) [870],
denopamine (Partial agonist) [870, 1903]
formoterol [85], salmeterol [85], zinterol [85], vilanterol
[1605], procaterol [85], indacaterol [114], fenoterol [59],
salbutamol (Partial agonist) [87, 870], terbutaline (Partial
agonist) [87], orciprenaline [1853]
L 755507 [85], L742791 [2086],
mirabegron [1922], CGP 12177
(Partial agonist) [163, 1210,
1318, 1355], SB251023 [850] –
Mouse, BRL 37344 [163, 456,
806, 1318], CL316243 [2168]
Antagonists carvedilol (pKi 9.5) [272], bupranolol (pKi 7.3–9) [272, 1210],
levobunolol (pKi 8.4) [71], labetalol (pKi 8.2) [71], metoprolol
(pKi 7–7.6) [87, 272, 806, 1210], esmolol (pKi 6.9) [71],
nadolol (pKi 6.9) [272], practolol (pKi 6.1–6.8) [87, 1210],
propafenone (pKi 6.7) [71], sotalol (pKi 6.1) [71]
carvedilol (pKi 9.4–9.9) [87, 272], timolol (pKi 9.7) [87],
propranolol (pKi 9.1–9.5) [87, 90, 870, 1210], levobunolol
(pKi 9.3) [71], bupranolol (pKi 8.3–9.1) [272, 1210],
alprenolol (pKi 9) [87], nadolol (pKi 7–8.6) [87, 272], labetalol
(pKi 8) [71], propafenone (pKi 7.4) [71], sotalol (pKi 6.5) [71]
carvedilol (pKi 9.4) [272],
SR59230A (pKi 6.9–8.4) [272,
430, 806], bupranolol (pKi
6.8–7.3) [163, 272, 1210, 1318],
propranolol (pKi 6.3–7.2) [1210,
1589], levobunolol (pKi 6.8)
[1589]
Selective antagonists CGP 20712A (pKi 8.5–9.2) [87, 272, 1210], levobetaxolol (pKi
9.1) [1785], betaxolol (pKi 8.8) [1210], nebivolol (pIC50
8.1–8.7) [1543] – Rabbit, atenolol (pKi 6.7–7.6) [87, 928,
1210], acebutolol (pKi 6.4) [71]
ICI 118551 (Inverse agonist) (pKi 9.2–9.5) [87, 90, 1210] L-748337 (pKi 8.4) [272],
L748328 (pKi 8.4) [272]
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(continued)
Nomenclature β1-adrenoceptor β2-adrenoceptor β3-adrenoceptor
Labelled ligands [125I]ICYP (Selective Antagonist) (pKd 10.4–11.3) [870, 1210,
1723]
[125I]ICYP (Antagonist) (pKd 11.1) [1210, 1723] [
125I]ICYP (Agonist, Partial
agonist) [1210, 1355, 1589,
1723, 1880]
Comments The agonists indicated have less than two orders of magnitude
selectivity [85].
– Agonist SB251023 has a pEC50 of
6.9 for the splice variant of the
mouse β3 receptor, β3b [850].
Comments: Adrenoceptors, α1
The α1C-adrenoceptor corresponds to the pharmacologically
deﬁned α1A-adrenoceptor [789]. Some tissues possess α1A-
adrenoceptors (α1L-adrenoceptors [559, 1382]) that display
relatively low afﬁnity in functional and binding assays for
prazosin indicative of different receptor states or locations.
α1A-adrenoceptor C-terminal splice variants form homo- and
heterodimers, but fail to generate a functional α1L-adrenoceptor
[1628]. α1D-Adrenoceptors form heterodimers with α1B- or
β2-adrenoceptors that show increased cell-surface expression
[1993]. Recombinant α1D-adrenoceptors have been shown
in some heterologous systems to be mainly located intra-
cellularly but cell-surface localization is encouraged by trun-
cation of the N-terminus, or by co-expression of α1B- or
β2-adrenoceptors [706, 1993]. In blood vessels all three
α1-adrenoceptor subtypes are located on the surface and in-
tracellularly [1320, 1321]. Signalling is predominantly via
Gq/11 but α1-adrenoceptors also couple to Gi/o, Gs and G12/13.
Several α1A-adrenoceptor agonists display ligand directed sig-
nalling bias relative to noradrenaline [521]. There are also
differences between subtypes in coupling efﬁciency to different
pathways. In vascular smooth muscle, the potency of agonists is
related to the predominant subtype, α1D- conveying greater ago-
nist sensitivity than α1A-adrenoceptors [553].
Adrenoceptors, α2
ARC-239 and prazosin show selectivity for α2B- and α2C-
adrenoceptors over α2A-adrenoceptors.Oxymetazoline is a re-
duced efﬁcacy imidazoline agonist but also binds to non-GPCR
binding sites for imidazolines, classiﬁed as I1, I2 and I3 sites [406];
catecholamines have a low afﬁnity, while rilmenidine and mox-
onidine are selective ligands evoking hypotensive effects in vivo.
I1-imidazoline receptors cause central inhibition of sympathetic
tone, I2-imidazoline receptors are an allosteric binding site on
monoamine oxidase B, and I3-imidazoline receptors regulate
insulin secretion from pancreatic β-cells. α2A-adrenoceptor stim-
ulation reduces insulin secretion from β-islets [2171], with a
polymorphism in the 5’-UTR of the ADRA2A gene being associated
with increased receptor expression in β-islets and heightened sus-
ceptibility to diabetes [1673]. α2A- and α2C-adrenoceptors form
homodimers [1829]. Heterodimers between α2A- and either the
α2c-adrenoceptor or μ opioid peptide receptor exhibit altered
signalling and trafﬁcking properties compared to the individual
receptors [1829, 1931, 2036]. Signalling by α2-adrenoceptors is
primarily via Gi/o, although the α2A-adrenoceptor also couples to
Gs [487]. Imidazoline compounds display bias relative to each
other at the α2A-adrenoceptor [1544]. The noradrenaline reup-
take inhibitor desipramine acts directly on the α2A-adrenoceptor
to promote internalisation via recruitment of arrestin [385].
Adrenoceptors, β
[125I]ICYP can be used to deﬁne β1- or β2-adrenoceptors when
conducted in the presence of a β1- or β2-adrenoceptor-selective
antagonist. A ﬂuorescent analogue of CGP 12177 can be used to
study β2-adrenoceptors in living cells [88]. [125I]ICYP at higher
(nM) concentrations can be used to label β3-adrenoceptors in
systems with few if any other β-adrenoceptor subtypes. The
β3-adrenoceptor has an intron in the coding region, but splice
variants have only been described for the mouse [522], where
the isoforms display different signalling characteristics [850].
There are 3 β-adrenoceptors in turkey (termed the tβ, tβ3c and
tβ4c) that have a pharmacology that differs from the human
β-adrenoceptors [86]. Numerous polymorphisms have been
described for the β-adrenoceptors; some are associated with
signalling and trafﬁcking, altered susceptibility to disease and/or
altered responses to pharmacotherapy [1169]. All β-adrenoceptors
couple to Gs (activating adenylyl cyclase and elevating cAMP
levels), but also activate Gi and β-arrestin-mediated signalling.
Many β1- and β2-adrenoceptor antagonists are agonists at β3-
adrenoceptors (CL316243, CGP 12177 and carazolol). Many ‘an-
tagonists’ of cAMP accumulation, for example carvedilol and
bucindolol, weakly activate MAP kinase pathways [89, 523, 589,
590, 1721, 1722] and thus display ’protean agonism’. Bupranolol
acts as a neutral antagonist in most systems so far examined. Ag-
onists also display biased signalling at the β2-adrenoceptor via Gs
or arrestins [470]. X-ray crystal structures have been described of
the agonist bound [2075] and antagonist bound forms of the β1-
[2076], agonist-bound [328] and antagonist-bound forms of the
β2-adrenoceptor [1632, 1672], as well as a fully active agonist-
bound, Gs protein-coupled β2-adrenoceptor [1633]. Carvedilol
and bucindolol bind to a site on the β1-adrenoceptor involving
contacts in TM2, 3, and 7 and extracellular loop 2 that may facili-
tate coupling to arrestins [2076]. Compounds displaying arrestin-
biased signalling at the β2-adrenoceptor have a greater effect on
the conformation of TM7, whereas full agonists for Gs coupling
promote movement of TM5 and TM6 [1192]. Recent studies using
NMR spectroscopy demonstrate signiﬁcant conformational ﬂex-
ibility in the β2-adrenoceptor that is stabilized by both agonist
and G proteins highlighting the dynamic nature of interactions
with both ligand and downstream signalling partners [992, 1260,
1479]. Such ﬂexibility likely has consequences for our understand-
ing of biased agonism, and for the future therapeutic exploitation
of this phenomenon.
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Angiotensin receptors
G protein-coupled receptors → Angiotensin receptors
Overview: The actions of angiotensin II (AGT, P01019) (Ang II) are mediated by AT1 and AT2 receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Angiotensin receptors
[423, 950]), which have around 30% sequence similarity. The decapeptide angiotensin I (AGT, P01019), the octapeptide angiotensin II (AGT, P01019) and the heptapeptide angiotensin III (AGT, P01019)
are endogenous ligands. Losartan, candesartan, telmisartan, etc. are clinically used AT1 receptor blockers.
Nomenclature AT1 receptor AT2 receptor
HGNC, UniProt AGTR1, P30556 AGTR2, P50052
Endogenous agonists angiotensin II (AGT, P01019) [425, 2021], angiotensin III (AGT, P01019) [425] angiotensin III (AGT, P01019) [394, 425, 2105], angiotensin II (AGT,
P01019) [425, 1838, 2105], angiotensin-(1-7) (AGT, P01019) [194]
Selective agonists L-162,313 [1559] CGP42112 [194], [p-aminoPhe6]ang II [425, 1860] – Rat
Antagonists telmisartan (pIC50 8.4) [1303], olmesartan (pIC50 8.1) [1027] –
Selective antagonists candesartan (pIC50 9.5–9.7) [2021], EXP3174 (pIC50 7.4–9.5) [1965, 2021], eprosartan (pIC50 8.4–8.8) [492],
irbesartan (pIC50 8.7–8.8) [2021], losartan (pIC50 7.4–8.7) [425, 1965], valsartan (pIC50 8.6) [424], azilsartan
(pIC50 8.1–8.1) [1623, 1917]
PD123177 (pIC50 8.5–9.5) [305, 336, 478] – Rat, EMA401 (pIC50
8.5–9.3) [543, 1656, 1836], PD123319 (pKd 8.7–9.2) [425, 477,
2115]
Labelled ligands [3H]A81988 (Antagonist) (pKd 9.2) [725] – Rat, [
3H]L158809 (Antagonist) (pKd 9.2) [320] – Rat,
[3H]eprosartan (Antagonist) (pKd 9.1) [22] – Rat, [
3H]valsartan (Antagonist) (pIC50 8.8–9) [2034],
[125I]EXP985 (Antagonist) (pKd 8.8) [337] – Rat, [
3H]losartan (Antagonist) (pKd 8.2) [309] – Rat
[125I]CGP42112 (Agonist) [425, 2105, 2106]
Comments telmisartan and candesartan are also reported to be agonists of PPARγ [1877]. –
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Comments: AT1 receptors are predominantly coupled to Gq/11,
however they are also linked to arrestin recruitment and stimulate
G protein-independent arrestin signalling [1221]. Most species ex-
press a single AGTR1 gene, but two related agtr1a and agtr1b recep-
tor genes are expressed in rodents. The AT2 receptor counteracts
several of the growth responses initiated by the AT1 receptors. The
AT2 receptor is much less abundant than the AT1 receptor in adult
tissues and is upregulated in pathological conditions. AT1 receptor
antagonists bearing substituted 4-phenylquinoline moieties have
been synthesized, which bind to AT1 receptors with nanomolar
afﬁnity and are slightly more potent than losartan in functional
studies [275]. The antagonist activity of CGP42112 at the AT2 re-
ceptor has also been reported [1469]. The AT1 and bradykinin B2
receptors have been proposed to form a heterodimeric complex
[3]. There is also evidence for an AT4 receptor that speciﬁcally
binds angiotensin IV (AGT, P01019) and is located in the brain
and kidney. An additional putative endogenous ligand for the
AT4 receptor has been described (LVV-hemorphin (HBB, P68871),
a globin decapeptide) [1351].
Further reading on Angiotensin receptors
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Apelin receptor
G protein-coupled receptors → Apelin receptor
Overview: The apelin receptor (nomenclature as agreed by
the NC-IUPHAR Subcommittee on the apelin receptor
[1582]) responds to apelin, a 36 amino-acid peptide derived ini-
tially from bovine stomach. Apelin-36 (APLN, Q9ULZ1), apelin-13
(APLN, Q9ULZ1) and [Pyr1]apelin-13 (APLN, Q9ULZ1) are the
predominant endogenous ligands which are cleaved from a 77
amino-acid precursor peptide (APLN, Q9ULZ1) by a so far uniden-
tiﬁed enzymatic pathway [1938]. A second family of peptides dis-
covered independently and named Elabela [338] or Toddler, that
has little sequence similarity to apelin, has been proposed as a sec-
ond endogenous apelin receptor ligand [1542]. Structure-activity
relationship Elabela analogues have been decsribed [1406].
Nomenclature apelin receptor
HGNC, UniProt APLNR, P35414
Potency order of endogenous ligands [Pyr1]apelin-13 (APLN, Q9ULZ1) ≥ apelin-13 (APLN, Q9ULZ1) > apelin-36 (APLN, Q9ULZ1) [529, 1938]
Endogenous agonists apelin-13 (APLN, Q9ULZ1) [529, 824, 1315], apelin receptor early endogenous ligand (APELA, P0DMC3) [436], apelin-17 (APLN, Q9ULZ1) [496, 1315],
[Pyr1]apelin-13 (APLN, Q9ULZ1) [961, 1315], Elabela/Toddler-21 (APELA, P0DMC3) [2174], Elabela/Toddler-32 (APELA, P0DMC3) [2174], apelin-36 (APLN, Q9ULZ1)
[529, 824, 961, 1315], Elabela/Toddler-11 (APELA, P0DMC3) [2174]
Selective agonists CMF-019 (Biased agonist) [1639], MM07 (Biased agonist) [209]
Antagonists MM54 (pKi 8.2) [1227]
Labelled ligands [125I][Nle75,Tyr77]apelin-36 (human) (Agonist) [961], [125I][Glp65Nle75,Tyr77]apelin-13 (Agonist) [824], [125I](Pyr1)apelin-13 (Agonist) [955], [125I]apelin-13
(Agonist) [529], [3H](Pyr1)[Met(0)11]-apelin-13 (Agonist) [1315]
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Comments: Potency order determined for heterologously expressed human apelin receptor (pD2 values range from 9.5 to 8.6). The apelin receptor may also act as a co-receptor with CD4 for isolates of
human immunodeﬁciency virus, with apelin blocking this function [293]. A modiﬁed apelin-13 peptide, apelin-13(F13A) was reported to block the hypotensive response to apelin in rat in vivo [1132],
however, this peptide exhibits agonist activity in HEK293 cells stably expressing the recombinant apelin receptor [529].
Further reading on Apelin receptor
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Langelaan DN et al. (2009) Structural insight into G-protein coupled receptor binding by apelin.
Biochemistry 48: 537-48 [PMID:19123778]
O’Carroll AM et al. (2013) The apelin receptor APJ: journey from an orphan to a multifaceted reg-
ulator of homeostasis. J. Endocrinol. 219: R13-35 [PMID:23943882]
Pitkin SL et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIV. Apelin re-
ceptor nomenclature, distribution, pharmacology, and function. Pharmacol. Rev. 62: 331-42
[PMID:20605969]
Yang P et al. (2015) Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the
cardiovascular system. Trends Pharmacol. Sci. [PMID:26143239]
Bile acid receptor
G protein-coupled receptors → Bile acid receptor
Overview: The bile acid receptor (GPBA) responds to bile acids produced during the liver metabolism of cholesterol. Selective agonists are promising drugs for the treatment of metabolic disorders, such
as type II diabetes, obesity and atherosclerosis.
Nomenclature GPBA receptor
HGNC, UniProt GPBAR1, Q8TDU6
Potency order of endogenous ligands lithocholic acid > deoxycholic acid > chenodeoxycholic acid, cholic acid [960, 1278]
Selective agonists S-EMCA [1550] – Mouse, betulinic acid [621], oleanolic acid [1720]
Comments: The triterpenoid natural product betulinic acid has also been reported to inhibit inﬂammatory signalling through the NFκB pathway [1916]. Disruption of GPBA expression is reported to
protect from cholesterol gallstone formation [2031]. A new series of 5-phenoxy-1,3-dimethyl-1H-pyrazole-4-carboxamides have been reported as highly potent agonists [1204].
Further reading on Bile acid receptor
Duboc H et al. (2014) The bile acid TGR5 membrane receptor: from basic research to clinical appli-
cation. Dig Liver Dis 46: 302-12 [PMID:24411485]
Lefebvre P et al. (2009) Role of bile acids and bile acid receptors in metabolic regulation. Physiol.
Rev. 89: 147-91 [PMID:19126757]
Lieu T et al. (2014) GPBA: a GPCR for bile acids and an emerging therapeutic target for disorders of
digestion and sensation. Br. J. Pharmacol. 171: 1156-66 [PMID:24111923]
van Nierop FS et al. (2016) Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet
Diabetes Endocrinol [PMID:27639537]
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Bombesin receptors
G protein-coupled receptors → Bombesin receptors
Overview: Mammalian bombesin (Bn) receptors comprise 3
subtypes: BB1, BB2, BB3 (nomenclature recommended by
the NC-IUPHAR Subcommittee on bombesin receptors,
[900]). BB1 and BB2 are activated by the endogenous ligands
gastrin-releasing peptide (GRP, P07492) (GRP), neuromedin B
(NMB, P08949) (NMB) and GRP-(18-27) (GRP, P07492) (previously
named neuromedin C). Bombesin is a tetradecapeptide, originally
derived from amphibians. The three Bn receptor subtypes couple
primarily to the Gq/11 and G12/13 family of G proteins [900] (but
see also [908, 1995]). Each of these receptors is widely distributed
in the CNS and peripheral tissues [659, 900, 1590, 1626, 1626,
1715, 1715, 2208]. Activation of BB1 and BB2 receptors causes
a wide range of physiological actions, including the stimulation
of normal and neoplastic tissue growth, smooth-muscle contrac-
tion, appetite and feeding behavior, secretion and many central
nervous system effects [900, 901, 902, 1248, 1371, 1626, 1626].
A physiological role for the BB3 receptor has yet to be fully de-
ﬁned although recently studies using receptor knockout mice and
newly described agonists/antagonists suggest an important role in
glucose and insulin regulation, metabolic homeostasis, feeding,
regulation of body temperature and other CNS behaviors, obesity,
diabetes mellitus and growth of normal/neoplastic tissues [659,
1249, 1249, 1496, 1496, 2145].
Nomenclature BB1 receptor BB2 receptor BB3 receptor
HGNC, UniProt NMBR, P28336 GRPR, P30550 BRS3, P32247
Endogenous agonists neuromedin B (NMB, P08949) [900,
1626, 1995]
neuromedin C [1995], gastrin releasing peptide(14-27) (human) [1995] –
Selective agonists – – compound 8a [1194], compound 9g [1284],
MK-7725 [339], MK-5046 [1375, 1759],
[D-Tyr6,Apa-4Cl11,Phe13,Nle14]bombesin-(6-14)
[1263], compound 17c [1283], compound 9f
[1284], bag-1 [692], compound 22e [761], bag-2
[692]
Antagonists D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Nal-NH2
(pIC50 6.2–6.6) [658]
– –
Selective antagonists PD 176252 (pIC50 9.3–9.8) [658],
PD 168368 (pIC50 9.3–9.6) [658],
dNal-cyc(Cys-Tyr-dTrp-Orn-Val)-Nal-NH2
[D-Phe6, Leu13, Cpa14,ψ13-14]bombesin-(6-14) (pKi 9.8) [658], JMV641 (pIC50
9.3) [1970] – Mouse,
[(3-Ph-Pr6), His7,D-Ala11,D-Pro13,ψ13-14),Phe14]bombesin-(6-14) (pIC50 9.2)
[658, 1125], JMV594 (pIC50 8.9) [1199, 1970] – Mouse,
[D-Tpi6, Leu13 ψ (CH2NH)-Leu14]bombesin-(6-14) (pIC50 8.9) [658],
Ac-GRP-(20-26)-methylester (pIC50 8.7) [658]
bantag-1 (pIC50 8.6–8.7) [692, 1375], ML-18
(pIC50 5.3) [1370]
Labelled ligands [125I]BH-NMB (human, mouse, rat)
(Agonist), [125I][Tyr4]bombesin (Agonist)
[125I][D-Tyr6]bombesin-(6-13)-methyl ester (Selective Antagonist) (pKd 9.3)
[1262] – Mouse, [125I][Tyr4]bombesin (Agonist) [135], [125I]GRP (human)
(Agonist)
[3H]bag-2 (Agonist) [692] – Mouse,
[125I][D-Tyr6,β-Ala11,Phe13,Nle14]bombesin-(6-14)
(Agonist) [1264, 1375]
Comments: All three human subtypes may be activated by [D-Phe6,β-Ala11,Phe13,Nle14]bombesin-(6-14) [1264]. [D-Tyr6,Apa-4Cl11,Phe13,Nle14]bombesin-(6-14) has more than 200-fold selectivity for
BB3 receptors over BB1 and BB2 [1263, 1264, 1626, 1627].
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Further reading on Bombesin receptors
Ferreira CA et al. (2017) Radiolabeled bombesin derivatives for preclinical oncological imaging.
Biomed. Pharmacother. 87: 58-72 [PMID:28040598]
González N et al. (2015) Bombesin receptor subtype 3 as a potential target for obesity and diabetes.
Expert Opin. Ther. Targets 1-18 [PMID:26066663]
Jensen RT et al. (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin re-
ceptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and
disease states. Pharmacol. Rev. 60: 1-42 [PMID:18055507]
Jensen RT et al. (2013) Bombesin Peptides (Cancer). In Handbook of Biologically Active Peptides. 2nd
Revised edition. Edited by Kastin AJ: Elsevier: 506-511 [ISBN: 9780123850959]
Ramos-Álvarez I et al. (2015) Insights into bombesin receptors and ligands: Highlighting recent
advances. Peptides [PMID:25976083]
Sayegh AI. (2013) The role of bombesin and bombesin-related peptides in the short-term control of
food intake. Prog Mol Biol Transl Sci 114: 343-70 [PMID:23317790]
Bradykinin receptors
G protein-coupled receptors → Bradykinin receptors
Overview: Bradykinin (or kinin) receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Bradykinin (kinin) Receptors [1136]) are activated by the endogenous peptides
bradykinin (KNG1, P01042) (BK), [des-Arg9]bradykinin (KNG1, P01042), Lys-BK (kallidin (KNG1, P01042)), [des-Arg10]kallidin (KNG1, P01042), T-kinin (KNG1, P01042) (Ile-Ser-BK), [Hyp3]bradykinin
(KNG1, P01042) and Lys-[Hyp3]-bradykinin (KNG1, P01042). The variation in afﬁnity or inactivity of B2 receptor antagonists could reﬂect the existence of species homologues of B2 receptors.
Nomenclature B1 receptor B2 receptor
HGNC, UniProt BDKRB1, P46663 BDKRB2, P30411
Potency order of endogenous ligands [des-Arg10]kallidin (KNG1, P01042) > [des-Arg9]bradykinin (KNG1, P01042) = kallidin
(KNG1, P01042) > bradykinin (KNG1, P01042)
kallidin (KNG1, P01042) > bradykinin (KNG1, P01042) 
[des-Arg9]bradykinin (KNG1, P01042), [des-Arg10]kallidin (KNG1, P01042)
Endogenous agonists [des-Arg10]kallidin (KNG1, P01042) [72, 110, 919] –
Selective agonists [Sar,D-Phe8,des-Arg9]bradykinin [919] [Hyp3,Tyr(Me)8]BK, [Phe8,ψ (CH2-NH)Arg9]BK
Antagonists [Leu9,des-Arg10]kallidin (pKi 9.1–9.3) [72, 110] –
Selective antagonists B-9958 (pKi 9.2–10.3) [630, 1642], R-914 (pA2 8.6) [650], R-715 (pA2 8.5) [651] icatibant (pKi 10.2) [39], FR173657 (pA2 8.2) [1666], anatibant (pKi 8.2)
[1608]
Labelled ligands [125I]Hpp-desArg10HOE140 (pKd 10), [
3H]Lys-[des-Arg9]BK (Agonist),
[3H]Lys-[Leu8][des-Arg9]BK (Antagonist)
[3H]BK (human, mouse, rat) (Agonist) [2123] – Mouse, [3H]NPC17731
(Antagonist) (pKd 9.1–9.4) [2211, 2212], [
125I][Tyr8]bradykinin (Agonist)
Further reading on Bradykinin receptors
Campos MM et al. (2006) Non-peptide antagonists for kinin B1 receptors: new insights into their
therapeutic potential for the management of inﬂammation and pain. Trends Pharmacol. Sci. 27:
646-51 [PMID:17056130]
Duchene J et al. (2009) The kinin B(1) receptor and inﬂammation: new therapeutic target for car-
diovascular disease. Curr Opin Pharmacol 9: 125-31 [PMID:19124274]
Marceau F et al. (2004) Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov
3: 845-52 [PMID:15459675]
Paquet JL et al. (1999) Pharmacological characterization of the bradykinin B2 receptor: inter-species
variability and dissociation between binding and functional responses. Br. J. Pharmacol. 126:
1083-90 [PMID:10204994]
Thornton E et al. (2010) Kinin receptor antagonists as potential neuroprotective agents in central
nervous system injury. Molecules 15: 6598-618 [PMID:20877247]
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Calcitonin receptors
G protein-coupled receptors → Calcitonin receptors
Overview: This receptor family comprises a group of recep-
tors for the calcitonin/CGRP family of peptides. The calcitonin
(CT), amylin (AMY), calcitonin gene-related peptide (CGRP) and
adrenomedullin (AM) receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on CGRP, AM, AMY, and
CT receptors [755, 1600]) are generated by the genes CALCR
(which codes for the CT receptor) and CALCRL (which codes for
the calcitonin receptor-like receptor, CLR, previously known as
CRLR). Their function and pharmacology are altered in the pres-
ence of RAMPs (receptor activity-modifying proteins), which are
single TM domain proteins of ca. 130 amino acids, identiﬁed as a
family of three members; RAMP1, RAMP2 and RAMP3. There are
splice variants of the CT receptor; these in turn produce variants of
the AMY receptor [1600], some of which can be potently activated
by CGRP. The endogenous agonists are the peptides calcitonin
(CALCA, P01258), α-CGRP (CALCA, P06881) (formerly known as
CGRP-I), β-CGRP (CALCB, P10092) (formerly known as CGRP-II),
amylin (IAPP, P10997) (occasionally called islet-amyloid polypep-
tide, diabetes-associated polypeptide), adrenomedullin (ADM,
P35318) and adrenomedullin 2/intermedin (ADM2, Q7Z4H4).
There are species differences in peptide sequences, particularly for
the CTs. CTR-stimulating peptide {Pig} (CRSP) is another member
of the family with selectivity for the CT receptor but it is not ex-
pressed in humans [952]. Olcegepant (also known as BIBN4096BS,
pKi ˜10.5) and telcagepant (also known as MK0974, pKi ˜9) are the
most selective antagonists available, showing selectivity for CGRP
receptors, with a particular preference for those of primate origin.
CLR (calcitonin receptor-like receptor) by itself binds no known
endogenous ligand, but in the presence of RAMPs it gives receptors
for CGRP, adrenomedullin and adrenomedullin 2/intermedin.
Nomenclature CT receptor AMY1 receptor AMY2 receptor AMY3 receptor
HGNC, UniProt CALCR, P30988 – – –
Subunits – CT receptor, RAMP1 (Accessory protein) CT receptor, RAMP2
(Accessory protein)
CT receptor, RAMP3 (Accessory protein)
Potency order of endogenous ligands calcitonin (salmon) ≥ calcitonin (CALCA,
P01258) ≥ amylin (IAPP, P10997), α-CGRP
(CALCA, P06881) > adrenomedullin (ADM,
P35318), adrenomedullin 2/intermedin
(ADM2, Q7Z4H4)
calcitonin (salmon) ≥ amylin (IAPP, P10997)
≥ α-CGRP (CALCA, P06881) >
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) ≥ calcitonin (CALCA, P01258) >
adrenomedullin (ADM, P35318)
Poorly deﬁned calcitonin (salmon) ≥ amylin (IAPP, P10997)
> α-CGRP (CALCA, P06881) ≥
adrenomedullin 2/intermedin (ADM2,
Q7Z4H4) ≥ calcitonin (CALCA, P01258) >
adrenomedullin (ADM, P35318)
Endogenous agonists calcitonin (CALCA, P01258) [32, 62, 752,
1080, 1153, 1396]
α-CGRP (CALCA, P06881) [752, 1079, 1080,
1153, 2057], amylin (IAPP, P10997) [643]
amylin (IAPP,
P10997) [643]
amylin (IAPP, P10997) [643]
Sub/family-selective agonists pramlintide [643] pramlintide [643] – pramlintide [643]
Sub/family-selective antagonists CT-(8-32) (salmon) (pKd 9) [793], AC187
(pKi 7.2) [752]
AC187 (pKi 8) [752], CT-(8-32) (salmon)
(pKi 7.8) [752], olcegepant (pKd 7.2) [2057]
– CT-(8-32) (salmon) (pKi 7.9) [752], AC187
(pKi 7.7) [752]
Labelled ligands [125I]CT (human) (Agonist),
[125I]CT (salmon) (Agonist)
[125I]αCGRP (human) (Agonist),
[125I]BH-AMY (rat, mouse) (Agonist)
[125I]BH-AMY (rat,
mouse) (Agonist)
[125I]BH-AMY (rat, mouse) (Agonist)
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Nomenclature calcitonin
receptor-like receptor
CGRP receptor AM1 receptor AM2 receptor
HGNC, UniProt CALCRL, Q16602 – – –
Subunits – calcitonin receptor-like receptor, RAMP1
(Accessory protein)
calcitonin receptor-like receptor, RAMP2
(Accessory protein)
calcitonin receptor-like receptor, RAMP3
(Accessory protein)
Potency order of endogenous
ligands
– α-CGRP (CALCA, P06881) > adrenomedullin
(ADM, P35318) ≥ adrenomedullin 2/intermedin
(ADM2, Q7Z4H4) > amylin (IAPP, P10997) ≥
calcitonin (salmon)
adrenomedullin (ADM, P35318) >
adrenomedullin 2/intermedin (ADM2, Q7Z4H4)
> α-CGRP (CALCA, P06881), amylin (IAPP,
P10997) > calcitonin (salmon)
adrenomedullin (ADM, P35318) ≥
adrenomedullin 2/intermedin (ADM2, Q7Z4H4)
≥ α-CGRP (CALCA, P06881) > amylin (IAPP,
P10997) > calcitonin (salmon)
Endogenous agonists – β-CGRP (CALCB, P10092) [21, 1313], α-CGRP
(CALCA, P06881) [21, 1313]
adrenomedullin (ADM, P35318) [21, 1313] adrenomedullin (ADM, P35318) [21, 568]
Antagonists – olcegepant (pKi 10.7–11) [462, 753, 754, 929,
1256], telcagepant (pKi 9.1) [1706]
– –
Sub/family-selective
antagonists
– – AM-(22-52) (human) (pKi 7–7.8) [754] –
Labelled ligands – [125I]αCGRP (human) (Agonist),
[125I]αCGRP (mouse, rat) (Agonist)
[125I]AM (rat) (Agonist) [125I]AM (rat) (Agonist)
Comments: It is important to note that a complication with the
interpretation of pharmacological studies with AMY receptors in
transfected cells is that most of this work has likely used a mixed
population of receptors, encompassing RAMP-coupled CTR as well
as CTR alone. This means that although in binding assays human
calcitonin (CALCA, P01258) has low afﬁnity for 125I-AMY binding
sites, cells transfected with CTR and RAMPs can display potent
CT functional responses. Transfection of human CTR with any
RAMP can generate receptors with a high afﬁnity for both salmon
CT and AMY and varying afﬁnity for different antagonists [353,
752, 753]. The major human CTR splice variant (hCT(a), which
does not contain an insert) with RAMP1 (i.e. the AMY1(a) recep-
tor) has a high afﬁnity for CGRP [2057], unlike hCT(a)-RAMP3 (i.e.
AMY3(a) receptor) [353, 752]. Actions of CGRP at AMY (and the
AM2) receptors led to proposals for a CGRP2 receptor in early liter-
ature [755]. However, the AMY receptor phenotype is RAMP-type,
splice variant and cell-line-dependent [1376, 1614, 1964].
The ligands described have limited selectivity. Adrenomedullin
has appreciable afﬁnity for CGRP receptors. CGRP can show
signiﬁcant cross-reactivity at AMY receptors and AM2 receptors.
Adrenomedullin 2/intermedin also has high afﬁnity for the AM2
receptor [818]. CGRP-(8-37) acts as an antagonist of CGRP (pKi ˜
8) and inhibits some AM and AMY responses (pKi ˜6-7). It is weak
at CT receptors. Human AM-(22-52) has some selectivity towards
AM receptors, but with modest potency (pKi ˜ 7), limiting its use
[754]. Olcegepant shows the greatest selectivity between receptors
but still has signiﬁcant afﬁnity for AMY1 receptors [2057].
Gs is a prominent route for effector coupling for CLR and CTR but
other pathways (e.g. Ca2+, ERK, Akt), and G proteins can be acti-
vated [2056]. There is evidence that CGRP-RCP (a 148 amino-acid
hydrophilic protein, ASL (P04424) is important for the coupling
of CLR to adenylyl cyclase [524].
[125I]-Salmon CT is the most common radioligand for CT recep-
tors but it has high afﬁnity for AMY receptors and is also poorly
reversible. [125I]-Tyr0-CGRP is widely used as a radioligand for
CGRP receptors.
Further reading on Calcitonin receptors
Booe JM et al. (2015) Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective
Peptide Recognition by a G Protein-Coupled Receptor. Mol. Cell 58: 1040-52 [PMID:25982113]
Hay DL et al. (2015) Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol. Rev. 67:
564-600 [PMID:26071095]
Hay DL et al. (2016) Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles. Annu.
Rev. Pharmacol. Toxicol. 56: 469-87 [PMID:26514202]
Kato J et al. (2015) Bench-to-bedside pharmacology of adrenomedullin. Eur. J. Pharmacol. 764:
140-8 [PMID:26144371]
Russell FA et al. (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol.
Rev. 94: 1099-142 [PMID:25287861]
Russo AF. (2015) Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu. Rev.
Pharmacol. Toxicol. 55: 533-52 [PMID:25340934]
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Calcium-sensing receptor
G protein-coupled receptors → Calcium-sensing receptor
Overview: The calcium-sensing receptor (CaS, provisional
nomenclature as recommended by NC-IUPHAR [557])
responds to multiple endogenous ligands, including extracel-
lular calcium and other divalent/trivalent cations, polyamines
and polycationic peptides, L-amino acids (particularly L-Trp
and L-Phe), glutathione and various peptide analogues, ionic
strength and extracellular pH (reviewed in [1122]). While diva-
lent/trivalent cations, polyamines and polycations are CaS recep-
tor agonists [234, 1618], L-amino acids, glutamyl peptides, ionic
strength and pH are allosteric modulators of agonist function
[375, 557, 803, 1616, 1617]. Indeed, L-amino acids have been
identiﬁed as "co-agonists", with both concomitant calcium and
L-amino acid binding required for full receptor activation [623,
2205]. The sensitivity of the CaS receptor to primary agonists is
increased by elevated extracellular pH [270] or decreased extracel-
lular ionic strength [1617]. This receptor bears no sequence or
structural relation to the plant calcium receptor, also called CaS.
Nomenclature CaS receptor
HGNC, UniProt CASR, P41180
Amino-acid rank order of potency L-phenylalanine, L-tryptophan, L-histidine > L-alanine > L-serine, L-proline, L-glutamic acid > L-aspartic acid (not L-lysine, L-arginine, L-leucine and L-isoleucine) [375]
Cation rank order of potency Gd3+ > Ca2+ > Mg2+ [234]
Glutamyl peptide rank order of
potency
S-methylglutathione ≈ γGlu-Val-Gly > glutathione > γGlu-Cys [226, 1498, 2068]
Polyamine rank order of potency spermine > spermidine > putrescine [1618]
Allosteric modulators ATF 936 (Negative) (pIC50 8.9) [2109], encaleret (Negative) (pIC50 7.9) [1795], SB-423562 (Negative) (pIC50 7.1) [1074], ronacaleret (Negative) (pIC50 6.5–6.8) [92],
NPS 2143 (Negative) (pKB 6.2–6.7) [418, 1120, 1123], cinacalcet (Positive) (pKB 5.9–6.6) [378, 418, 1120, 1123], tecalcet (Positive) (pKB 6.2–6.6) [378, 418], AC265347
(Positive) (pKB 6.3–6.4) [378, 1120], calhex 231 (Negative) (pIC50 6.4) [1569], calindol (Positive) (pKB 6.3) [378]
Comments: The CaS receptor has a number of physiological
functions, but it is best known for its central role in parathy-
roid and renal regulation of extracellular calcium homeostasis
[728]. This is seen most clearly in patients with loss-of-function
CaS receptor mutations who develop familial hypocalciuric
hypercalcaemia (heterozygous mutations) or neonatal severe
hyperparathyroidism (heterozygous, compound heterozygous or
homozygous mutations) [728] and in Casr null mice [307, 803],
which exhibit similar increases in PTH secretion and blood cal-
cium levels. Gain-of-function CaS mutations are associated with
autosomal dominant hypocalcaemia and Bartter syndrome type V
[728].
The CaS receptor primarily couples to Gq/11, G12/13 and Gi/o [418,
634, 836, 1954], but in some cell types can couple to Gs [1258].
However, the CaS receptor can form heteromers with Class C
GABAB [308, 327] and mGlu1/5 receptors [595], which may in-
troduce further complexity in its signalling capabilities.
Multiple other small molecule chemotypes are positive and nega-
tive allosteric modulators of the CaS receptor [980, 1441]. Further,
etelcalcetide is a novel peptide agonist of the receptor [2059]. Ag-
onists and positive allosteric modulators of the CaS receptor are
termed Type I and II calcimimetics, respectively, and can suppress
parathyroid hormone (PTH (PTH, P01270)) secretion [1443]. Neg-
ative allosteric modulators are called calcilytics and can act to in-
crease PTH (PTH, P01270) secretion [1442].
Where functional pKB values are provided for allosteric modu-
lators, this refers to ligand afﬁnity determined in an assay that
measures a functional readout of receptor activity (i.e. a receptor
signalling assay), as opposed to afﬁnity determined in a radioli-
gand binding assay. The functional pKB may differ depending on
the signalling pathway studied. Consult the ’More detailed page’
for the assay description, as well as other functional readouts.
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Further reading on Calcium-sensing receptor
Breitwieser GE. (2012) Minireview: the intimate link between calcium sensing receptor trafﬁcking
and signaling: implications for disorders of calcium homeostasis. Mol. Endocrinol. 26: 1482-95
[PMID:22745192]
Brown EM. (2013) Role of the calcium-sensing receptor in extracellular calcium homeostasis. Best
Pract. Res. Clin. Endocrinol. Metab. 27: 333-43 [PMID:23856263]
Conigrave AD et al. (2013) Calcium-sensing receptor (CaSR): pharmacological properties and sig-
naling pathways. Best Pract. Res. Clin. Endocrinol. Metab. 27: 315-31 [PMID:23856262]
Nemeth EF et al. (2013) Calcimimetic and calcilytic drugs for treating bone and mineral-related
disorders. Best Pract. Res. Clin. Endocrinol. Metab. 27: 373-84 [PMID:23856266]
Cannabinoid receptors
G protein-coupled receptors → Cannabinoid receptors
Overview: Cannabinoid receptors (nomenclature
as agreed by the NC-IUPHAR Subcommittee on
Cannabinoid Receptors [1564]) are activated by en-
dogenous ligands that include N-arachidonoylethanolamine
(anandamide), N-homo-γ-linolenoylethanolamine,
N-docosatetra-7,10,13,16-enoylethanolamine and
2-arachidonoylglycerol. Potency determinations of endogenous
agonists at these receptors are complicated by the possibility of
differential susceptibility of endogenous ligands to enzymatic
conversion [35].
There are currently three licenced cannabinoid medicines each of
which contains a compound that can activate CB1 and CB2 re-
ceptors [1562]. Two of these medicines were developed to sup-
press nausea and vomiting produced by chemotherapy. These
are nabilone (Cesamet®), a synthetic CB1/CB2 receptor ago-
nist, and synthetic 9-tetrahydrocannabinol (Marinol®; dron-
abinol), which can also be used as an appetite stimulant. The third
medicine, Sativex®, contains mainly 9-tetrahydrocannabinol
and cannabidiol, both extracted from cannabis, and is used to
treat multiple sclerosis and cancer pain.
Nomenclature CB1 receptor CB2 receptor
HGNC, UniProt CNR1, P21554 CNR2, P34972
Agonists cannabinol (Partial agonist) [535, 1801] –
Sub/family-selective agonists HU-210 [535, 1801], CP55940 [535, 1676, 1801], WIN55212-2 [535, 1798, 1801],
9-tetrahydrocannabinol (Partial agonist) [535, 1801]
HU-210 [535, 1653, 1801], WIN55212-2 [535, 1798, 1801], CP55940 [535, 1676,
1801], 9-tetrahydrocannabinol (Partial agonist) [113, 535, 1653, 1801]
Selective agonists arachidonyl-2-chloroethylamide [791] – Rat, arachidonylcyclopropylamide [791] – Rat,
O-1812 [443] – Rat, R-(+)-methanandamide [976] – Rat
JWH-133 [844, 1563], L-759,633 [607, 1676], AM1241 [2175], L-759,656 [607,
1676], HU-308 [734]
Selective antagonists rimonabant (pKi 7.9–8.7) [534, 535, 1660, 1687, 1801], AM251 (pKi 8.1) [1094] –
Rat, AM281 (pKi 7.9) [1093] – Rat, LY320135 (pKi 6.9) [534]
SR144528 (pKi 8.3–9.2) [1661, 1676], AM-630 (pKi 7.5) [1676]
Allosteric modulators GAT100 (Negative) (pEC50 7.7) [1070], ZCZ011 (Positive) (pEC50 6.3) [857] – Mouse,
cannabidiol (Negative) [1100]
–
Labelled ligands [3H]rimonabant (Antagonist) (pKd 8.9–10) [211, 799, 932, 1568, 1662, 1811, 1948]
– Rat
–
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Comments: Both CB1 and CB2 receptors may be labelled with
[3H]CP55940 (0.5 nM; [1801]) and [3H]WIN55212-2 (2–2.4 nM;
[1826, 1852]). Anandamide is also an agonist at vanilloid recep-
tors (TRPV1) and PPARs [1484]. There is evidence for an allosteric
site on the CB1 receptor [1603]. All of the compounds listed as
antagonists behave as inverse agonists in some bioassay systems
[1564]. Forsome cannabinoid receptor ligands, additional pharma-
cological targets that include GPR55 and GPR119 have been iden-
tiﬁed [1564]. Moreover, GPR18, GPR55 and GPR119, although
showing little structural similarity to CB1 and CB2 receptors, re-
spond to endogenous agents that are structurally similar to the
endogenous cannabinoid ligands [1564].
Further reading on Cannabinoid receptors
Howlett AC et al. (2002) International Union of Pharmacology. XXVII. Classiﬁcation of cannabi-
noid receptors. Pharmacol. Rev. 54: 161-202 [PMID:12037135]
Pertwee RG. (2010) Receptors and channels targeted by synthetic cannabinoid receptor agonists
and antagonists. Curr. Med. Chem. 17: 1360-81 [PMID:20166927]
Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabi-
noid receptors and their ligands: beyond CB1 and CB2. Pharmacol. Rev. 62: 588-631
[PMID:21079038]
Chemerin receptor
G protein-coupled receptors → Chemerin receptor
Overview: The chemerin receptor (nomenclature as recommended by NC-IUPHAR [414]) is activated by the lipid-derived, anti-inﬂammatory ligand resolvin E1 (RvE1), which is the result of
sequential metabolism of EPA by aspirin-modiﬁed cyclooxygenase and lipoxygenase [60, 61]. In addition, two GPCRs for resolvin D1 (RvD1) have been identiﬁed, FPR2/ALX, the lipoxin A4 receptor, and
GPR32, an orphan receptor [1052].
Nomenclature chemerin receptor
HGNC, UniProt CMKLR1, Q99788
Potency order of endogenous ligands resolvin E1 > chemerin C-terminal peptide > 18R-HEPE > EPA [60]
Selective agonists resolvin E1
Labelled ligands [3H]resolvin E1 (Agonist) [60, 61]
Comments: CCX832 (structure not disclosed) is a selective antagonist, pKi=9.2 [969].
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Chemokine receptors
G protein-coupled receptors → Chemokine receptors
Overview: Chemokine receptors (nomenclature as agreed
by the NC-IUPHAR Subcommittee on Chemokine Recep-
tors [81, 1402, 1403]) comprise a large subfamily of 7TM pro-
teins that bind one or more chemokines, a large family of small
cytokines typically possessing chemotactic activity for leukocytes.
Chemokine receptors can be divided by function into two main
groups: G protein-coupled chemokine receptors, which mediate
leukocyte trafﬁcking, and "Atypical chemokine receptors", which
may signal through non-G protein-coupled mechanisms and act
as chemokine scavengers to downregulate inﬂammation or shape
chemokine gradients [81].
Chemokines in turn can be divided by structure into four sub-
classes by the number and arrangement of conserved cysteines.
CC (also known as β-chemokines; n= 28), CXC (also known as
α-chemokines; n= 17) and CX3C (n= 1) chemokines all have four
conserved cysteines, with zero, one and three amino acids separat-
ing the ﬁrst two cysteines respectively. C chemokines (n= 2) have
only the second and fourth cysteines found in other chemokines.
Chemokines can also be classiﬁed by function into homeostatic
and inﬂammatory subgroups. Most chemokine receptors are able
to bind multiple high-afﬁnity chemokine ligands, but the ligands
for a given receptor are almost always restricted to the same struc-
tural subclass. Most chemokines bind to more than one recep-
tor subtype. Receptors for inﬂammatory chemokines are typically
highly promiscuous with regard to ligand speciﬁcity, andmay lack
a selective endogenous ligand. G protein-coupled chemokine re-
ceptors are named acccording to the class of chemokines bound,
whereas ACKR is the root acronym for atypical chemokine re-
ceptors [82]. Listed are those human agonists with EC50 values
<50nM in either Ca2+ ﬂux or chemotaxis assays at human recom-
binant G protein-coupled chemokine receptors expressed inmam-
malian cell lines. There can be substantial cross-species differences
in the sequences of both chemokines and chemokine receptors,
and in the pharmacology and biology of chemokine receptors. En-
dogenous and microbial non-chemokine ligands have also been
identiﬁed for chemokine receptors. Many chemokine receptors
function as HIV co-receptors, but CCR5 is the only one demon-
strated to play an essential role in HIV/AIDS pathogenesis. The ta-
bles include both standard chemokine receptor names [2191] and
aliases. Numerical data quoted are typically pKi or pIC50 values
from radioligand binding to heterologously expressed receptors.
Nomenclature CCR1 CCR2 CCR3
HGNC, UniProt CCR1, P32246 CCR2, P41597 CCR3, P51677
Endogenous agonists CCL3 (CCL3, P10147) [342, 370, 783, 2228], CCL23
(CCL23, P55773) [342], CCL5 (CCL5, P13501) [370,
783], CCL7 (CCL7, P80098) [342, 703], CCL15 (CCL15,
Q16663) [387], CCL14 (CCL14, Q16627) [342], CCL13
(CCL13, Q99616), CCL8 (CCL8, P80075)
CCL2 (CCL2, P13500) [387, 1224, 1347, 1533,
1996], CCL13 (CCL13, Q99616) [1224, 1996],
CCL7 (CCL7, P80098) [387, 1224, 1996], CCL11
(CCL11, P51671) (Partial agonist) [1224, 1533],
CCL16 (CCL16, O15467)
CCL13 (CCL13, Q99616) [1385, 1996], CCL24 (CCL24, O00175)
[1385, 1533], CCL5 (CCL5, P13501) [409], CCL7 (CCL7, P80098)
[409], CCL11 (CCL11, P51671) [480, 1009, 1385, 1700, 1996],
CCL26 (CCL26, Q9Y258) [1009, 1385, 1533], CCL15 (CCL15,
Q16663) [387], CCL28 (CCL28, Q9NRJ3), CCL8 (CCL8, P80075)
Agonists – – CCL11 {Mouse} [409]
Endogenous antagonists CCL4 (CCL4, P13236) (pKi 7.1–7.8) [342, 370] CCL26 (CCL26, Q9Y258) (pIC50 8.5) [1533] CXCL10 (CXCL10, P02778), CXCL11 (CXCL11, O14625), CXCL9
(CXCL9, Q07325)
Selective antagonists BX 471 (pKi 8.2–9) [1164], compound 2b-1 (pIC50
8.7) [1429], UCB35625 (pIC50 8) [1700], CP-481,715
(pKd 8) [646]
GSK Compound 34 (pKi 7.6) banyu (I) (Inverse agonist) (pKi 8.5) [2063], SB328437 (pKi 8.4),
BMS compound 87b (pKi 8.1) [2048]
Labelled ligands [125I]CCL7 (human) (Agonist) [131],
[125I]CCL3 (human) (Agonist) [131, 656, 1719],
[125I]CCL5 (human) (Agonist) [1719]
[125I]CCL2 (human) (Agonist),
[125I]CCL7 (human) (Agonist)
[125I]CCL11 (human) (Antagonist) (pKd 8.3) [2063],
[125I]CCL5 (human) (Agonist), [125I]CCL7 (human) (Agonist)
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Nomenclature CCR4 CCR5 CCR6 CCR7 CCR8 CCR9 CCR10
HGNC, UniProt CCR4, P51679 CCR5, P51681 CCR6, P51684 CCR7, P32248 CCR8, P51685 CCR9, P51686 CCR10, P46092
Endogenous agonists CCL22 (CCL22,
O00626) [862],
CCL17 (CCL17,
Q92583) [862]
CCL5 (CCL5, P13501) [78, 1424,
1685], CCL4 (CCL4, P13236) [1424,
1685], CCL8 (CCL8, P80075) [1685],
CCL3 (CCL3, P10147) [1424, 1685,
2228], CCL11 (CCL11, P51671)
[161], CCL2 (CCL2, P13500) [1424],
CCL14 (CCL14, Q16627) [1424],
CCL16 (CCL16, O15467)
CCL20 (CCL20,
P78556) [20, 77,
1598],
beta-defensin 4A
(DEFB4A DEFB4B,
O15263) [2169]
CCL21 (CCL21,
O00585) [2189],
CCL19 (CCL19,
Q99731) [1517,
2188, 2189]
CCL1 (CCL1,
P22362) [403, 745,
863], CCL8 {Mouse}
– Mouse
CCL25 (CCL25,
O15444)
CCL27 (CCL27,
Q9Y4X3) [816],
CCL28 (CCL28,
Q9NRJ3)
Agonists vMIP-III R5-HIV-1 gp120 – – vMIP-I [403, 863] – –
Endogenous
antagonists
– CCL7 (CCL7, P80098) (pKi 7.5)
[1424]
– – – – –
Antagonists – vicriviroc (pKi 9.1) [1879], ancriviroc
(pKi 7.8–8.7) [1237, 1523, 1879]
– – – – –
Selective antagonists compound 8ic
(pIC50 7.7) [2186],
plerixafor (pIC50
6.2) [577]
E913 (pIC50 8.7) [1238], aplaviroc
(pKi 8.5) [1237], maraviroc (pIC50
8.1) [1424], TAK-779 (pKi 7.5)
[1237], MRK-1 [1073] – Rat
– – vMCC-I (pIC50 9.4)
[403]
– –
Selective allosteric
modulators
– – – – – vercirnon
(Antagonist) (pIC50
8.2) [2060]
–
Antibodies mogamulizumab
(Inhibition) [54,
1799]
– – – – – –
Labelled ligands [125I]CCL17
(human) (Agonist),
[125I]CCL27
(human) (Agonist)
[125I]CCL4 (human) (Agonist)
[1424], [125I]CCL3 (human)
(Agonist), [125I]CCL5 (human)
(Agonist), [125I]CCL8 (human)
(Agonist)
[125I]CCL20 (human)
(Agonist) [675]
[125I]CCL19 (human)
(Agonist),
[125I]CCL21 (human)
(Agonist) [899]
[125I]CCL1 (human)
(Agonist) [863,
1671]
[125I]CCL25 (human)
(Agonist)
–
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Nomenclature CXCR1 CXCR2 CXCR3 CXCR4 CXCR5 CXCR6 CX3CR1
HGNC, UniProt CXCR1, P25024 CXCR2, P25025 CXCR3, P49682 CXCR4, P61073 CXCR5, P32302 CXCR6, O00574 CX3CR1, P49238
Endogenous agonists CXCL8 (CXCL8,
P10145) [145, 711,
1133, 2121, 2137],
CXCL6 (CXCL6,
P80162) [2141]
CXCL1 (CXCL1, P09341) [711, 1133,
2137], CXCL8 (CXCL8, P10145) [145,
711, 1133, 2121, 2137], CXCL7
(PPBP, P02775) [18], CXCL3 (CXCL3,
P19876) [18], CXCL2 (CXCL2,
P19875) [18], CXCL5 (CXCL5,
P42830) [18], CXCL6 (CXCL6,
P80162) [2141]
CXCL11 (CXCL11,
O14625) [768],
CXCL10 (CXCL10,
P02778) [768, 2093],
CXCL9 (CXCL9,
Q07325) [768, 2093]
CXCL12α (CXCL12,
P48061) [782,
1202], CXCL12β
(CXCL12, P48061)
[782]
CXCL13 (CXCL13,
O43927) [103]
CXCL16
(CXCL16,
Q9H2A7) [2116]
CX3CL1
(CX3CL1,
P78423) [608]
Agonists vCXCL1 [1223],
HIV-1
matrix protein p17
[637]
vCXCL1 [1223],
HIV-1 matrix protein p17 [637]
– – – – –
Selective agonists – – – ALX40-4C (Partial
agonist) [2213],
X4-HIV-1 gp120
– – –
Endogenous antagonists – – CCL11 (CCL11,
P51671) (pKi 7.2)
[2093], CCL7 (CCL7,
P80098) (pKi 6.6)
[2093]
– – – –
Antagonists – – – plerixafor (pKi 7)
[2213]
– – –
Selective antagonists – navarixin (pIC50 10.3) [81, 484],
danirixin (pIC50 7.9) [1343],
SB 225002 (pIC50 7.7) [2103],
elubirixin (pIC50 7.7) [81], SX-517
(pIC50 7.2) [1236]
– T134 (pIC50 8.4)
[1929], X4P-001
(pIC50 7.9) [1819],
HIV-Tat
– – –
Allosteric modulators reparixin (Negative)
(pIC50 9) [145]
reparixin (Negative) (pIC50 6.4) [145] – – – – –
Labelled ligands [125I]CXCL8 (human)
(Agonist) [711, 1658]
[125I]CXCL8 (human) (Agonist) [711,
1658], [125I]CXCL1 (human)
(Agonist), [125I]CXCL5 (human)
(Agonist), [125I]CXCL7 (human)
(Agonist)
[125I]CXCL10 (human)
(Agonist),
[125I]CXCL11 (human)
(Agonist)
[125I]CXCL12α
(human) (Agonist)
[444, 782]
[125I]CXCL13
(mouse) (Agonist)
[227] – Mouse
[125I]CXCL16
(human)
(Agonist)
[125I]CX3CL1
(human)
(Agonist)
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Nomenclature XCR1 ACKR1 ACKR2 ACKR3 ACKR4 CCRL2
HGNC, UniProt XCR1, P46094 ACKR1, Q16570 ACKR2, O00590 ACKR3, P25106 ACKR4, Q9NPB9 CCRL2, O00421
Endogenous ligands – CXCL5 (CXCL5, P42830), CXCL6 (CXCL6,
P80162), CXCL8 (CXCL8, P10145),
CXCL11 (CXCL11, O14625), CCL2 (CCL2,
P13500), CCL5 (CCL5, P13501), CCL7
(CCL7, P80098), CCL11 (CCL11, P51671),
CCL14 (CCL14, Q16627), CCL17 (CCL17,
Q92583)
– – – chemerin
C-terminal
peptide, CCL19
(CCL19, Q99731)
[101]
Endogenous agonists XCL1 (XCL1, P47992)
[564], XCL2 (XCL2,
Q9UBD3) [564]
– CCL2 (CCL2, P13500), CCL3 (CCL3,
P10147), CCL4 (CCL4, P13236), CCL5
(CCL5, P13501), CCL7 (CCL7,
P80098), CCL8 (CCL8, P80075),
CCL11 (CCL11, P51671), CCL13
(CCL13, Q99616), CCL14 (CCL14,
Q16627), CCL17 (CCL17, Q92583),
CCL22 (CCL22, O00626)
CXCL12α (CXCL12,
P48061) [674, 1854],
CXCL11 (CXCL11,
O14625)
CCL19 (CCL19,
Q99731) [2085],
CCL25 (CCL25,
O15444) [2085],
CCL21 (CCL21,
O00585) [2085]
–
Comments XCL1 cannot be
iodinated, but a
secreted alkaline
phophatase
(SEAP)-XCL1 fusion
peptide can be used
as a probe at XCR1.
ACKR1 is used by Plasmodium vivax and
Plasmodium knowlsei for entering
erythrocytes.
– Several lines of evidence
have suggested that
adrenomedullin is a
ligand for ACKR3;
however, classical direct
binding to the receptor
has not yet been
convincingly
demonstrated.
– –
Comments: Speciﬁc chemokine receptors facilitate cell entry
by microbes, such as ACKR1 for Plasmodium vivax, and CCR5
and CXCR4 for HIV-1. Virally encoded chemokine receptors
are known (e.g. US28, a homologue of CCR1 from human cy-
tomegalovirus and ORF74, which encodes a homolog of CXCR2
in Herpesvirus saimiri and gamma-Herpesvirus-68), but their role
in viral life cycles is not established. Viruses can exploit or subvert
the chemokine system by producing chemokine antagonists and
scavengers. Two chemokine receptor antagonists have now been
approved by the FDA: the CCR5 antagonist maraviroc (Pﬁzer) for
treatment of HIV/AIDS in patients with CCR5-using strains; and
the CXCR4 antagonist plerixafor (Sanoﬁ) for hematopoietic stem
cell mobilization with G-CSF (CSF3, P09919) in patients undergo-
ing transplantation in the context of chemotherapy for Hodgkins’
Disease and multiple myeloma.
Further reading on Chemokine receptors
Bachelerie F et al. (2015) An atypical addition to the chemokine receptor nomenclature: IUPHAR
Review "15". Br. J. Pharmacol. [PMID:25958743]
Koelink PJ et al. (2012) Targeting chemokine receptors in chronic inﬂammatory diseases: an exten-
sive review. Pharmacol. Ther. 133: 1-18 [PMID:21839114]
Murphy PM. (2002) International Union of Pharmacology. XXX. Update on chemokine receptor
nomenclature. Pharmacol. Rev. 54: 227-9 [PMID:12037138]
Murphy PM et al. (2000) International Union of Pharmacology. XXII. Nomenclature for chemokine
receptors. Pharmacol. Rev. 52: 145-176 [PMID:10699158]
Scholten DJ et al. (2012) Pharmacological modulation of chemokine receptor function. Br. J. Phar-
macol. 165: 1617-43 [PMID:21699506]
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Cholecystokinin receptors
G protein-coupled receptors → Cholecystokinin receptors
Overview: Cholecystokinin receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on CCK
receptors [1471]) are activated by the endogenous pep-
tides cholecystokinin-8 (CCK-8 (CCK, P06307)), CCK-33 (CCK,
P06307), CCK-58 (CCK, P06307) and gastrin (gastrin-17 (GAST,
P01350)). There are only two distinct subtypes of CCK recep-
tors, CCK1 and CCK2 receptors [1038, 2073], with some alter-
natively spliced forms most often identiﬁed in neoplastic cells.
The CCK receptor subtypes are distinguished by their peptide se-
lectivity, with the CCK1 receptor requiring the carboxyl-terminal
heptapeptide-amide that includes a sulfated tyrosine for high
afﬁnity and potency, while the CCK2 receptor requires only the
carboxyl-terminal tetrapeptide shared by each CCK and gastrin
peptides. These receptors have characteristic and distinct distribu-
tions, with both present in both the central nervous system and
peripheral tissues.
Nomenclature CCK1 receptor CCK2 receptor
HGNC, UniProt CCKAR, P32238 CCKBR, P32239
Potency order of endogenous ligands CCK-8 (CCK, P06307)  gastrin-17 (GAST, P01350),
desulfated cholecystokinin-8 > CCK-4 (CCK, P06307)
CCK-8 (CCK, P06307) ≥ gastrin-17 (GAST, P01350), desulfated cholecystokinin-8, CCK-4 (CCK, P06307)
Endogenous agonists – desulfated cholecystokinin-8 [1135], gastrin-17 (GAST, P01350) [845] – Mouse, CCK-4 (CCK, P06307)
[871], desulfated gastrin-14 (GAST, P01350), desulfated gastrin-17 (GAST, P01350),
desulfated gastrin-34 (GAST, P01350), desulfated gastrin-71 (GAST, P01350), gastrin-14 (GAST,
P01350), gastrin-34 (GAST, P01350), gastrin-71 (GAST, P01350)
Selective agonists A-71623 [67] – Rat, JMV180 [971], GW-5823 [772] RB-400 [129] – Rat, PBC-264 [886] – Rat
Antagonists lintitript (pIC50 8.3) [667] –
Selective antagonists devazepide (pIC50 9.7) [845] – Rat, T-0632 (pIC50 9.6)
[1935] – Rat, PD-140548 (pIC50 8.6) [1817] – Rat,
lorglumide (pIC50 6.7–8.2) [845, 875] – Rat
YF-476 (pIC50 9.7) [201, 1927], GV150013 (pIC50 9.4) [2006], L-740093 (pIC50 9.2) [1464], YM-022
(pIC50 9.2) [1464], JNJ-26070109 (pIC50 8.5) [1390], L-365260 (pIC50 8.4) [1135], RP73870 (pIC50 8)
[1181] – Rat, LY262691 (pIC50 7.5) [1632] – Rat
Labelled ligands [3H]devazepide (Antagonist) (pKd 9.7) [306],
[125I]DTyr-Gly-[(Nle28,31)CCK-26-33 (Agonist) [1599]
[3H]PD140376 (Antagonist) (pKi 9.7–10) [849] – Guinea pig, [
125I]PD142308 (Antagonist) (pKd 9.6)
[820] – Guinea pig, [125I]DTyr-Gly-[(Nle28,31)CCK-26-33 (Agonist) [1599], [125I]gastrin (Agonist),
[3H]gastrin (Agonist), [3H]L365260 (Antagonist) (pKd 8.2–8.5) [1464], [
125I]-BDZ2 (Antagonist) (pKi
8.4) [25]
Comments: While a cancer-speciﬁc CCK receptor has been pos-
tulated to exist, which also might be responsive to incompletely
processed forms of CCK (Gly-extended forms), this has never been
isolated. An alternatively spliced form of the CCK2 receptor in
which intron 4 is retained, adding 69 amino acids to the intracel-
lular loop 3 (ICL3) region, has been described to be present par-
ticularly in certain neoplasms where mRNA mis-splicing has been
commonly observed [1833], but it is not clear that this receptor
splice form plays a special role in carcinogenesis. Another alter-
native splicing event for the CCK2 receptor was reported [1850],
with alternative donor sites in exon 4 resulting in long (452 amino
acids) and short (447 amino acids) forms of the receptor differing
by ﬁve residues in ICL3, however, no clear functional differences
have been observed.
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Further reading on Cholecystokinin receptors
Cawston EE et al. (2010) Therapeutic potential for novel drugs targeting the type 1 cholecystokinin
receptor. Br. J. Pharmacol. 159: 1009-21 [PMID:19922535]
Dockray GJ. (2009) Cholecystokinin and gut-brain signalling. Regul. Pept. 155: 6-10
[PMID:19345244]
Dufresne M et al. (2006) Cholecystokinin and gastrin receptors. Physiol. Rev. 86: 805-47
[PMID:16816139]
Miller LJ et al. (2008) Structural basis of cholecystokinin receptor binding and regulation. Pharma-
col. Ther. 119: 83-95 [PMID:18558433]
Class Frizzled GPCRs
G protein-coupled receptors → Class Frizzled GPCRs
Overview: Receptors of the Class Frizzled (FZD, nomencla-
ture as agreed by the NC-IUPHAR subcommittee on the
Class Frizzled GPCRs [1747]), are GPCRs originally identiﬁed
in Drosophila [300], which are highly conserved across species.
While SMO shows structural resemblance to the 10 FZDs, it is
functionally separated as it mediates effects in the Hedgehog sig-
naling pathway [1747]. FZDs are activated by WNTs, which are
cysteine-rich lipoglycoproteins with fundamental functions in
ontogeny and tissue homeostasis. FZD signalling was initially
divided into two pathways, being either dependent on the ac-
cumulation of the transcription regulator β-catenin (CTNNB1,
P35222) or being β-catenin-independent (often referred to as
canonical vs. non-canonical WNT/FZD signalling, respectively).
WNT stimulation of FZDs can, in cooperation with the low den-
sity lipoprotein receptors LRP5 (O75197) and LRP6 (O75581), lead
to the inhibition of a constitutively active destruction complex,
which results in the accumulation of β-catenin and subsequently
its translocation to the nucleus. β-Catenin, in turn, modiﬁes gene
transcription by interacting with TCF/LEF transcription factors.
β-Catenin-independent FZD signalling is far more complex with
regard to the diversity of the activated pathways. WNT/FZD
signalling can lead to the activation of heterotrimeric G proteins
[447], the elevation of intracellular calcium [1828], activation of
cGMP-speciﬁc PDE6 [19] and elevation of cAMP as well as RAC-1,
JNK, Rho and Rho kinase signalling [730]. Furthermore, the phos-
phoprotein Dishevelled constitutes a key player in WNT/FZD sig-
nalling. As with other GPCRs, members of the Frizzled family are
functionally dependent on the arrestin scaffolding protein for in-
ternalization [321], as well as for β-catenin-dependent [242] and
-independent [243, 986] signalling. The pattern of cell signalling is
complicated by the presence of additional ligands, which can en-
hance or inhibit FZD signalling (secreted Frizzled-related proteins
(sFRP), Wnt-inhibitory factor (WIF1, Q9Y5W5) (WIF), sclerostin
(SOST, Q9BQB4) or Dickkopf (DKK)), as well as modulatory (co)-
receptors with Ryk, ROR1, ROR2 and Kremen, which may also
function as independent signalling proteins.
Nomenclature FZD1 FZD2 FZD3 FZD4 FZD5 FZD6 FZD7
HGNC, UniProt FZD1, Q9UP38 FZD2, Q14332 FZD3, Q9NPG1 FZD4, Q9ULV1 FZD5, Q13467 FZD6, O60353 FZD7, O75084
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Nomenclature FZD8 FZD9 FZD10 SMO
HGNC, UniProt FZD8, Q9H461 FZD9, O00144 FZD10, Q9ULW2 SMO, Q99835
Antagonists – – – saridegib (pIC50 8.9) [1981], glasdegib (pIC50 8.3) [1398], sonidegib (pKi 8.2) [2065]
Selective antagonists – – – vismodegib (pKi 7.8) [2065]
Comments: There is limited knowledge about WNT/FZD speci-
ﬁcity and which molecular entities determine the signalling out-
come of a speciﬁc WNT/FZD pair. Understanding of the coupling
to G proteins is incomplete (see [447]). There is also a scarcity
of information on basic pharmacological characteristics of FZDs,
such as binding constants, ligand speciﬁcity or concentration-
response relationships [984].
Ligands associated with FZD signalling
WNTs: Wnt-1 (WNT1, P04628), Wnt-2 (WNT2, P09544) (also
known as Int-1-related protein), Wnt-2b (WNT2B, Q93097) (also
known as WNT-13), Wnt-3 (WNT3, P56703) , Wnt-3a (WNT3A,
P56704), Wnt-4 (WNT4, P56705), Wnt-5a (WNT5A, P41221) ,
Wnt-5b (WNT5B, Q9H1J7), Wnt-6 (WNT6, Q9Y6F9), Wnt-7a
(WNT7A, O00755), Wnt-7b (WNT7B, P56706), Wnt-8a (WNT8A,
Q9H1J5), Wnt-8b (WNT8B, Q93098), Wnt-9a (WNT9A, O14904)
(also known as WNT-14), Wnt-9b (WNT9B, O14905) (also known
as WNT-15 or WNT-14b), Wnt-10a (WNT10A, Q9GZT5), Wnt-10b
(WNT10B, O00744) (also known as WNT-12), Wnt-11 (WNT11,
O96014) and Wnt-16 (WNT16, Q9UBV4).
Extracellular proteins that interact with FZDs: norrin
(NDP, Q00604), R-spondin-1 (RSPO1, Q2MKA7), R-spondin-2
(RSPO2, Q6UXX9) , R-spondin-3 (RSPO3, Q9BXY4), R-spondin-4
(RSPO4, Q2I0M5), sFRP-1 (SFRP1, Q8N474), sFRP-2 (SFRP2,
Q96HF1), sFRP-3 (FRZB, Q92765), sFRP-4 (SFRP4, Q6FHJ7), sFRP-5
(SFRP5, Q6FHJ7).
Extracellular proteins that interact with WNTs or
LRPs: Dickkopf 1 (DKK1, O94907), WIF1 (Q9Y5W5), sclerostin
(SOST, Q9BQB4), kremen 1 (KREMEN1, Q96MU8) and kremen 2
(KREMEN2, Q8NCW0)
Small exogenous ligands: Foxy-5 [1910], Box-5, UM206 [1086],
and XWnt8 (P28026) also known as mini-Wnt8.
Further reading on Class Frizzled GPCRs
Angers S et al. (2009) Proximal events in Wnt signal transduction. Nat. Rev. Mol. Cell Biol. 10:
468-77 [PMID:19536106]
Schulte G. (2015) Frizzleds and WNT/β-catenin signaling–The black box of ligand-receptor se-
lectivity, complex stoichiometry and activation kinetics. Eur. J. Pharmacol. 763: 191-5
[PMID:26003275]
van Amerongen R. (2012) Alternative Wnt pathways and receptors. Cold Spring Harb Perspect Biol 4:
[PMID:22935904]
Wang Y et al. (2016) Frizzled Receptors in Development and Disease. Curr. Top. Dev. Biol. 117:
113-39 [PMID:26969975]
Complement peptide receptors
G protein-coupled receptors → Complement peptide receptors
Overview: Complement peptide receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Complement peptide receptors [1015]) are activated by the endogenous ˜ 75
amino-acid anaphylatoxin polypeptides C3a (C3, P01024) and C5a (C5, P01031), generated upon stimulation of the complement cascade.
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Nomenclature C3a receptor C5a1 receptor C5a2 receptor
HGNC, UniProt C3AR1, Q16581 C5AR1, P21730 C5AR2, Q9P296
Potency order of endogenous ligands C3a (C3, P01024) > C5a (C5, P01031) [41] C5a (C5, P01031), C5a des-Arg (C5) > C3a (C3, P01024) [41] –
Endogenous agonists – ribosomal protein S19 (RPS19, P39019) [2160] –
Agonists E7 [43], compound 17 [1644],
compound 21 [1643], Ac-RHYPLWR [707]
N-methyl-Phe-Lys-Pro-D-Cha-Cha-D-Arg-CO2H [959, 1035] –
Selective agonists – – P59 (Biased agonist) [396], P32
(Biased agonist) [396]
Antagonists SB290157 (pIC50 7.6) [40], compound 4
(pIC50 5.9) [1643]
avacopan (pIC50 9.7) [125], W54011 (pKi 8.7) [1893], DF2593A (pIC50 8.3)
[1380], AcPhe-Orn-Pro-D-Cha-Trp-Arg (pIC50 7.9) [2128],
N-methyl-Phe-Lys-Pro-D-Cha-Trp-D-Arg-CO2H (pIC50 7.2) [1035]
–
Labelled ligands [125I]C3a (human) (Agonist) [310] [125I]C5a (human) (Agonist) [843] [125I]C5a (human) (Agonist)
Comments: SB290157 has also been reported to have agonist
properties at the C3a receptor [1282]. The putative chemoattrac-
tant receptor termed C5a2 (also known as GPR77, C5L2) binds
[125I]C5a with no clear signalling function, but has a putative role
opposing inﬂammatory responses [267, 599, 616]. Binding to this
site may be displaced with the rank order C5a des-Arg (C5)> C5a
(C5, P01031) [267, 1508] while there is controversy over the abil-
ity of C3a (C3, P01024) and C3a des Arg (C3, P01024) to compete
[817, 936, 937, 1508]. C5a2 appears to lack G protein signalling
and has been termed a decoy receptor [1753]. However, C5a2 does
recruit arrestin after ligand binding, which might provide a sig-
naling pathway for this receptor [94, 2015], and forms heteromers
with C5a1. C5a, but not C5a-des Arg, induces upregulation of het-
eromer formation between complement C5a receptors C5a1 and
C5a2 [395]. There are also reports of pro-inﬂammatory activity of
C5a2, mediated by HMGB1, but the signaling pathway that under-
lies this is currently unclear (reviewed in [1161]). More recently,
work in T cells has shown that C5a1 and C5a2 act in opposition
to each other and that altering the equilibrium between the two
receptors, by differential expression or production of C5a-des Arg
(which favours C5a2), can affect the ﬁnal cellular response [57].
Further reading on Complement peptide receptors
Arbore G et al. (2016) A novel "complement-metabolism-inﬂammasome axis" as a key regulator of
immune cell effector function. Eur. J. Immunol. 46: 1563-73 [PMID:27184294]
Klos A et al. (2013) International Union of Pharmacology. LXXXVII. Complement peptide C5a,
C4a, and C3a receptors. Pharmacol. Rev. 65: 500-43 [PMID:23383423]
Li R et al. (2013) C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27:
855-64 [PMID:23239822]
Monk PN et al. (2007) Function, structure and therapeutic potential of complement C5a receptors.
Br. J. Pharmacol. 152: 429-48 [PMID:17603557]
Corticotropin-releasing factor receptors
G protein-coupled receptors → Corticotropin-releasing factor receptors
Overview: Corticotropin-releasing factor (CRF, nomen-
clature as agreed by the NC-IUPHAR subcommit-
tee on Corticotropin-releasing Factor Receptors
[750]) receptors are activated by the endogenous peptides
corticotrophin-releasing hormone (CRH, P06850), a 41 amino-
acid peptide, urocortin 1 (UCN, P55089), 40 amino-acids,
urocortin 2 (UCN2, Q96RP3), 38 amino-acids and urocortin 3
(UCN3, Q969E3), 38 amino-acids. CRF1 and CRF2 receptors are
activated non-selectively by corticotrophin-releasing hormone
(CRH, P06850) and urocortin 1 (UCN, P55089). Binding
to CRF receptors can be conducted using [125I]Tyr0-CRF or
[125I]Tyr0-sauvagine with Kd values of 0.1-0.4 nM. CRF1 and
CRF2 receptors are non-selectively antagonized by α-helical CRF,
D-Phe-CRF-(12-41) and astressin.
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Nomenclature CRF1 receptor CRF2 receptor
HGNC, UniProt CRHR1, P34998 CRHR2, Q13324
Endogenous agonists – urocortin 2 (UCN2, Q96RP3) [410], urocortin 3
(UCN3, Q969E3) [410]
Antagonists SSR125543A (pKi 8.7) [698] –
Selective antagonists CP 154,526 (pIC50 9.3–10.4) [1218] – Rat, DMP696 (pKi 8.3–9) [760], NBI27914 (pKi 8.3–9) [314], R121919 (pKi 8.3–9)
[2227], antalarmin (pKi 8.3–9) [2087], CP376395 (pIC50 8.3) [322] – Rat, CRA1000 (pIC50 6.4–7.1) [298]
antisauvagine (pKd 8.8–9.6) [412], K41498 (pKi 9.2)
[1105], K31440 (pKi 8.7–8.8) [1697]
Comments: A CRF binding protein has been identiﬁed (CRHBP, P24387) to which both corticotrophin-releasing hormone (CRH, P06850) and urocortin 1 (UCN, P55089) bind with high afﬁnities, which
has been suggested to bind and inactivate circulating corticotrophin-releasing hormone (CRH, P06850) [1558].
Further reading on Corticotropin-releasing factor receptors
Grammatopoulos DK. (2012) Insights into mechanisms of corticotropin-releasing hormone recep-
tor signal transduction. Br. J. Pharmacol. 166: 85-97 [PMID:21883143]
Gysling K. (2012) Relevance of both type-1 and type-2 corticotropin releasing factor recep-
tors in stress-induced relapse to cocaine seeking behaviour. Biochem. Pharmacol. 83: 1-5
[PMID:21843515]
Hauger RL et al. (2003) International Union of Pharmacology. XXXVI. Current status of the nomen-
clature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev. 55:
21-26 [PMID:12615952]
Valentino RJ et al. (2013) Sex-biased stress signaling: the corticotropin-releasing factor receptor as
a model. Mol. Pharmacol. 83: 737-45 [PMID:23239826]
Zhu H et al. (2011) Corticotropin-releasing factor family and its receptors: pro-inﬂammatory or
anti-inﬂammatory targets in the periphery? Inﬂamm. Res. 60: 715-21 [PMID:21476084]
Dopamine receptors
G protein-coupled receptors → Dopamine receptors
Overview: Dopamine receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Dopamine Receptors [1748]) are commonly divided into D1-like (D1 and D5) and D2-like
(D2, D3 and D4) families, where the endogenous agonist is dopamine.
Nomenclature D1 receptor D2 receptor
HGNC, UniProt DRD1, P21728 DRD2, P14416
Sub/family-selective labelled ligands [125I]SCH23982 (Antagonist) (pKd 9.5) [433],
[3H]SCH-23390 (Antagonist) (pKd 9.5) [2221]
[3H]spiperone (Antagonist) (pKd 10.2) [246, 805, 2219] – Rat
Endogenous agonists dopamine [1897, 1962] dopamine [252, 573, 1725]
Agonists fenoldopam [1962] rotigotine [448], cabergoline (Partial agonist) [1337], aripiprazole (Partial agonist) [2199], bromocriptine
[573, 1337, 1725], MLS1547 (Biased agonist) [572], ropinirole [766], apomorphine (Partial agonist) [252,
573, 1337, 1725, 1844], pramipexole [1332, 1725], benzquinamide [677]
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Nomenclature D1 receptor D2 receptor
Sub/family-selective agonists A68930 [1445], SKF-38393 (Partial agonist) [1897,
1962]
quinpirole [252, 1332, 1539, 1844, 1846, 2019]
Selective agonists SKF-83959 (Biased agonist) [377], SKF-81297 [47] –
Rat
sumanirole [1301]
Antagonists ﬂupentixol (pKi 7–8.4) [1897, 1962] blonanserin (pKi 9.9) [1487], pipotiazine (pKi 9.7) [1845], perphenazine (pKi 8.9–9.6) [1055, 1761],
risperidone (pKi 9.4) [64], perospirone (pKi 9.2) [1762], triﬂuoperazine (pKi 8.9–9) [1055, 1763]
Sub/family-selective antagonists SCH-23390 (pKi 7.4–9.5) [1897, 1962], SKF-83566
(pKi 9.5) [1897], ecopipam (pKi 8.3) [1963]
haloperidol (pKi 7.4–8.8) [573, 1230, 1332, 1844, 1963]
Selective antagonists – L-741,626 (pKi 7.9–8.5) [688, 1069], domperidone (pKi 7.9–8.4) [573, 1844], raclopride (pKi 8) [1339],
ML321 (pKi 7) [2147, 2148]
Labelled ligands – [3H]raclopride (Antagonist) (pKd 8.9) [1081] – Rat
Nomenclature D3 receptor D4 receptor D5 receptor
HGNC, UniProt DRD3, P35462 DRD4, P21917 DRD5, P21918
Sub/family-selective labelled ligands – [3H]spiperone (Antagonist) (pKd 9.5) [786, 2019] [
3H]SCH-23390 (Antagonist) (pKd
9.2) [1654]
Endogenous agonists dopamine [252, 573, 1725, 1846] dopamine [2019] dopamine [1897]
Agonists pramipexole [1332, 1725], bromocriptine (Partial agonist) [573, 1337,
1725], ropinirole [766], apomorphine (Partial agonist) [252, 573, 1337,
1725, 1844]
apomorphine (Partial agonist) [1337] –
Sub/family-selective agonists quinpirole [252, 1332, 1339, 1539, 1725, 1844, 1846, 2019] quinpirole [1337, 1539, 2019] A68930 [1445]
Selective agonists PD 128907 [1610, 1725] PD168,077 (Partial agonist) [1040] – Rat,
A412997 [1373] – Rat, A412997 [1373]
–
Antagonists perospirone (pKi 9.6) [1844], sertindole (pKi 8–8.8) [64, 1746, 1761],
prochlorperazine (pKi 8.4) [71], (-)-sulpiride (pKi 6.7–7.7) [573, 1844,
1934], loxapine (pKi 7.7) [1761], domperidone (pKi 7.1–7.6) [573,
1844], promazine (pKi 6.8) [253]
perospirone (pKi 10.1) [1764], sertindole (pKi
7.8–9.1) [253, 1761, 1763, 1764], sonepiprazole
(pKi 8.9) [1739], loxapine (pKi 8.1) [1763]
–
Sub/family-selective antagonists haloperidol (pKi 7.5–8.6) [573, 1782, 1844, 1963] haloperidol (pKi 8.7–8.8) [1088, 1782, 1963] SCH-23390 (pKi 7.5–9.5) [1897],
SKF-83566 (pKi 9.4) [1897],
ecopipam (pKi 8.3) [1897]
Selective antagonists S33084 (pKi 9.6) [1336], nafadotride (pKi 9.5) [1726], PG01037 (pKi
9.2) [689], NGB 2904 (pKi 8.8) [2143], SB 277011-A (pKi 8) [1641],
(+)-S-14297 (pKi 6.9–7.9) [1334, 1339]
L745870 (pKi 9.4) [1069], A-381393 (pKi 8.8)
[1420], L741742 (pKi 8.5) [1683], ML398 (pKi
7.4) [142]
–
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Nomenclature D3 receptor D4 receptor D5 receptor
Selective allosteric modulators SB269652 (Negative) (pKi ∼9) [588] – –
Labelled ligands [3H]spiperone (Antagonist) (pKd 9.9) [805, 2219] – Rat, [
3H]7-OH-DPAT
(Agonist) [1655], [3H]PD128907 (Agonist) [27]
[125I]L750667 (Antagonist) (pKd 9.8) [1539],
[3H]NGD941 (Antagonist) (pKd 8.3) [1604]
[125I]SCH23982 (Antagonist) (pKd
9.1)
Comments: The selectivity of many of these agents is less than
two orders of magnitude. [3H]raclopride exhibits similar high
afﬁnity for D2 and D3 receptors (low afﬁnity for D4), but has been
used to label D2 receptors in the presence of a D3-selective antago-
nist. [3H]7-OH-DPAT has similar afﬁnity for D2 and D3 receptors,
but labels only D3 receptors in the absence of divalent cations.
The pharmacological proﬁle of the D5 receptor is similar to, yet
distinct from, that of the D1 receptor. The splice variants of the
D2 receptor are commonly termed D2S and D2L (short and long).
The DRD4 gene encoding the D4 receptor is highly polymorphic
in humans, with allelic variations of the protein from amino acid
387 to 515.
Further reading on Dopamine receptors
Beaulieu JM et al. (2015) Dopamine receptors - IUPHAR Review 13. Br. J. Pharmacol. 172: 1-23
[PMID:25671228]
Beaulieu JM et al. (2011) The physiology, signaling, and pharmacology of dopamine receptors.
Pharmacol. Rev. 63: 182-217 [PMID:21303898]
Cumming P. (2011) Absolute abundances and afﬁnity states of dopamine receptors in mammalian
brain: A review. Synapse 65: 892-909 [PMID:21308799]
Maggio R et al. (2010) Dopamine D2-D3 receptor heteromers: pharmacological properties and ther-
apeutic signiﬁcance. Curr Opin Pharmacol 10: 100-7 [PMID:19896900]
Ptácek R et al. (2011) Dopamine D4 receptor gene DRD4 and its association with psychiatric disor-
ders. Med. Sci. Monit. 17: RA215-20 [PMID:21873960]
Schwartz J-C et al.. (1998) Dopamine Receptors. In The IUPHAR Compendium of Receptor Characteri-
zation and Classiﬁcation Edited by Girdlestone D: IUPHAR Media: 141-151
Undieh AS. (2010) Pharmacology of signaling induced by dopamine D(1)-like receptor activation.
Pharmacol. Ther. 128: 37-60 [PMID:20547182]
Endothelin receptors
G protein-coupled receptors → Endothelin receptors
Overview: Endothelin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Endothelin Receptors [413]) are activated by the endogenous 21 amino-acid peptides
endothelins 1-3 (endothelin-1 (EDN1, P05305), endothelin-2 (EDN2, P20800) and endothelin-3 (EDN3, P14138)).
Nomenclature ETA receptor ETB receptor
HGNC, UniProt EDNRA, P25101 EDNRB, P24530
Family selective agonists – endothelin-1 (EDN1, P05305) = endothelin-2 (EDN2, P20800), endothelin-3
(EDN3, P14138)
Potency order of endogenous ligands endothelin-1 (EDN1, P05305) = endothelin-2 (EDN2, P20800) > endothelin-3 (EDN3,
P14138) [1242]
–
Selective agonists – sarafotoxin S6c [1062, 1690], BQ 3020 [1650], [Ala1,3,11,15]ET-1 [1354],
IRL 1620 [2078]
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Nomenclature ETA receptor ETB receptor
Sub/family-selective antagonists SB209670 (pKB 9.4) [502] – Rat, TAK 044 (pA2 8.4) [2081] – Rat, bosentan (pA2 7.2)
[367] – Rat
SB209670 (pKB 9.4) [502] – Rat, TAK 044 (pA2 8.4) [2081] – Rat, bosentan
(pKi 7.1) [1405]
Selective antagonists macitentan (pIC50 9.3) [177], sitaxsentan (pA2 8) [2135], FR139317 (Inverse agonist)
(pIC50 7.3–7.9) [1242], BQ123 (pA2 6.9–7.4) [1242], ambrisentan (pA2 7.1) [178]
A192621 (pKd 8.1) [2043], BQ788 (pKd 7.9–8) [1690], IRL 2500 (pKd 7.2)
[1690], Ro 46-8443 (pIC50 7.2) [215]
Labelled ligands [125I]PD164333 (Antagonist) (pKd 9.6–9.8) [416], [
3H]S0139 (Antagonist) (pKd 9.2),
[125I]PD151242 (Antagonist) (pKd 9–9.1) [417], [
3H]BQ123 (Antagonist) (pKd 8.5)
[858]
[125I]IRL1620 (Agonist) [1421], [125I]BQ3020 (Agonist) [737, 1354, 1565],
[125I][Ala1,3,11,15]ET-1 (Agonist) [1354]
Comments: Splice variants of the ETA receptor have been identiﬁed in rat pituitary cells; one of these, ETAR-C13, appeared to show loss of function with comparable plasma membrane expression to
wild type receptor [748]. Subtypes of the ETB receptor have been proposed, although gene disruption studies in mice suggest that only a single gene product exists [1350].
Further reading on Endothelin receptors
Clozel M et al. (2013) Endothelin receptor antagonists. Handb Exp Pharmacol 218: 199-227
[PMID:24092342]
Davenport AP. (2002) International Union of Pharmacology. XXIX. Update on endothelin receptor
nomenclature. Pharmacol. Rev. 54: 219-26 [PMID:12037137]
Davenport AP et al. (2016) Endothelin. Pharmacol. Rev. 68: 357-418 [PMID:26956245]
Maguire JJ et al. (2014) Endothelin@25 - new agonists, antagonists, inhibitors and emerging research
frontiers: IUPHAR Review 12. Br. J. Pharmacol. 171: 5555-72 [PMID:25131455]
G protein-coupled estrogen receptor
G protein-coupled receptors → G protein-coupled estrogen receptor
Overview: The G protein-coupled estrogen receptor (GPER, nomenclature as agreed by the NC-IUPHAR Subcommittee on the G protein-coupled estrogen receptor [1607]) was identiﬁed
following observations of estrogen-evoked cyclic AMP signalling in breast cancer cells [65], which mirrored the differential expression of an orphan 7-transmembrane receptor GPR30 [276]. There are
observations of both cell-surface and intracellular expression of the GPER receptor [1647, 1953].
Nomenclature GPER
HGNC, UniProt GPER1, Q99527
Agonists raloxifene [1570]
Selective agonists G1 [179]
Selective antagonists G36 (pIC50 6.8–6.9) [438], G15 (pIC50 6.7) [437]
Labelled ligands [3H]17β-estradiol (Agonist) [1953]
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Comments: Antagonists at the nuclear estrogen receptor, such as fulvestrant, tamoxifen [540] and raloxifene [1570], as well as the ﬂavonoid ‘phytoestrogens’ genistein and quercetin [1241], are agonists
at GPER receptors. A complete review of GPER pharmacology has been recently published [1607].
Further reading on G protein-coupled estrogen receptor
Prossnitz ER et al. (2015) International Union of Basic and Clinical Pharmacology. XCVII. G Protein-
Coupled Estrogen Receptor and Its Pharmacologic Modulators. Pharmacol. Rev. 67: 505-40
[PMID:26023144]
Prossnitz ER et al. (2015) What have we learned about GPER function in physiology and disease
from knockout mice? J. Steroid Biochem. Mol. Biol. 153: 114-26 [PMID:26189910]
Formylpeptide receptors
G protein-coupled receptors → Formylpeptide receptors
Overview: The formylpeptide receptors (nomenclature agreed by the NC-IUPHAR Subcommittee on the formylpeptide receptor family [2180]) respond to exogenous ligands such as
the bacterial product fMet-Leu-Phe (fMLP) and endogenous ligands such as annexin I (ANXA1, P04083) , cathepsin G (CTSG, P08311), amyloid β42, serum amyloid A and spinorphin, derived from
β-haemoglobin (HBB, P68871).
Nomenclature FPR1 FPR2/ALX FPR3
HGNC, UniProt FPR1, P21462 FPR2, P25090 FPR3, P25089
Potency order of endogenous ligands fMet-Leu-Phe > cathepsin G (CTSG, P08311) >
annexin I (ANXA1, P04083) [1118, 1895]
LXA4 = aspirin triggered lipoxin A4 = ATLa2 = resolvin D1 > LTC4 =
LTD4  15-deoxy-LXA4  fMet-Leu-Phe [365, 544, 546, 684, 1919]
–
Endogenous agonists – LXA4 [1052], resolvin D1 [1052], aspirin-triggered resolvin D1 [1051],
aspirin triggered lipoxin A4
F2L (HEBP1, Q9NRV9) [1333]
Agonists fMet-Leu-Phe [575, 1802] – –
Selective agonists – ATLa2 [697] –
Endogenous antagonists spinorphin (pIC50 4.3) [1165, 1404] – –
Antagonists t-Boc-FLFLF (pKi 6–6.5) [2095] – –
Selective antagonists cyclosporin H (pKi 6.1–7.1) [2095, 2167] WRWWWW (pIC50 6.6) [83], t-Boc-FLFLF (pIC50 4.3–6) [574, 1867,
2061]
–
Labelled ligands [3H]fMet-Leu-Phe (Agonist) [1036] [3H]LXA4 (Agonist) [544, 545] –
Comments A FITC-conjugated fMLP analogue has been used for
binding to the mouse recombinant receptor [758].
– –
Comments: Note that the data for FPR2/ALX are also reproduced on the leukotriene receptor page.
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Further reading on Formylpeptide receptors
Dorward DA et al. (2015) The Role of Formylated Peptides and Formyl Peptide Receptor 1 in
Governing Neutrophil Function during Acute Inﬂammation. Am. J. Pathol. 185: 1172-1184
[PMID:25791526]
Dufton N et al. (2010) Therapeutic anti-inﬂammatory potential of formyl-peptide receptor agonists.
Pharmacol. Ther. 127: 175-88 [PMID:20546777]
Liu M et al. (2012) G protein-coupled receptor FPR1 as a pharmacologic target in inﬂammation and
human glioblastoma. Int. Immunopharmacol. 14: 283-8 [PMID:22863814]
Rabiet MJ et al. (2011) N-formyl peptide receptor 3 (FPR3) departs from the homologous
FPR2/ALX receptor with regard to the major processes governing chemoattractant receptor reg-
ulation, expression at the cell surface, and phosphorylation. J. Biol. Chem. 286: 26718-31
[PMID:21543323]
Yazid S et al. (2012) Anti-inﬂammatory drugs, eicosanoids and the annexin A1/FPR2 anti-
inﬂammatory system. Prostaglandins Other Lipid Mediat. 98: 94-100 [PMID:22123264]
Ye RD et al. (2009) International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature
for the formyl peptide receptor (FPR) family. Pharmacol. Rev. 61: 119-61 [PMID:19498085]
Free fatty acid receptors
G protein-coupled receptors → Free fatty acid receptors
Overview: Free fatty acid receptors (FFA, nomenclature
as agreed by the NC-IUPHAR Subcommittee on free
fatty acid receptors [414, 1876]) are activated by free fatty
acids. Long-chain saturated and unsaturated fatty acids (C14.0
(myristic acid), C16:0 (palmitic acid), C18:1 (oleic acid), C18:2
(linoleic acid), C18:3, (α-linolenic acid), C20:4 (arachidonic acid),
C20:5,n-3 (EPA) and C22:6,n-3 (docosahexaenoic acid)) activate
FFA1 [223, 872, 1043] and FFA4 receptors [795, 852, 1494], while
short chain fatty acids (C2 (acetic acid), C3 (propanoic acid), C4
(butyric acid) and C5 (pentanoic acid)) activate FFA2 [231, 1117,
1465] and FFA3 [231, 1117] receptors. The crystal structure for
agonist bound FFA1 has been described [1862].
Nomenclature FFA1 receptor FFA2 receptor
HGNC, UniProt FFAR1, O14842 FFAR2, O15552
Endogenous agonists docosahexaenoic acid [223, 872], α-linolenic acid [223, 872, 1043], oleic acid [223, 872, 1043],
myristic acid [223, 872, 1043]
propanoic acid [231, 1117, 1465, 1741], acetic acid [231, 1117, 1465,
1741], butyric acid [231, 1117, 1465, 1741], trans-2-methylcrotonic acid
[1741], 1-methylcyclopropanecarboxylic acid [1741]
Selective agonists AMG-837 [1176], compound 4 [347], TUG-770 [346], TUG-905 [345], GW9508 (Partial agonist)
[222], fasiglifam [935, 1434, 1862, 1985]
compound 1 [840] – Rat
Selective antagonists GW1100 (pIC50 6) [222, 1875] GLPG0974 (pIC50 8.1) [1423, 1584], CATPB (pIC50 6.5) [841]
Comments Antagonist GW1100 is also an oxytocin receptor antagonist [222]. Fasiglifam, TUG-770 and
GW9508 are approximately 100 fold selective for FFA1 over FFA4 [222, 346, 1434]. AMG-837 and
the related analogue AM6331 have been suggested to have an allosteric mechanism of action at
FFA1, with respect to the orthosteric fatty acid binding site [1176, 2153].
–
Searchable database: http://www.guidetopharmacology.org/index.jsp Free fatty acid receptors S66
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129
Nomenclature FFA3 receptor FFA4 receptor GPR42
HGNC, UniProt FFAR3, O14843 FFAR4, Q5NUL3 GPR42, O15529
Endogenous agonists propanoic acid [231, 1117, 1741, 2152], butyric acid [231, 1117, 1741,
2152], 1-methylcyclopropanecarboxylic acid [1741]
α-linolenic acid [1794], myristic acid [2084], α-linolenic acid [1932] – Rat,
oleic acid [2084]
–
Agonists acetic acid [231, 1117, 1741, 2152] – –
Selective agonists – compound A [1493], TUG-891 [1794], NCG21 [1902] –
Comments Beta-hydroxybutyrate has been reported to antagonise FFA3 responses to
short chain fatty acids [997]. A range of FFA3 selective molecules with
agonist and antagonist properties, but which bind at sites distinct from
the short chain fatty acid binding site (i.e. allosteric modulators), have
recently been described [180, 839, 1226].
A wide range of both saturated and unsaturated fatty acids containing from 6 to
22 carbons have been shown to act as agonists at FFA4 [348] with a small subset
listed above. Compound A [PMID 24997608] exhibits more than 1000 fold
selectivity [1493], and TUG-891 50-1000 fold selectivity for FFA4 over FFA1
[1794], dependent on the assay. NGC21 exhibits approximately 15 fold selectivity
for FFA4 over FFA1 [1894].
–
Comments: Short (361 amino acids) and long (377 amino acids)
splice variants of human FFA4 have been reported [1372], which
differ by a 16 amino acid insertion in intracellular loop 3, and
exhibit differences in intracellular signalling properties in recom-
binant systems [2084]. The long FFA4 splice variant has not been
identiﬁed in other primates or rodents to date [795, 1372].
GPR42 was originally described as a pseudogene within the family
(ENSFM00250000002583), but the discovery of several polymor-
phisms suggests that some versions of GPR42 may be functional
[1167]. GPR84 is a structurally-unrelated G protein-coupled recep-
tor which has been found to respond to medium chain fatty acids
[2067].
Further reading on Free fatty acid receptors
Bolognini D et al. (2016) The Pharmacology and Function of Receptors for Short-Chain Fatty Acids.
Mol. Pharmacol. 89: 388-98 [PMID:26719580]
Mancini AD et al. (2013) The fatty acid receptor FFA1/GPR40 a decade later: how much do we
know? Trends Endocrinol. Metab. 24: 398-407 [PMID:23631851]
Moniri NH. (2016) Free-fatty acid receptor-4 (GPR120): Cellular and molecular function and its role
in metabolic disorders. Biochem. Pharmacol. 110-111: 1-15 [PMID:26827942]
Stoddart LA et al. (2008) International Union of Pharmacology. LXXI. Free fatty acid receptors
FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60: 405-17
[PMID:19047536]
Talukdar S et al. (2011) Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin
resistance and inﬂammatory diseases. Trends Pharmacol. Sci. 32: 543-50 [PMID:21663979]
Watterson KR et al. (2014) Treatment of type 2 diabetes by free Fatty Acid receptor agonists. Front
Endocrinol (Lausanne) 5: 137 [PMID:25221541]
GABAB receptors
G protein-coupled receptors → GABAB receptors
Overview: Functional GABAB receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on GABAB re-
ceptors [199, 1579]) are formed from the heterodimerization
of two similar 7TM subunits termed GABAB1 and GABAB2 [199,
506, 1578, 1579, 2002]. GABAB receptors are widespread in
the CNS and regulate both pre- and postsynaptic activity. The
GABAB1 subunit, when expressed alone, binds both antagonists
and agonists, but the afﬁnity of the latter is generally 10-100-
fold less than for the native receptor. Co-expression of GABAB1
and GABAB2 subunits allows transport of GABAB1 to the cell sur-
face and generates a functional receptor that can couple to signal
transduction pathways such as high-voltage-activated Ca2+ chan-
nels (Cav2.1, Cav2.2), or inwardly rectifying potassium channels
(Kir3) [147, 199, 200]. The GABAB1 subunit harbours the GABA
(orthosteric)-binding site within an extracellular domain (ECD)
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venus ﬂytrap module (VTM), whereas the GABAB2 subunit medi-
ates G protein-coupled signalling [199, 622, 624, 1578]. The two
subunits interact by direct allosteric coupling [1367], such that
GABAB2 increases the afﬁnity of GABAB1 for agonists and recip-
rocally GABAB1 facilitates the coupling of GABAB2 to G proteins
[622, 1060, 1578]. GABAB1 and GABAB2 subunits assemble in a
1:1 stoichiometry by means of a coiled-coil interaction between
α-helices within their carboxy-termini that masks an endoplas-
mic reticulum retention motif (RXRR) within the GABAB1 subunit
but other domains of the proteins also contribute to their het-
eromerization [147, 250, 1578]. Recent evidence indicates that
higher order assemblies of GABAB receptor comprising dimers of
heterodimers occur in recombinant expression systems and in vivo
and that such complexes exhibit negative functional cooperativ-
ity between heterodimers [373, 1577]. Adding further complex-
ity, KCTD (potassium channel tetramerization proteins) 8, 12, 12b
and 16 associate as tetramers with the carboxy terminus of the
GABAB2 subunit to impart altered signalling kinetics and agonist
potency to the receptor complex [108, 1751, 1990] and are re-
viewed by [1580]. The molecular complexity of GABAB receptors
is further increased through association with trafﬁcking and ef-
fector proteins [Schwenk et al., 2016, Nature Neuroscience 19(2):
233-42] and reviewed by [1576]. Four isoforms of the human
GABAB1 subunit have been cloned. The predominant GABAB1a
and GABAB1b isoforms, which are most prevalent in neonatal
and adult brain tissue respectively, differ in their ECD sequences
as a result of the use of alternative transcription initiation sites.
GABAB1a-containing heterodimers localise to distal axons andme-
diate inhibition of glutamate release in the CA3-CA1 terminals,
and GABA release onto the layer 5 pyramidal neurons, whereas
GABAB1b-containing receptors occur within dendritic spines and
mediate slow postsynaptic inhibition [1613, 2035]. Only the 1a
and 1b variants are identiﬁed as components of native receptors
[199]. Additional GABAB1 subunit isoforms have been described
in rodents and humans [1130] and reviewed by [147].
Nomenclature GABAB receptor
Subunits kctd12b (Accessory protein), KCTD16 (Accessory protein), KCTD12 (Accessory protein), GABAB2, GABAB1, KCTD8 (Accessory protein)
Agonists CGP 44532 [581] – Rat, (-)-baclofen [581] – Rat, 3-APPA [800], baclofen [800, 2130], 3-APMPA [2130]
Antagonists CGP 62349 (pKi 8.5–8.9) [800, 2130], CGP 55845 (pKi 7.8) [2130], SCH 50911 (pKi 5.5–6) [800, 2130], CGP 35348 (pKi 4.4) [2130], 2-hydroxy-saclofen (pIC50 4.1) [957] – Rat
Labelled ligands [3H]CGP 54626 (Antagonist) (pKi 9.1) [922] – Rat, [
3H]CGP 62349 (Antagonist) (pKd 9.1) [964] – Rat, [
125I]CGP 64213 (Antagonist) (pKd 9) [594] – Rat, [
125I]CGP 71872
(Antagonist) (pKd 9) [957] – Rat, [
3H](R)-(-)-baclofen (Agonist)
Subunits
Nomenclature GABAB1 GABAB2
HGNC, UniProt GABBR1, Q9UBS5 GABBR2, O75899
Comments: Potencies of agonists and antagonists listed in the ta-
ble, quantiﬁed as IC50 values for the inhibition of [
3H]CGP27492
binding to rat cerebral cortex membranes, are from [199, 580,
581]. Radioligand KD values relate to binding to rat brain mem-
branes. CGP 71872 is a photoafﬁnity ligand for the GABAB1
subunit [128]. CGP27492 (3-APPA), CGP35024 (3-APMPA) and
CGP 44532 act as antagonists at humanGABAA ρ1 receptors, with
potencies in the low micromolar range [580]. In addition to the
ligands listed in the table, Ca2+ binds to the VTM of the GABAB1
subunit to act as a positive allosteric modulator of GABA [594].
Synthetic positive allosteric modulators with low, or no, intrinsic
activity include CGP7930, GS39783, BHF-177 [2040] and (+)-BHFF
[9, 147, 154, 580]. The site of action of CGP7930 and GS39783
appears to be on the heptahelical domain of the GABAB2 subunit
[483, 1578]. In the presence of CGP7930 or GS39783, CGP 35348
and 2-hydroxy-saclofen behave as partial agonists [580]. A neg-
ative allosteric modulator of GABAB activity has been reported
[318]. Knock-out of the GABAB1 subunit in C57B mice causes
the development of severe tonic-clonic convulsions that prove
fatal within a month of birth, whereas GABAB1
-/- BALB/c mice,
although also displaying spontaneous epileptiform activity, are vi-
able. The phenotype of the latter animals additionally includes
hyperalgesia, hyperlocomotion (in a novel, but not familiar, en-
vironment), hyperdopaminergia, memory impairment and be-
haviours indicative of anxiety [510, 2008]. A similar phenotype
has been found for GABAB2
-/- BALB/c mice [613].
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Further reading on GABAB receptors
Bowery NG et al. (2002) International Union of Pharmacology. XXXIII. Mammalian gamma-
aminobutyricacid(B) receptors: structure and function. Pharmacol Rev. 54: 247-264
[PMID:12037141]
Froestl W. (2011) An historical perspective on GABAergic drugs. Future Med Chem 3: 163-75
[PMID:21428811]
Gassmann M et al. (2012) Regulation of neuronal GABA(B) receptor functions by subunit composi-
tion. Nat. Rev. Neurosci. 13: 380-94 [PMID:22595784]
Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature
540: 60-68 [PMID:27905440]
Galanin receptors
G protein-coupled receptors → Galanin receptors
Overview: Galanin receptors (provisional nomencla-
ture as recommended by NC-IUPHAR [557]) are acti-
vated by the endogenous peptides galanin (GAL, P22466) and
galanin-like peptide (GALP, Q9UBC7). Human galanin (GAL,
P22466) is a 30 amino-acid non-amidated peptide [525]; in other
species, it is 29 amino acids long and C-terminally amidated.
Amino acids 1–14 of galanin are highly conserved in mammals,
birds, reptiles, amphibia and ﬁsh. Shorter peptide species (e.g.
human galanin-1–19 [143] and porcine galanin-5–29 [1809]) and
N-terminally extended forms (e.g. N-terminally seven and nine
residue elongated forms of porcine galanin [144, 1809]) have been
reported.
Nomenclature GAL1 receptor GAL2 receptor GAL3 receptor
HGNC, UniProt GALR1, P47211 GALR2, O43603 GALR3, O60755
Potency order of endogenous ligands galanin (GAL, P22466) > galanin-like peptide (GALP,
Q9UBC7) [1500]
galanin-like peptide (GALP, Q9UBC7) ≥
galanin (GAL, P22466) [1500]
galanin-like peptide (GALP, Q9UBC7) > galanin (GAL,
P22466) [1095]
Agonists – galanin(2-29) (rat/mouse) [1526, 2069,
2070, 2071] – Rat
–
Selective agonists – [D-Trp2]galanin-(1-29) [1834] – Rat –
Selective antagonists 2,3-dihydro-1,4-dithiin-1,1,4,4-tetroxide (pIC50 5.6)
[1758]
M871 (pKi 7.9) [1848] SNAP 398299 (pKi 8.3) [1033, 1034, 1906],
SNAP 37889 (pKi 7.8–7.8) [1033, 1034, 1906]
Selective allosteric modulators – CYM2503 (Positive) (pEC50 9.2) [1213] – Rat –
Labelled ligands [125I][Tyr26]galanin (human) (Agonist) [552],
[125I][Tyr26]galanin (human) (Agonist) [552]
[125I][Tyr26]galanin (human) (Agonist) [2070]
– Rat
[125I][Tyr26]galanin (pig) (Agonist) [191, 1835]
Comments – The CYM2503 PAM potentiates the
anticonvulsant activity of endogenous galanin
in mouse seizure models [1213].
–
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Comments: galanin-(1-11) is a high-afﬁnity agonist at
GAL1/GAL2 (pKi 9), and galanin(2-11) is selective for GAL2 and
GAL3 compared with GAL1 [1212]. [
125I]-[Tyr26]galanin binds to
all three subtypes with Kd values generally reported to range from
0.05 to 1 nM, depending on the assay conditions used [552, 1821,
1834, 1835, 2070]. Porcine galanin-(3-29) does not bind to cloned
GAL1, GAL2 or GAL3 receptors, but a receptor that is functionally
activated by porcine galanin-(3–29) has been reported in pituitary
and gastric smooth muscle cells [691, 2142]. Additional galanin
receptor subtypes are also suggested from studies with chimeric
peptides (e.g. M15, M35 and M40), which act as antagonists in
functional assays in the cardiovascular system [2000], spinal cord
[2114], locus coeruleus, hippocampus [106] and hypothalamus
[107, 1142], but exhibit agonist activity at some peripheral sites
[107, 691]. The chimeric peptides M15, M32, M35, M40 and C7
are agonists at GAL1 receptors expressed endogenously in Bowes
human melanoma cells [1500], and at heterologously expressed
recombinant GAL1, GAL2 and GAL3 receptors [552, 1834, 1835].
Recent studies have described the synthesis of a series of novel,
systemically-active, galanin analogues, with modest preferential
binding at the GAL2 receptor. Speciﬁc chemical modiﬁcations
to the galanin backbone increased brain levels of these peptides
after i.v. injection and several of these peptides exerted a potent
antidepressant-like effect in mouse models of depression [1698].
Further reading on Galanin receptors
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Lang R et al. (2015) Physiology, signaling, and pharmacology of galanin peptides and receptors:
three decades of emerging diversity. Pharmacol. Rev. 67: 118-75 [PMID:25428932]
Lang R et al. (2011) The galanin peptide family in inﬂammation. Neuropeptides 45: 1-8
[PMID:21087790]
Lawrence C et al. (2011) Galanin-like peptide (GALP) is a hypothalamic regulator of energy home-
ostasis and reproduction. Front Neuroendocrinol 32: 1-9 [PMID:20558195]
Webling KE et al. (2012) Galanin receptors and ligands. Front Endocrinol (Lausanne) 3: 146
[PMID:23233848]
Ghrelin receptor
G protein-coupled receptors → Ghrelin receptor
Overview: The ghrelin receptor (nomenclature as agreed
by the NC-IUPHAR Subcommittee for the Ghrelin recep-
tor [415]) is activated by a 28 amino-acid peptide originally
isolated from rat stomach, where it is cleaved from a 117 amino-
acid precursor (GHRL, Q9UBU3). The human gene encoding the
precursor peptide has 83% sequence homology to rat prepro-
ghrelin, although the mature peptides from rat and human dif-
fer by only two amino acids [1285]. Alternative splicing results
in the formation of a second peptide, [des-Gln14]ghrelin (GHRL,
Q9UBU3) with equipotent biological activity [822]. A unique
post-translational modiﬁcation (octanoylation of Ser3, catalysed
by ghrelin O-acyltransferase (MBOAT4, Q96T53) [2170] occurs in
both peptides, essential for full activity in binding to ghrelin re-
ceptors in the hypothalamus and pituitary, and for the release
of growth hormone from the pituitary [1029]. Structure activ-
ity studies showed the ﬁrst ﬁve N-terminal amino acids to be
the minimum required for binding [122], and receptor mutage-
nesis has indicated overlap of the ghrelin binding site with those
for small molecule agonists and allosteric modulators of ghrelin
(GHRL, Q9UBU3) function [814]. In cell systems, the ghrelin re-
ceptor is constitutively active [815], but this is abolished by a nat-
urally occurring mutation (A204E) that results in decreased cell
surface receptor expression and is associated with familial short
stature [1527].
Nomenclature ghrelin receptor
HGNC, UniProt GHSR, Q92847
Potency order of endogenous ligands ghrelin (GHRL, Q9UBU3) = [des-Gln14]ghrelin (GHRL, Q9UBU3) [121, 1285]
Selective antagonists GSK1614343 (pIC50 8.4) [1699], GSK1614343 (pKB 8) [1556] – Rat
Labelled ligands [125I][His9]ghrelin (human) (Agonist) [956], [125I][Tyr4]ghrelin (human) (Agonist) [1394]
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Comments: [des-octanoyl]ghrelin (GHRL, Q9UBU3) has been
shown to bind (as [125I]Tyr4-des-octanoyl-ghrelin) and have ef-
fects in the cardiovascular system [121], which raises the possible
existence of different receptor subtypes in peripheral tissues and
the central nervous system. A potent inverse agonist has been
identiﬁed ([D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, pD2 8.3;
[812]). Ulimorelin, described as a ghrelin receptor agonist (pKi 7.8
and pD2 7.5 at human recombinant ghrelin receptors), has been
shown to stimulate ghrelin receptor mediated food intake and gas-
tric emptying but not elicit release of growth hormone, or modify
ghrelin stimulated growth hormone release, thus pharmacolog-
ically discriminating the orexigenic and gastrointestinal actions
of ghrelin (GHRL, Q9UBU3) from the release of growth hormone
[567]. A number of selective antagonists have been reported, in-
cluding peptidomimetic [1393] and non-peptide small molecules
including GSK1614343 [1556, 1699].
Further reading on Ghrelin receptor
Andrews ZB. (2011) The extra-hypothalamic actions of ghrelin on neuronal function. Trends Neu-
rosci. 34: 31-40 [PMID:21035199]
Angelidis G et al. (2010) Current and potential roles of ghrelin in clinical practice. J. Endocrinol.
Invest. 33: 823-38 [PMID:21293171]
Briggs DI et al. (2011) Metabolic status regulates ghrelin function on energy homeostasis. Neuroen-
docrinology 93: 48-57 [PMID:21124019]
Callaghan B et al. (2014) Novel and conventional receptors for ghrelin, desacyl-ghrelin, and phar-
macologically related compounds. Pharmacol. Rev. 66: 984-1001 [PMID:25107984]
Davenport AP et al. (2005) International Union of Pharmacology. LVI. Ghrelin receptor nomencla-
ture, distribution, and function. Pharmacol. Rev. 57: 541-6 [PMID:16382107]
Glucagon receptor family
G protein-coupled receptors → Glucagon receptor family
Overview: The glucagon family of receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on the Glucagon receptor family [1296]) are activated by the endogenous
peptide (27-44 aa) hormones glucagon (GCG, P01275), glucagon-like peptide 1 (GCG, P01275), glucagon-like peptide 2 (GCG, P01275), glucose-dependent insulinotropic polypeptide (also known as
gastric inhibitory polypeptide (GIP, P09681)), GHRH (GHRH, P01286) and secretin (SCT, P09683). One common precursor (GCG) generates glucagon (GCG, P01275), glucagon-like peptide 1 (GCG,
P01275) and glucagon-like peptide 2 (GCG, P01275) peptides [866].
Nomenclature GHRH receptor GIP receptor GLP-1 receptor
HGNC, UniProt GHRHR, Q02643 GIPR, P48546 GLP1R, P43220
Endogenous agonists – gastric inhibitory polypeptide (GIP, P09681) [2042] glucagon-like peptide 1-(7-36) amide (GCG, P01275) [927],
glucagon-like peptide 1-(7-37) (GCG, P01275) [449]
Agonists JI-38 [265], sermorelin – liraglutide [1020], lixisenatide [2097], WB4-24 [528]
Selective agonists BIM28011 [393], tesamorelin – exendin-4 [1346], exendin-4 [927], exendin-3 (P20394) [1635]
Selective antagonists JV-1-36 (pKi 10.1–10.4) [1733, 2026, 2027] – Rat,
JV-1-38 (pKi 10.1) [1733, 2026, 2027] – Rat
[Pro3]GIP [615] – Mouse exendin-(9-39) (pKi 8.1) [927], GLP-1-(9-36) (pIC50 6.9) [1368] –
Rat, T-0632 (pIC50 4.7) [1961]
Labelled ligands [125I]GHRH (human) (Agonist) [196] – Rat [125I]GIP (human) (Agonist) [593] – Rat [125I]GLP-1-(7-36)-amide (Agonist) [927], [125I]exendin-(9-39)
(Antagonist) (pKd 8.3) [927], [
125I]GLP-1-(7-37) (human)
(Agonist)
Searchable database: http://www.guidetopharmacology.org/index.jsp Glucagon receptor family S71
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129
Nomenclature GLP-2 receptor glucagon receptor secretin receptor
HGNC, UniProt GLP2R, O95838 GCGR, P47871 SCTR, P47872
Endogenous agonists glucagon-like peptide 2 (GCG, P01275) [1958] glucagon (GCG, P01275) [1587] secretin (SCT, P09683) [343]
Agonists teduglutide [1310] – –
Selective antagonists – L-168,049 (pIC50 8.4) [282], adomeglivant (pKi
8.2) [963, 967], des-His1-[Glu9]glucagon-NH2
(pA2 7.2) [2004, 2005] – Rat, NNC 92-1687 (pKi
5) [1234], BAY27-9955 [1566]
[(CH2NH)4,5]secretin (pKi 5.3) [704]
Labelled ligands – [125I]glucagon (human, mouse, rat) (Agonist) [125I](Tyr10)secretin-27 (rat) (Agonist) [2001] – Rat
Comments: The glucagon receptor has been reported to interact with receptor activity modifying proteins (RAMPs), speciﬁcally RAMP2, in heterologous expression systems [349], although the physio-
logical signiﬁcance of this has yet to be established.
Further reading on Glucagon receptor family
Ahrén B. (2015) Glucagon–Early breakthroughs and recent discoveries. Peptides 67: 74-81
[PMID:25814364]
Campbell JE et al. (2013) Pharmacology, physiology, and mechanisms of incretin hormone action.
Cell Metab. 17: 819-37 [PMID:23684623]
Donnelly D. (2012) The structure and function of the glucagon-like peptide-1 receptor and its lig-
ands. Br. J. Pharmacol. 166: 27-41 [PMID:21950636]
Kazda CM et al. (2016) Evaluation of Efﬁcacy and Safety of the Glucagon Receptor Antagonist
LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care
39: 1241-9 [PMID:26681715]
Mayo KE et al. (2003) International Union of Pharmacology. XXXV. The glucagon receptor family.
Pharmacol. Rev. 55: 167-94 [PMID:12615957]
Trujillo JM et al. (2014) GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments
and emerging agents. Pharmacotherapy 34: 1174-86 [PMID:25382096]
Glycoprotein hormone receptors
G protein-coupled receptors → Glycoprotein hormone receptors
Overview: Glycoprotein hormone receptors (provisional
nomenclature [557]) are activated by a non-covalent het-
erodimeric glycoprotein made up of a common α chain
(glycoprotein hormone common alpha subunit (CGA, P01215)
CGA, P01215), with a unique β chain that confers the biologi-
cal speciﬁcity to FSH (CGA FSHB, P01215 P01225), LH (CGA LHB,
P01215 P01229), hCG (CGA CGB3, P01215 P01233) or TSH (CGA
TSHB, P01215 P01222). There is binding cross-reactivity across
the endogenous agonists for each of the glycoprotein hormone re-
ceptors. The deglycosylated hormones appear to exhibit reduced
efﬁcacy at these receptors [1701].
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Nomenclature FSH receptor LH receptor TSH receptor
HGNC, UniProt FSHR, P23945 LHCGR, P22888 TSHR, P16473
Potency order of endogenous ligands FSH (CGA FSHB, P01215 P01225) LH (CGA LHB, P01215 P01229), hCG (CGA CGB3, P01215 P01233) TSH (CGA TSHB, P01215 P01222)
Endogenous agonists FSH (CGA FSHB, P01215 P01225) hCG (CGA CGB3, P01215 P01233) [907, 1411], LH (CGA LHB, P01215 P01229) [907,
1411]
TSH (CGA TSHB, P01215 P01222)
Labelled ligands [125I]FSH (human) (Agonist) [125I]LH (Agonist), [125I]chorionic gonadotropin (human) (Agonist) [125I]TSH (human) (Agonist)
Further reading on Glycoprotein hormone receptors
Jiang X et al. (2012) Structure of follicle-stimulating hormone in complex with the entire
ectodomain of its receptor. Proc. Natl. Acad. Sci. U.S.A. 109: 12491-6 [PMID:22802634]
Kleinau G et al. TSH receptor mutations and disease. Accessed on 2017-02-23.
Thyroid Disease Manager.
Tao YX et al. (2009) Follicle stimulating hormone receptor mutations and reproductive disorders.
Prog Mol Biol Transl Sci 89: 115-31 [PMID:20374735]
Troppmann B et al. (2013) Structural and functional plasticity of the luteinizing hor-
mone/choriogonadotrophin receptor. Hum. Reprod. Update 19: 583-602 [PMID:23686864]
Gonadotrophin-releasing hormone receptors
G protein-coupled receptors → Gonadotrophin-releasing hormone receptors
Overview: GnRH1 and GnRH2 receptors (provisonal nomen-
clature [557], also called Type I and Type II GnRH receptor, re-
spectively [1342]) have been cloned from numerous species, most
of which express two or three types of GnRH receptor [1341, 1342,
1810]. GnRH I (GNRH1, P01148) (p-Glu-His-Trp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2) is a hypothalamic decapeptide also known as
luteinizing hormone-releasing hormone, gonadoliberin, luliberin,
gonadorelin or simply as GnRH. It is a member of a family of
similar peptides found in many species [1341, 1342, 1810] includ-
ing GnRH II (GNRH2, O43555) (pGlu-His-Trp-Ser-His-Gly-Trp-Tyr-
Pro-Gly-NH2 (which is also known as chicken GnRH-II). Recep-
tors for three forms of GnRH exist in some species but only GnRH
I and GnRH II and their cognate receptors have been found in
mammals [1341, 1342, 1810]. GnRH1 receptors are expressed
by pituitary gonadotrophs, where they mediate the effects of
GnRH on gonadotropin hormone synthesis and secretion that
underpin central control of mammalian reproduction. GnRH
analogues are used in assisted reproduction and to treat steroid
hormone-dependent conditions [981]. Notably, agonists cause de-
sensitization of GnRH-stimulated gonadotropin secretion and the
consequent reduction in circulating sex steroids is exploited
to treat hormone-dependent cancers of the breast, ovary and
prostate [981]. GnRH1 receptors are selectively activated by GnRH
I and all lack the COOH-terminal tails found in other GPCRs.
GnRH2 receptors do have COOH-terminal tails and (where tested)
are selective for GnRH II over GnRH I. GnRH2 receptors are ex-
pressed by some primates but not by humans [1377]. Phyloge-
netic classiﬁcations divide GnRH receptors into three [1342] or
ﬁve groups [2117] and highlight examples of gene loss through
evolution, with humans retaining only one ancient gene.
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Nomenclature GnRH1 receptor GnRH2 receptor
HGNC, UniProt GNRHR, P30968 GNRHR2, Q96P88
Potency order of endogenous ligands GnRH I (GNRH1, P01148) > GnRH II (GNRH2, O43555) [1342] GnRH II (GNRH2, O43555) > GnRH I (GNRH1, P01148)
(Monkey) [1340]
Endogenous agonists GnRH I (GNRH1, P01148) [1214], GnRH II (GNRH2, O43555) [550, 1214, 1869] GnRH II (GNRH2, O43555) [1340] – Monkey, GnRH I
(GNRH1, P01148) [1340] – Monkey
Selective agonists buserelin [1432], buserelin [1431], buserelin [1431], triptorelin [118], leuprolide [1881], goserelin,
histrelin, nafarelin
–
Antagonists iturelix (pKi 9.5) [1664] –
Selective antagonists cetrorelix (pKi 9.3–10) [119, 120, 1881], abarelix (pKi 9.1–9.5) [1881], degarelix (pKi 8.8) [2017],
ganirelix
trptorelix-1 [1246] – Monkey
Labelled ligands [125I]cetrorelix (Antagonist) (pKd 9.7) [807], [
125I]triptorelin (Agonist) [435] – Rat, [125I]buserelin
(Agonist) [1076] – Rat, [125I]GnRH I (human, mouse, rat) (Agonist)
–
Comments: GnRH1 and GnRH2 receptors couple primarily to
Gq/11 [686] but coupling to Gs and Gi is evident in some sys-
tems [1056, 1076]. GnRH2 receptors may also mediate (het-
erotrimeric) G protein-independent signalling to protein kinases
[289]. There is increasing evidence for expression of GnRH recep-
tors on hormone-dependent cancer cells where they can exert an-
tiproliferative and/or proapoptotic effects and mediate effects of
cytotoxins conjugated to GnRH analogues [324, 741, 1174, 1732].
In some human cancer cell models GnRH II (GNRH2, O43555)
is more potent than GnRH I (GNRH1, P01148), implying medi-
ation by GnRH2 receptors [690], but GnRH2 receptors are not ex-
pressed by humans because the human GNRHR2 gene contains
a frame shift and internal stop codon [1377]. The possibility re-
mains that this gene generates GnRH2 receptor’related proteins
(other than the full-length receptor) that mediate responses to
GnRH II (GNRH2, O43555) (see [1436]). Alternatively, evidence
for multiple active GnRH receptor conformations [289, 290, 541,
1293, 1342] raises the possibility that GnRH1 receptor-mediated
proliferation inhibition in hormone-dependent cancer cells is de-
pendent upon different conformations than effects on Gq/11 in pi-
tuitary cells [290, 1293]. Loss-of-functionmutations in theGnRH1
receptor and deﬁciency of GnRH I (GNRH1, P01148) are associ-
ated with hypogonadotropic hypogonadism although some ’loss
of function’ mutations may actually prevent trafﬁcking of ’func-
tional’ GnRH1 receptors to the cell surface, as evidenced by recov-
ery of function by nonpeptide antagonists [1124]. Human GnRH1
receptors are poorly expressed at the cell surface because of failure
to meet structural quality control criteria for endoplasmic reticu-
lum exit [542, 1124], and this increase susceptibility to point mu-
tations that further impair trafﬁcking [542, 1124]. GnRH receptor
signalling may require receptor oligomerisation [376, 1054].
Further reading on Gonadotrophin-releasing hormone receptors
Limonta P et al. (2012) GnRH receptors in cancer: from cell biology to novel targeted therapeutic
strategies. Endocr. Rev. 33: 784-811 [PMID:22778172]
McArdle CA and Roberson MS.. (2015) Gonadotropes and gonadotropin-releasing hormone signal-
ing. In Knobil and Neill’s Physiology of Reproduction (4th edition). Edited by Plant TM and Zeleznik
AJ.: Elsevier Inc.: [ISBN: 9780123971753]
Millar RP et al. (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25: 235-275
[PMID:15082521]
Tao YX et al. (2014) Chaperoning G protein-coupled receptors: from cell biology to therapeutics.
Endocr. Rev. 35: 602-47 [PMID:24661201]
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GPR18, GPR55 and GPR119
G protein-coupled receptors → GPR18, GPR55 and GPR119
Overview: GPR18, GPR55 and GPR119 (provisional nomenclature), although showing little structural similarity to CB1 and CB2 cannabinoid receptors, respond to endogenous agents analogous
to the endogenous cannabinoid ligands, as well as some natural/synthetic cannabinoid receptor ligands [1564]. Although there are multiple reports to indicate that GPR18, GPR55 and GPR119 can be
activated in vitro by N-arachidonoylglycine, lysophosphatidylinositol and N-oleoylethanolamide, respectively, there is a lack of evidence for activation by these lipid messengers in vivo. As such, therefore,
these receptors retain their orphan status.
Nomenclature GPR18 GPR55 GPR119
HGNC, UniProt GPR18, Q14330 GPR55, Q9Y2T6 GPR119, Q8TDV5
Potency order of endogenous ligands – – N-oleoylethanolamide,
N-palmitoylethanolamine > SEA (anandamide
is ineffective) [1520]
Endogenous agonists N-arachidonoylglycine [1026] lysophosphatidylinositol [773, 1502,
1854],
2-arachidonoylglycerolphosphoinositol
[1504]
N-oleoylethanolamide [354, 1520, 1854],
N-palmitoylethanolamine, SEA
Selective agonists – AM251 [773, 948, 1695] AS1269574 [2190], PSN632408 [1520],
PSN375963 [1520]
Selective antagonists – CID16020046 (pA2 7.3) [949] –
Comments The pairing of N-arachidonoylglycine with GPR18 was not replicated
in two studies based on arrestin assays [1854, 2182]. See [414] for
discussion.
See reviews [414] and [1800]. In addition to those shown above, further small
molecule agonists have been reported [722].
Comments: GPR18 failed to respond to a variety of lipid-
derived agents in an in vitro screen [2182], but has been re-
ported to be activated by9-tetrahydrocannabinol [1308]. GPR55
responds to AM251 and rimonabant at micromolar concentra-
tions, compared to their nanomolar afﬁnity as CB1 receptor
antagonists/inverse agonists [1564]. It has been reported that
lysophosphatidylinositol acts at other sites in addition to GPR55
[2164]. N-Arachidonoylserine has been suggested to act as a
low efﬁcacy agonist/antagonist at GPR18 in vitro [1306]. It has
also been suggested oleoyl-lysophosphatidylcholine acts, at least
in part, through GPR119 [1466]. Although PSN375963 and
PSN632408 produce GPR119-dependent responses in heterolo-
gous expression systems, comparisonwith N-oleoylethanolamide-
mediated responses suggests additional mechanisms of action
[1466].
Further reading on GPR18, GPR55 and GPR119
Davenport AP et al. (2013) International Union of Basic and Clinical Pharmacology. LXXXVIII. G
protein-coupled receptor list: recommendations for new pairings with cognate ligands. Phar-
macol. Rev. 65: 967-86 [PMID:23686350]
Hassing HA et al. (2016) Biased signaling of lipids and allosteric actions of synthetic molecules for
GPR119. Biochem Pharmacol 119: 66-75 [PMID:27569424]
Liu B et al. (2015) GPR55: from orphan to metabolic regulator? Pharmacol Ther 145: 35-42
[PMID:24972076]
Pertwee RG et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabi-
noid receptors and their ligands: beyond CB_1 and CB_2. Pharmacol. Rev. 62: 588-631
[PMID:21079038]
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Histamine receptors
G protein-coupled receptors → Histamine receptors
Overview: Histamine receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on Histamine Receptors
[790, 1528]) are activated by the endogenous ligand histamine.
Marked species differences exist between histamine receptor or-
thologues [790]. The human and rat H3 receptor genes are subject
to signiﬁcant splice variance [91]. The potency order of histamine
at histamine receptor subtypes is H3 =H4 >H2 >H1 [1528]. Some
agonists at the human H3 receptor display signiﬁcant ligand bias
[1659]. Antagonists of all 4 histamine receptors have clinical uses:
H1 antagonists for allergies (e.g. cetirizine), H2 antagonists for
acid-reﬂux diseases (e.g. ranitidine), H3 antagonists for narcolepsy
(e.g. pitolisant/WAKIX; Registered) and H4 antagonists for atopic
dermatitis (e.g. ZPL-3893787; Phase IIa) [1528].
Nomenclature H1 receptor H2 receptor H3 receptor H4 receptor
HGNC, UniProt HRH1, P35367 HRH2, P25021 HRH3, Q9Y5N1 HRH4, Q9H3N8
Selective agonists methylhistaprodifen [1766], histaprodifen
[1173]
amthamine [1048] immethridine [1011], methimepip [1010],
MK-0249 (Inverse agonist) [1413]
clobenpropit (Partial agonist)
[517, 1173, 1188, 1189, 1389],
4-methylhistamine [617, 1173],
ST-1006 [1528], VUF 8430 [1172]
Antagonists cyproheptadine (pKi 10.2) [1352],
promethazine (pKi 9.6) [636], pyrilamine
(Inverse agonist) (pKi 8.7–9) [188, 1634],
cetirizine (Inverse agonist) (pKi 8.2) [1352],
diphenhydramine (pKi 7.9) [188]
– iodophenpropit (pKi 8.2–8.7) [2112, 2139] –
Sub/family-selective antagonists – – thioperamide (Selective for H3/H4 compared to
H1 and H3.) (pKi 7.1–7.7) [368, 516, 517,
1170, 1211, 2112, 2139]
thioperamide (Selective for H3/H4
compared to H1 and H3.) (pKi
6.3–7.6) [516, 517, 1188, 1189,
1389, 2226]
Selective antagonists clemastine (pKi 10.3) [71], desloratadine (pKi
9) [1156], triprolidine (pKi 8.5–9) [188, 1352],
azelastine (pKi 8.9) [1606], astemizole (pKi
8.5) [1547]
tiotidine (pKi 7.5) [149] – Rat,
ranitidine (pKi 7.1) [1152],
cimetidine (pKi 6.8) [274]
pitolisant (pKi 8.1–8.6) [1528, 2254], A331440
(pKi 8.5) [723], conessine (pKi 8.3) [1528],
MK-0249 (pKi 8.2) [1528], ciproxifan (pKi
6.7–7.3) [368, 516, 517, 1170, 1528, 2139]
ZPL-3893787 (pKi 8.3) [1528],
INCB-38579 (pKi 8.3) [1528],
JNJ 7777120 (pKi 7.8–8.3) [1173,
1839, 1959], JNJ-39758979 (pKi
7.9) [1528, 1727]
Labelled ligands [3H]pyrilamine (Antagonist, Inverse agonist)
(pKd 8.4–9.1) [422, 1352, 1746, 1766],
[11C]doxepin (Antagonist) (pKd 9) [869],
[11C]pyrilamine (Antagonist, Inverse agonist)
[125I]iodoaminopotentidine
(Antagonist) (pKd 8.7) [1082]
– Rat, [3H]tiotidine
(Antagonist) (pKd 7.7–8.7)
[1363]
[123I]iodoproxyfan (Antagonist) (pKd 10.2)
[1170], [125I]iodophenpropit (Antagonist) (pKd
9.2) [891] – Rat, [3H](R)-α-methylhistamine
(Agonist) [1188], N-[3H]α-methylhistamine
(Agonist) [317] – Mouse
[3H]JNJ 7777120 (Antagonist)
(pKd 8.4) [1959]
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Comments: histaprodifen and methylhistaprodifen are reduced
efﬁcacy agonists. The H4 receptor appears to exhibit broadly simi-
lar pharmacology to the H3 receptor for imidazole-containing lig-
ands, although (R)-α-methylhistamine and N-α-methylhistamine
are less potent, while clobenpropit acts as a reduced efﬁcacy ago-
nist at the H4 receptor and an antagonist at the H3 receptor [1188,
1419, 1455, 1489, 2226]. Moreover, 4-methylhistamine is iden-
tiﬁed as a high afﬁnity, full agonist for the human H4 receptor
[1173]. [3H]histamine has been used to label the H4 receptor in
heterologous expression systems.
Further reading on Histamine receptors
Gbahou F et al. (2012) The histamine autoreceptor is a short isoform of the H_3 receptor. Br. J.
Pharmacol. 166: 1860-71 [PMID:22356432]
Nieto-Alamilla G et al. (2016) The Histamine H3 Receptor: Structure, Pharmacology, and Function.
Mol. Pharmacol. 90: 649-673 [PMID:27563055]
Panula P et al. (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine
Receptors. Pharmacol. Rev. 67: 601-55 [PMID:26084539]
van Rijn RM et al. (2008) Cloning and characterization of dominant negative splice variants of the
human histamine H4 receptor. Biochem. J. 414: 121-31 [PMID:18452403]
Hydroxycarboxylic acid receptors
G protein-coupled receptors → Hydroxycarboxylic acid receptors
Overview: The hydroxycarboxylic acid family of receptors
(ENSFM00500000271913, nomenclature as agreed by the
NC-IUPHAR Subcommittee on Hydroxycarboxylic acid
receptors [414, 1491]) respond to organic acids, including the
endogenous hydroxy carboxylic acids 3-hydroxy butyric acid and
L-lactic acid, as well as the lipid lowering agents nicotinic acid
(niacin), acipimox and acifran [1842, 1989, 2125]. These receptors
were provisionally described as nicotinic acid receptors, although
nicotinic acid shows submicromolar potency at HCA2 receptors
only and is unlikely to be the natural ligand [1989, 2125].
Nomenclature HCA1 receptor HCA2 receptor HCA3 receptor
HGNC, UniProt HCAR1, Q9BXC0 HCAR2, Q8TDS4 HCAR3, P49019
Potency order of endogenous ligands – β-D-hydroxybutyric acid > butyric acid –
Endogenous agonists L-lactic acid [16, 266, 1190, 1854] β-D-hydroxybutyric acid [1912], butyric acid 3-hydroxyoctanoic acid [15]
Agonists 3,5-dihydroxybenzoic acid [1187] SCH 900271 [1522], GSK256073 [1861] –
Selective agonists – MK 6892 [1788], MK 1903 [166], nicotinic acid [1842, 1989, 2125],
acipimox [1842, 2125], monomethylfumarate [1933]
compound 6o [1820], IBC 293
[1769]
Labelled ligands – [3H]nicotinic acid (Agonist) [1842, 1989, 2125] –
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Comments: Further closely-related GPCRs include the
5-oxoeicosanoid receptor (OXER1, Q8TDS5) andGPR31 (O00270).
Lactate activates HCA1 on adipocytes in an autocrine manner. It
inhibits lipolysis and thereby promotes anabolic effects. HCA2
and HCA3 regulate adipocyte lipolysis and immune functions un-
der conditions of increased FFA formation through lipolysis (e.g.,
during fasting). HCA2 agonists acting mainly through the recep-
tor on immune cells exert antiatherogenic and anti-inﬂammatory
effects. HCA2 is also a receptor for butyrate and mediates some
of the beneﬁcial effects of short-chain fatty acids produced by gut
microbiota.
Further reading on Hydroxycarboxylic acid receptors
Boatman PD et al. (2008) Nicotinic acid receptor agonists. J. Med. Chem. 51: 7653-62
[PMID:18983141]
Graff EC et al. (2016) Anti-inﬂammatory effects of the hydroxycarboxylic acid receptor 2. Metab.
Clin. Exp. 65: 102-13 [PMID:26773933]
Kamanna VS et al. (2013) Recent advances in niacin and lipid metabolism. Curr. Opin. Lipidol. 24:
239-45 [PMID:23619367]
Offermanns S. (2017) Hydroxy-Carboxylic Acid Receptor Actions in Metabolism. Trends Endocrinol.
Metab. [PMID:28087125]
Offermanns S et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXII:
Nomenclature and Classiﬁcation of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and
GPR109B). Pharmacol. Rev. 63: 269-90 [PMID:21454438]
Offermanns S et al. (2015) Nutritional or pharmacological activation of HCA(2) ameliorates neu-
roinﬂammation. Trends Mol Med 21: 245-55 [PMID:25766751]
Kisspeptin receptor
G protein-coupled receptors → Kisspeptin receptor
Overview: The kisspeptin receptor (nomenclature as agreed
by the NC-IUPHAR Subcommittee on the kisspeptin re-
ceptor [1004]), like neuropeptide FF (NPFF), prolactin-releasing
peptide (PrP) and QRFP receptors (provisional nomenclature) re-
sponds to endogenous peptides with an arginine-phenylalanine-
amide (RFamide) motif. Kisspeptin-54 (KISS1, Q15726) (KP54,
originally named metastin), kisspeptin-13 (KISS1, Q15726) (KP13)
and kisspeptin-10 (KISS1) (KP10) are biologically-active peptides
cleaved from the KISS1 (Q15726) gene product. Kisspeptins have
roles in, for example, cancer metastasis, fertility/puberty regula-
tion and glucose homeostasis.
Nomenclature kisspeptin receptor
HGNC, UniProt KISS1R, Q969F8
Endogenous agonists kisspeptin-10 (KISS1) [1041, 1501], kisspeptin-54 (KISS1, Q15726) [1041, 1501], kisspeptin-14 (KISS1, Q15726) [1041], kisspeptin-13 (KISS1, Q15726) [1041]
Selective agonists 4-ﬂuorobenzoyl-FGLRW-NH2 [1973], [dY]1KP-10 [401] – Mouse
Selective antagonists peptide 234 [1674]
Labelled ligands [125I]Tyr45-kisspeptin-15 (Agonist) [1501], [125I]kisspeptin-13 (human) (Agonist) [1314], [125I]kisspeptin-10 (human) (Agonist) [1041], [125I]kisspeptin-14 (human) (Agonist)
[1314]
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Further reading on Kisspeptin receptor
Kanda S et al. (2013) Structure, synthesis, and phylogeny of kisspeptin and its receptor. Adv. Exp.
Med. Biol. 784: 9-26 [PMID:23550000]
Kirby HR et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVII.
Kisspeptin receptor nomenclature, distribution, and function. Pharmacol. Rev. 62: 565-78
[PMID:21079036]
Millar RP et al. (2010) Kisspeptin antagonists: unraveling the role of kisspeptin in reproductive
physiology. Brain Res. 1364: 81-9 [PMID:20858467]
Oakley AE et al. (2009) Kisspeptin signaling in the brain. Endocr. Rev. 30: 713-43 [PMID:19770291]
Pasquier J et al. (2014) Molecular evolution of GPCRs: Kisspeptin/kisspeptin receptors. J. Mol. En-
docrinol. 52: T101-17 [PMID:24577719]
Leukotriene receptors
G protein-coupled receptors → Leukotriene receptors
Overview: The leukotriene receptors (nomenclature as
agreed by the NC-IUPHAR subcommittee on Leukotriene
Receptors [257, 258]) are activated by the endogenous
ligands leukotrienes (LT), synthesized from lipoxygenase
metabolism of arachidonic acid. The human BLT1 recep-
tor is the high afﬁnity LTB4 receptor whereas the BLT2 re-
ceptor in addition to being a low-afﬁnity LTB4 receptor also
binds several other lipoxygenase-products, such as 12S-HETE,
12S-HPETE, 15S-HETE, and the thromboxane synthase product
12-hydroxyheptadecatrienoic acid. The BLT receptors mediate
chemotaxis and immunomodulation in several leukocyte popu-
lations and are in addition expressed on non-myeloid cells, such
as vascular smooth muscle and endothelial cells. In addition to
BLT receptors, LTB4 has been reported to bind to the peroxisome
proliferator activated receptor (PPAR) α [1178] and the vanilloid
TRPV1 ligand-gated nonselective cation channel [1307]. The re-
ceptors for the cysteinyl-leukotrienes (i.e. LTC4, LTD4 and LTE4)
are termed CysLT1 andCysLT2 and exhibit distinct expression pat-
terns in human tissues, mediating for example smoothmuscle cell
contraction, regulation of vascular permeability, and leukocyte
activation. There is also evidence in the literature for additional
CysLT receptor subtypes, derived from functional in vitro studies,
radioligand binding and in mice lacking both CysLT1 and CysLT2
receptors [258]. Cysteinyl-leukotrienes have also been suggested
to signal through the P2Y12 receptor [570, 1473, 1534], GPR17
[359] and GPR99 [943].
Nomenclature BLT1 receptor BLT2 receptor CysLT1 receptor CysLT2 receptor
HGNC, UniProt LTB4R, Q15722 LTB4R2, Q9NPC1 CYSLTR1, Q9Y271 CYSLTR2, Q9NS75
Potency order of endogenous
ligands
LTB4 >20-hydroxy-LTB4
12R-HETE [2185]
12-hydroxyheptadecatrienoic acid > LTB4
> 12S-HETE = 12S-HPETE > 15S-HETE >
12R-HETE > 20-hydroxy-LTB4 [1510, 2185]
LTD4 > LTC4 > LTE4 [1222, 1716] LTC4 ≥ LTD4  LTE4 [767, 1477,
1920]
Endogenous agonists – 12S-HETE (Partial agonist) [2185] – –
Antagonists – – ICI198615 (pKi 9.7) [591] – Guinea pig BAYu9773 (pA2 6.8–7.7) [1988] – Rat
Selective antagonists BIIL 260 (pKi 8.8) [156, 485],
CP105696 (pIC50 8.1) [1803],
U75302 (pKi 6.4) [174]
LY255283 (pIC50 6–7.1) [780, 2185] zaﬁrlukast (pIC50 8.6–8.7) [1222, 1716],
SR2640 (pKi 8.7), montelukast (pIC50
8.3–8.6) [1222, 1716], sulukast (pKi 8.3),
pobilukast (pIC50 7.5) [1716]
BayCysLT2 (pIC50 6.6–7.3) [1456]
Labelled ligands [3H]LTB4 (Agonist) [2184],
[3H]CGS23131 (Antagonist) (pKd
7.9) [877]
[3H]LTB4 (pKd 7.6–9.7) [
3H]LTD4 (Agonist), [3H]ICI-198615
(Antagonist) (pKd 10.6) [1682]
[3H]LTD4 (Agonist) [767]
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Nomenclature OXE receptor FPR2/ALX
HGNC, UniProt OXER1, Q8TDS5 FPR2, P25090
Potency order of endogenous
ligands
5-oxo-ETE, 5-oxo-C20:3, 5-oxo-ODE > 5-oxo-15-HETE > 5S-HPETE > 5S-HETE
[823, 920, 1538]
LXA4 = aspirin triggered lipoxin A4 = ATLa2 = resolvin D1 > LTC4 = LTD4 
15-deoxy-LXA4  fMet-Leu-Phe [365, 544, 546, 684, 1919]
Endogenous agonists 5-oxo-ETE [672, 1483, 1538, 1597, 1752] LXA4 [1052], resolvin D1 [1052], aspirin-triggered resolvin D1 [1051],
aspirin triggered lipoxin A4
Selective agonists – ATLa2 [697]
Endogenous antagonists 5-oxo-12-HETE (pIC50 6.3) [1596] –
Selective antagonists – WRWWWW (pIC50 6.6) [83], t-Boc-FLFLF (pIC50 4.3–6) [574, 1867, 2061]
Labelled ligands [3H]5-oxo-ETE (Agonist) [1483] [3H]LXA4 (Agonist) [544, 545]
Comments: The FPR2/ALX receptor (nomenclature as agreed
by the NC-IUPHAR subcommittee on Leukotriene and
Lipoxin Receptors [258]) is activated by the endogenous lipid-
derived, anti-inﬂammatory ligands lipoxin A4 (LXA4) and 15-epi-
LXA4 (aspirin triggered lipoxin A4, ATL). The FPR2/ALX recep-
tor also interacts with endogenous peptide and protein ligands,
such as MHC binding peptide [330] as well as annexin I (ANXA1,
P04083) (ANXA1) and its N-terminal peptides [379, 1560]. In
addition, a soluble hydrolytic product of protease action on the
urokinase-type plasminogen activator receptor has been reported
to activate the FPR2/ALX receptor [1646]. Furthermore, FPR2/ALX
has been suggested to act as a receptor mediating the proinﬂam-
matory actions of the acute-phase reactant, serum amyloid A
[1840, 1883]. The agonist activity of the lipid mediators described
has been questioned [732, 1585], whichmay derive from batch-to-
batch differences, partial agonism or biased agonism. Recent re-
sults from Cooray et al. (2013) [379] have addressed this issue and
the role of homodimers and heterodimers in intracellular signal-
ing. A receptor selective for LXB4 has been suggested from func-
tional studies [58, 1232, 1670]. Note that the data for FPR2/ALX
are also reproduced on the Formylpeptide receptor pages.
Oxoeicosanoid receptors (OXE, nomenclature agreed by the
NC-IUPHAR subcommittee on Oxoeicosanoid Receptors
[219]) are activated by endogenous chemotactic eicosanoid lig-
ands oxidised at the C-5 position, with 5-oxo-ETE the most potent
agonist identiﬁed for this receptor. Initial characterization of the
heterologously expressed OXE receptor suggested that polyunsat-
urated fatty acids, such as docosahexaenoic acid and EPA, acted as
receptor antagonists [823].
Further reading on Leukotriene receptors
Bäck M et al. (2011) International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene
receptor nomenclature, distribution, and pathophysiological functions. Pharmacol. Rev. 63:
539-84 [PMID:21771892]
Bäck M et al. (2014) Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review
7. Br. J. Pharmacol. 171: 3551-74 [PMID:24588652]
Brink C et al. (2004) International Union of Pharmacology XLIV. Nomenclature for the Oxoe-
icosanoid Receptor. Pharmacol. Rev. 56: 149-157 [PMID:15001665]
Brink C et al. (2003) International Union of Pharmacology XXXVII. Nomenclature for leukotriene
and lipoxin receptors. Pharmacol. Rev. 55: 195-227 [PMID:12615958]
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Lysophospholipid (LPA) receptors
G protein-coupled receptors → Lysophospholipid (LPA) receptors
Overview: Lysophosphatidic acid (LPA) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee
on Lysophospholipid Receptors [414, 983]) are activated
by the endogenous phospholipid metabolite LPA. The ﬁrst
receptor, LPA1, was identiﬁed as ventricular zone gene-1 (vzg-1),
leading to deorphanisation of members of the endothelial dif-
ferentiation gene (edg) family as other LPA receptors along with
sphingosine 1-phosphate (S1P) receptors. Additional LPA recep-
tor GPCRs were later identiﬁed. Gene names have been codi-
ﬁed as LPAR1, etc. to reﬂect the receptor function of proteins.
The crystal structure of LPA1 was recently solved and demon-
strates extracellular LPA access to the binding pocket, consis-
tent with proposed delivery via autotaxin. These studies have
also implicated cross-talk with endocannabinoids via phospho-
rylated intermediates that can also activate these receptors. The
identiﬁed receptors can account for most, although not all, LPA-
induced phenomena in the literature, indicating that amajority of
LPA-dependent phenomena are receptor-mediated. Radioligand
binding has been conducted in heterologous expression systems
using [3H]LPA (e.g. [586]). In native systems, analysis of binding
data is complicated by metabolism and high levels of nonspeciﬁc
binding, and therefore the relationship between recombinant and
endogenously expressed receptors is unclear. Targeted deletion
of LPA receptors has clariﬁed signalling pathways and identiﬁed
physiological and pathophysiological roles. Independent valida-
tion by multiple groups has been reported in the peer-reviewed
literature for all six LPA receptors described in the tables, includ-
ing further validation using a distinct read-out via a novel TGFα
"shedding" assay [864]. LPA has also been described as an ago-
nist for the transient receptor potential (Trp) ion channel TRPV1
[1461] and TRPA1 [1012]. In addition, orphan GPCRs (PSP24 [547]
and GPR87 [1488]) are proposed as LPA receptors. LPA was origi-
nally proposed to be a ligand for GPCR35, but recent data shows
that in fact it is a receptor for CXCL17 (CXCL17, Q6UXB2) [1266].
Further, the nuclear hormone receptor PPARγ [1309, 1812], has
been reported as an LPA receptor. All of these proposed entities
require conﬁrmation and are not currently recognized as bona ﬁde
LPA receptors.
Nomenclature LPA1 receptor LPA2 receptor LPA3 receptor LPA4 receptor LPA5 receptor LPA6 receptor
HGNC, UniProt LPAR1, Q92633 LPAR2, Q9HBW0 LPAR3, Q9UBY5 LPAR4, Q99677 LPAR5, Q9H1C0 LPAR6, P43657
Selective agonists – dodecylphosphate [2038],
decyl dihydrogen phosphate
[2038], GRI977143 [1007]
OMPT [744] – – –
Sub/family-selective antagonists Ki16425 (pIC50 6.6–6.9) [1499] –
Mouse, VPC12249 (pKi 5.2–6.9) [769] –
Mouse, VPC32179 [763]
– Ki16425 (pKi 6.4) [1499],
VPC12249 (pKi 6.4)
[769], VPC32179 [763]
– – –
Selective antagonists BMS-986020 (pIC50 8.9), AM966 (pIC50
6.7–7.8) [1905], ONO-7300243 (pIC50
6.8) [1940], AM095 (pIC50 6–6.1) [1905]
– dioctanoylglycerol
pyrophosphate (pKi
5.5–7) [548, 1499]
– TCLPA5 (pIC50 6.1)
[1047]
–
Comments: Ki16425 [1499], VPC12249 [769] and VPC32179 [763] have dual antagonist activity at LPA1 and LPA3 receptors. There is growing evidence for in vivo efﬁcacy of these chemical antagonists
in several disorders, including fetal hydrocephalus [2197], fetal hypoxia [778], lung ﬁbrosis [1495], systemic sclerosis [1495] and atherosclerosis progression [1053]. Virtual screening experiments have
shown H2L5186303 to be a potent antagonist of LPA2 [536]. Dodecylphosphate is also an antagonist at LPA3 receptors [2038].
Searchable database: http://www.guidetopharmacology.org/index.jsp Lysophospholipid (LPA) receptors S81
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129
Further reading on Lysophospholipid (LPA) receptors
Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophos-
pholipid receptor nomenclature. Pharmacol. Rev. 62: 579-87 [PMID:21079037]
Kihara Y et al. (2014) Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br. J.
Pharmacol. 171: 3575-94 [PMID:24602016]
Yung YC et al. (2014) LPA receptor signaling: pharmacology, physiology, and pathophysiology. J.
Lipid Res. 55: 1192-1214 [PMID:24643338]
Yung YC et al. (2015) Lysophosphatidic Acid signaling in the nervous system. Neuron 85: 669-82
[PMID:25695267]
Lysophospholipid (S1P) receptors
G protein-coupled receptors → Lysophospholipid (S1P) receptors
Overview: Sphingosine 1-phosphate (S1P) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Lysophospholipid receptors [983]) are activated by the en-
dogenous lipid sphingosine 1-phosphate (S1P) and with lower
apparent afﬁnity, sphingosylphosphorylcholine (SPC). Originally
cloned as orphan members of the endothelial differentiation gene
(edg) family, deorphanisation as lysophospholipid receptors for
S1P was based on sequence homology to LPA receptors. Cur-
rent gene names have been codiﬁed as S1P1R, etc. to reﬂect the
receptor function of these proteins. Most cellular phenomena
ascribed to S1P can be explained by receptor-mediated mecha-
nisms; S1P has also been described to act at intracellular sites
[1915], and awaits precise deﬁnition. Previously-proposed SPC
(or lysophophosphatidylcholine) receptors- G2A, TDAG8, OGR1
and GPR4- continue to lack conﬁrmation of these roles [414]. The
relationship between recombinant and endogenously expressed
receptors is unclear. Radioligand binding has been conducted
in heterologous expression systems using [32P]S1P (e.g [1505]).
In native systems, analysis of binding data is complicated by
metabolism and high levels of nonspeciﬁc binding. Targeted dele-
tion of several S1P receptors and key enzymes involved in S1P
biosynthesis or degradation has clariﬁed signalling pathways and
physiological roles. A crystal structure of an S1P1-T4 fusion pro-
tein has been described [733].
The S1P receptor modulator, ﬁngolimod (FTY720, Gilenya), has
received world-wide approval as the ﬁrst oral therapy for relaps-
ing forms of multiple sclerosis. This drug has a novel mechanism
of action involving modulation of S1P receptors in both the im-
mune and nervous systems [340, 369, 687], although the precise
nature of its interaction requires clariﬁcation.
Nomenclature S1P1 receptor S1P2 receptor S1P3 receptor S1P4 receptor S1P5 receptor
HGNC, UniProt S1PR1, P21453 S1PR2, O95136 S1PR3, Q99500 S1PR4, O95977 S1PR5, Q9H228
Potency order of endogenous
ligands
sphingosine 1-phosphate >
dihydrosphingosine 1-phosphate >
sphingosylphosphorylcholine [46, 1505]
sphingosine 1-phosphate >
dihydrosphingosine
1-phosphate >
sphingosylphosphorylcholine
[46, 1505]
sphingosine 1-phosphate >
dihydrosphingosine
1-phosphate >
sphingosylphosphorylcholine
[1505]
sphingosine 1-phosphate >
dihydrosphingosine
1-phosphate >
sphingosylphosphorylcholine
[2012]
sphingosine 1-phosphate >
dihydrosphingosine
1-phosphate >
sphingosylphosphorylcholine
[861]
Agonists amiselimod phosphate [1887],
FTY720-phosphate [220, 560, 1525],
siponimod [1524], AUY954 [1525], AFD(R)
[220], etrasimod [254], ﬁngolimod [708]
– – – –
Selective agonists ozanimod [657, 1274, 1757], ponesimod [176],
KRP 203-phosphate [1851] – Mouse, CYM5181
[657], SEW2871 [1713] – Mouse
– – – –
Antagonists VPC23019 (pKi 7.9) [419], VPC03090-P (pKi
7.6–7.7) [972], VPC44116 (pIC50 7.6) [561]
– VPC44116 (pKi 6.5) [561],
VPC23019 (pKi 5.9) [419]
– –
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(continued)
Nomenclature S1P1 receptor S1P2 receptor S1P3 receptor S1P4 receptor S1P5 receptor
Selective antagonists NIBR-0213 (pIC50 8.6) [1615], W146 (pKi 7.1)
[1714]
JTE-013 (pIC50 7.8) [1515] – – –
Comments: The FDA-approved immunomodulator ﬁngolimod (FTY720) can be phosphorylated in vivo [31] to generate a relatively potent agonist with activity at S1P1, S1P3, S1P4 and S1P5 receptors [220,
1259]. The physiological consequences of FTY720-phosphate administration, as well as those of other S1P1 agonists, may involve functional antagonism via ubiquitination and subsequent degradation
of S1P1 [1514].
Further reading on Lysophospholipid (S1P) receptors
Chew WS et al. (2016) To ﬁngolimod and beyond: The rich pipeline of drug candidates that target
S1P signaling. Pharmacol. Res. 113: 521-532 [PMID:27663260]
Chun J et al. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophos-
pholipid receptor nomenclature. Pharmacol. Rev. 62: 579-87 [PMID:21079037]
Pyne NJ et al. (2017) Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells. Molecules
22: [PMID:28241498]
Rosen H et al. (2013) Sphingosine-1-phosphate and its receptors: structure, signaling, and inﬂuence.
Annu. Rev. Biochem. 82: 637-62 [PMID:23527695]
Melanin-concentrating hormone receptors
G protein-coupled receptors → Melanin-concentrating hormone receptors
Overview: Melanin-concentrating hormone (MCH) receptors (provisional nomenclature as recommended by NC-IUPHAR [557]) are activated by an endogenous nonadecameric cyclic peptide
identical in humans and rats (DFDMLRCMLGRVYRPCWQV) generated from a precursor (PMCH, P20382), which also produces neuropeptide EI (PMCH, P20382) and neuropeptide GE (PMCH, P20382).
Nomenclature MCH1 receptor MCH2 receptor
HGNC, UniProt MCHR1, Q99705 MCHR2, Q969V1
Selective antagonists GW803430 (pIC50 9.3) [781], SNAP-7941 (pA2 9.2) [190], T-226296 (pIC50 8.3) [1926], ATC0175 (pIC50 7.9–8.1) [297] –
Labelled ligands [125I]S36057 (Antagonist) (pKd 9.2–9.5) [69], [
125I][Phe13,Tyr19]MCH (Agonist) [249], [3H]MCH (human, mouse, rat)
(Agonist) [249]
–
Comments: The MCH2 receptor appears to be a non-functional pseudogene in rodents [1930].
Searchable database: http://www.guidetopharmacology.org/index.jsp Melanin-concentrating hormone receptors S83
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129
Further reading on Melanin-concentrating hormone receptors
Chung S et al. (2011) Recent updates on the melanin-concentrating hormone (MCH) and its recep-
tor system: lessons from MCH1R antagonists. J. Mol. Neurosci. 43: 115-21 [PMID:20582487]
Eberle AN et al. (2010) Cellular models for the study of the pharmacology and signaling of
melanin-concentrating hormone receptors. J. Recept. Signal Transduct. Res. 30: 385-402
[PMID:21083507]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Takase K et al. (2014) Meta-analysis of melanin-concentrating hormone signaling-deﬁcient mice on
behavioral and metabolic phenotypes. PLoS ONE 9: e99961 [PMID:24924345]
Melanocortin receptors
G protein-coupled receptors → Melanocortin receptors
Overview: Melanocortin receptors (provisional nomenclature as recommended by NC-IUPHAR [557]) are activated by members of the melanocortin family (α-MSH (POMC, P01189), β-MSH
(POMC, P01189) and γ-MSH (POMC, P01189) forms; δ form is not found in mammals) and adrenocorticotrophin (ACTH (POMC, P01189)). Endogenous antagonists include agouti (ASIP, P42127) and
agouti-related protein (AGRP, O00253). ACTH(1-24) was approved by the US FDA as a diagnostic agent for adrenal function test. At least 2 synthetic melanocortin receptor agonists are under clinical
development as of 2017.
Nomenclature MC1 receptor MC2 receptor MC3 receptor MC4 receptor MC5 receptor
HGNC, UniProt MC1R, Q01726 MC2R, Q01718 MC3R, P41968 MC4R, P32245 MC5R, P33032
Potency order of endogenous
ligands
α-MSH (POMC, P01189) >
β-MSH (POMC, P01189) >
ACTH (POMC, P01189), γ-MSH
(POMC, P01189)
ACTH (POMC,
P01189)
γ-MSH (POMC, P01189), β-MSH
(POMC, P01189) > ACTH (POMC,
P01189), α-MSH (POMC, P01189)
β-MSH (POMC, P01189) > α-MSH
(POMC, P01189), ACTH (POMC, P01189)
> γ-MSH (POMC, P01189)
α-MSH (POMC, P01189) >
β-MSH (POMC, P01189) >
ACTH (POMC, P01189) >
γ-MSH (POMC, P01189)
Selective agonists – corticotropin zinc
hydroxide
[D-Trp8]γ-MSH [679] THIQ [1760] –
Antagonists – – PG-106 (pIC50 6.7) [680] – –
Selective antagonists – – – MBP10 (pIC50 10) [123], HS014 (pKi
8.5) [1738]
–
Labelled ligands [125I]NDP-MSH (Agonist)
[1037]
[125I]ACTH-(1-24)
(Agonist)
[125I]NDP-MSH (Agonist) [1037],
[125I]SHU9119 (Antagonist) [1457]
[125I]SHU9119 (Antagonist) (pKd 9.2)
[1457], [125I]NDP-MSH (Agonist) [1037,
1736]
[125I]NDP-MSH (Agonist)
[1037]
Comments: Polymorphisms of the MC1 receptor have been linked to variations in skin pigmentation. Defects of the MC2 receptor underlie familial glucocorticoid deﬁciency. Polymorphisms of the
MC4 receptor have been linked to obesity [296, 531].
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Further reading on Melanocortin receptors
Caruso V et al. (2014) Synaptic changes induced by melanocortin signalling. Nat. Rev. Neurosci. 15:
98-110 [PMID:24588018]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Renquist BJ et al. (2011) Physiological roles of the melanocortin MC_3 receptor. Eur. J. Pharmacol.
660: 13-20 [PMID:21211527]
Melatonin receptors
G protein-coupled receptors → Melatonin receptors
Overview: Melatonin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Melatonin Receptors [474]) are activated by the endogenous ligands melatonin and clinically
used drugs like ramelteon and agomelatine.
Nomenclature MT1 receptor MT2 receptor
HGNC, UniProt MTNR1A, P48039 MTNR1B, P49286
Endogenous agonists melatonin [70, 473, 475] melatonin [70, 473, 475]
Agonists ramelteon [954], agomelatine [70, 136] agomelatine [70, 136], ramelteon [954, 1636]
Selective agonists – UCM1014 [1855], IIK7 [532, 1888], 5-methoxy-luzindole (Partial agonist) [475]
Selective antagonists – 4P-PDOT (pKi 8.8–9.4) [70, 475, 476], K185 (pKi 9.3) [532, 1888], DH97 (pKi 8) [1939]
Labelled ligands [125I]SD6 (Agonist) [1138], 2-[125I]melatonin (Agonist) [70, 475],
[3H]melatonin (Agonist) [235]
[125I]SD6 (Agonist) [1138], 2-[125I]melatonin (Agonist) [70, 475], [125I]DIV880 (Agonist, Partial agonist)
[1138], [3H]melatonin (Agonist) [235]
Comments: melatonin, 2-iodo-melatonin, agomelatine,
GR 196429, LY 156735 and ramelteon [954] are nonselective
agonists for MT1 and MT2 receptors. (-)-AMMTC displays an
˜400-fold greater agonist potency than (+)-AMMTC at rat MT1
receptors (see AMMTC for structure) [1966]. Luzindole is an
MT1/MT2 non-selective competitive melatonin receptor antago-
nist with about 15-25 fold selectivity for the MT2 receptor [476].
MT1/MT2 heterodimers present different pharmacological proﬁles
from MT1 and MT2 receptors [75].
The MT3 binding site of hamster brain and peripheral tissues
such as kidney and testis, also termed the ML2 receptor, binds
selectively 2-iodo-[125I]5MCA-NAT [1356]. Pharmacological in-
vestigations of MT3 binding sites have primarily been con-
ducted in hamster tissues. At this site, The endogenous ligand
N-acetylserotonin [495, 1215, 1356, 1588] and 5MCA-NAT [1588]
appear to function as agonists, while prazosin [1215] functions as
an antagonist. The MT3 binding site of hamster kidney was also
identiﬁed as the hamster homologue of human quinone reduc-
tase 2 (NQO2, P16083 [1474, 1475]). The MT3 binding site acti-
vated by 5MCA-NAT in eye ciliary body is positively coupled to
adenylyl cyclase and regulates chloride secretion [842]. Xenopus
melanophores and chick brain express a distinct receptor (x420,
P49219; c346, P49288, initially termedMel1C) coupled to the Gi/o
family of G proteins, for which GPR50 has recently been suggested
to be a mammalian counterpart [479] although melatonin does
not bind to GPR50 receptors. Several variants of theMTNR1B gene
have been associated with increased type 2 diabetes risk.
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Further reading on Melatonin receptors
Dubocovich ML et al. (2010) International Union of Basic and Clinical Pharmacology. LXXV.
Nomenclature, classiﬁcation, and pharmacology of G protein-coupled melatonin receptors.
Pharmacol. Rev. 62: 343-80 [PMID:20605968]
Jockers R et al. (2016) Update on melatonin receptors: IUPHAR Review 20. Br. J. Pharmacol. 173:
2702-25 [PMID:27314810]
Liu J et al. (2016) MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective. Annu. Rev. Phar-
macol. Toxicol. 56: 361-83 [PMID:26514204]
Zlotos DP et al. (2013) MT1 and MT2 Melatonin Receptors: Ligands, Models, Oligomers, and Ther-
apeutic Potential. J. Med. Chem. [PMID:24228714]
Metabotropic glutamate receptors
G protein-coupled receptors → Metabotropic glutamate receptors
Overview: Metabotropic glutamate (mGlu) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Metabotropic Glutamate Receptors [1743]) are a family
of G-protein coupled receptors activated by the neurotransmit-
ter glutamate. The mGlu family is composed of eight members
(namedmGlu1 tomGlu8) which are divided in three groups based
on similarities of agonist pharmacology, primary sequence and G
protein coupling to effector: Group-I (mGlu1 andmGlu5), Group-
II (mGlu2 and mGlu3) and Group-III (mGlu4, mGlu6, mGlu7 and
mGlu8) (see Further reading).
Structurally, mGlu are composed of three juxtaposed domains:
a core G-protein-activating seven-transmembrane domain (TM),
common to all GPCRs, is linked via a rigid cysteine-rich domain
(CRD) to the Venus Flytrap domain (VFTD), a large bi-lobed ex-
tracellular domain where glutamate binds. The structures of the
VFTD of mGlu1, mGlu2, mGlu3, mGlu5 and mGlu7 have been
solved [1075, 1364, 1408, 1984]. The structure of the 7 trans-
membrane (TM) domains of both mGlu1 and mGlu5 have been
solved, and conﬁrm a general helical organization similar to that
of other GPCRs, although the helices appear more compacted
[465, 2136]. mGlu form constitutive dimers crosslinked by a disul-
ﬁde bridge. Although mGlu receptors have been thought to only
form homodimers, recent studies revealed the possible formation
of heterodimers between either group-I receptors, or within and
between group-II and -III receptors [468]. Although well charac-
terized in transfected cells, co-localization and speciﬁc pharmaco-
logical properties also suggest the existence of such heterodimers
in the brain [2183].
The endogenous ligands of mGlu are L-glutamic acid,
L-serine-O-phosphate, N-acetylaspartylglutamate (NAAG) and
L-cysteine sulphinic acid. Group-I mGlu receptors may be ac-
tivated by 3,5-DHPG and (S)-3HPG [204] and antagonized by
(S)-hexylhomoibotenic acid [1235]. Group-II mGlu receptors may
be activated by LY389795 [1365], LY379268 [1365], eglumegad
[1744, 2138], DCG-IV and (2R,3R)-APDC [1745], and antago-
nised by eGlu [890] and LY307452 [518, 2096]. Group-III mGlu
receptors may be activated by L-AP4 and (R,S)-4-PPG [610]. An ex-
ample of an antagonist selective for mGlu receptors is LY341495,
which blocks mGlu2 and mGlu3 at low nanomolar concentra-
tions, mGlu8 at high nanomolar concentrations, and mGlu4,
mGlu5, and mGlu7 in the micromolar range [1001]. In addition
to orthosteric ligands that directly interact with the glutamate
recognition site, allosteric modulators that bind within the TM
domain have been described. Negative allosteric modulators are
listed separately. The positive allosteric modulators most often
act as ‘potentiators’ of an orthosteric agonist response, without
signiﬁcantly activating the receptor in the absence of agonist.
Nomenclature mGlu1 receptor mGlu2 receptor mGlu3 receptor mGlu4 receptor mGlu5 receptor
HGNC, UniProt GRM1, Q13255 GRM2, Q14416 GRM3, Q14832 GRM4, Q14833 GRM5, P41594
Endogenous agonists L-glutamic acid [1574] L-glutamic acid [1574] L-glutamic acid [1574],
NAAG [1750]
L-glutamic acid [1574] L-glutamic acid [1574]
Agonists – – – L-AP4 [2138],
L-serine-O-phosphate
[2138]
–
Selective agonists – – – LSP4-2022 [666] (S)-(+)-CBPG (Partial agonist) [1261]
– Rat, CHPG [1407]
Antagonists LY367385 (pIC50 5.1) [364] – – MAP4 (pKi 4.6) [721] – Rat –
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(continued)
Nomenclature mGlu1 receptor mGlu2 receptor mGlu3 receptor mGlu4 receptor mGlu5 receptor
Selective antagonists 3-MATIDA (pIC50 5.2) [1386] – Rat,
(S)-(+)-CBPG (pIC50 4.2) [1261] –
Rat, (S)-TBPG (pIC50 4.2) [381] – Rat,
AIDA (pA2 4.2) [1387]
PCCG-4 (pIC50 5.1) [1551] –
Rat
– – ACDPP (pIC50 6.9) [186]
Allosteric modulators – CBiPES (Positive) (pEC50 7)
[917], 4-MPPTS (Positive)
(pIC50 5.8) [100, 916, 917,
1731]
– SIB-1893 (Positive) (pEC50
6.3–6.8) [1281], MPEP
(Positive) (pEC50 6.3–6.6)
[1281], PHCCC (Positive)
(pEC50 4.5) [1247]
3,3’-diﬂuorobenzaldazine (Positive)
(pIC50 5.6–8.5) [1481, 1482],
alloswitch-1 (Negative) (pIC50 8.1)
[1583] – Rat, CDPPB (Positive)
(pEC50 7.6–8) [1002, 1180], MTEP
(Negative) (pKi 7.8) [228], MPEP
(Negative) (pIC50 7.4–7.7) [609,
611], fenobam (Negative) (pIC50
7.2) [1592], SIB-1893 (Negative)
(pIC50 5.9–6.5) [609, 2028],
SIB-1757 (Negative) (pIC50 6–6.4)
[609, 2028], CPPHA (Positive) (pIC50
6.3) [1482]
Selective allosteric modulators BAY 367620 (Negative) (pKi 9.5)
[279] – Rat, JNJ16259685 (Negative)
(pIC50 8.9) [1104], Ro01-6128
(Positive) (pKi 7.5–7.7) [1019] – Rat,
LY456236 (Negative) (pIC50 6.9)
[1160], CPCCOEt (Negative) (pIC50
5.2–5.8) [1183]
Ro64-5229 (Negative) (pIC50
7) [1031] – Rat,
biphenylindanone A (Positive)
(pEC50 7) [187]
– VU0361737 (Positive)
(pEC50 6.6) [508],
VU0155041 (Positive)
(pEC50 6.1) [1468]
VU-1545 (Positive) (pEC50 8) [429]
Nomenclature mGlu6 receptor mGlu7 receptor mGlu8 receptor
HGNC, UniProt GRM6, O15303 GRM7, Q14831 GRM8, O00222
Endogenous agonists L-glutamic acid [1574] L-glutamic acid [1574] L-serine-O-phosphate [1254, 2138], L-glutamic acid
[1574]
Agonists – LSP4-2022 [666], L-serine-O-phosphate [2138], L-AP4 [2138] (S)-3,4-DCPG [1952], L-AP4 [1254]
Selective agonists 1-benzyl-APDC [1987] – Rat, homo-AMPA
[244]
– –
Antagonists MAP4 (pIC50 3.5) [1575] – Rat, THPG [1956] – MPPG (pIC50 4.3) [2138]
Allosteric modulators – MMPIP (Negative) (pIC50 6.1–7.6) [1467, 1900] – Rat, ADX71743
(Negative) (pIC50 7.2) [938], AMN082 (Positive) (pEC50 6.5–6.8)
[1349], XAP044 (Negative) (pIC50 5.6) [618]
–
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Comments: The activity of NAAG as an agonist at mGlu3 recep-
tors was questioned on the basis of contamination with glutamate
[341, 576], but this has been refuted [1430].
Radioligand binding using a variety of radioligands has been
conducted on recombinant receptors (for example, [3H]R214127
[1103] and [3H]YM298198 [1025] at mGlu1 receptors and
[3H]M-MPEP [609] and [3H]methoxymethyl-MTEP [48] at mGlu5
receptors. Although a number of radioligands have been used
to examine binding in native tissues, correlation with individ-
ual subtypes is limited. Many pharmacological agents have not
been fully tested across all known subtypes of mGlu receptors. Po-
tential differences linked to the species (e.g. human versus rat or
mouse) of the receptors and the receptor splice variants are gen-
erally not known. The inﬂuence of receptor expression level on
pharmacology and selectivity has not been controlled for in most
studies, particularly those involving functional assays of receptor
coupling.
(S)-(+)-CBPG is an antagonist at mGlu1, but is an agonist (albeit
of reduced efﬁcacy) at mGlu5 receptors. DCG-IV also exhibits
agonist activity at NMDA glutamate receptors [2007], and is
an antagonist at all Group-III mGluRs with an IC50 of 30μM.
A potential novel metabotropic glutamate receptor coupled to
phosphoinositide turnover has been observed in rat brain; it is ac-
tivated by 4-methylhomoibotenic acid (ineffective as an agonist
at recombinant Group I metabotropic glutamate receptors), but is
resistant to LY341495 [356]. There are also reports of a distinct
metabotropic glutamate receptor coupled to phospholipase D in
rat brain, which does not readily ﬁt into the current classiﬁcation
[1013, 1549]
A related class C receptor composed of two distinct subunits, T1R1
+ T1R3 is also activated by glutamate and is responsible for umami
taste detection.
All selective antagonists at metabotropic glutamate receptors are
competitive.
Further reading on Metabotropic glutamate receptors
Conn PJ et al. (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev.
Pharmacol. Toxicol. 37: 205-237 [PMID:9131252]
Ferraguti F et al. (2006) Metabotropic glutamate receptors. Cell Tissue Res. 326: 483-504
[PMID:16847639]
Nicoletti F et al. (2011) Metabotropic glutamate receptors: from the workbench to the bedside.
Neuropharmacology 60: 1017-41 [PMID:21036182]
Niswender CM et al. (2010) Metabotropic glutamate receptors: physiology, pharmacology, and dis-
ease. Annu. Rev. Pharmacol. Toxicol. 50: 295-322 [PMID:20055706]
Pin JP et al. (2016) Organization and functions of mGlu and GABAB receptor complexes. Nature
540: 60-68 [PMID:27905440]
Rondard P et al. (2011) The complexity of their activation mechanism opens new possibilities for
the modulation of mGlu and GABAB class C G protein-coupled receptors. Neuropharmacology
60: 82-92 [PMID:20713070]
Motilin receptor
G protein-coupled receptors → Motilin receptor
Overview: Motilin receptors (provisional nomenclature) are activated by motilin (MLN, P12872), a 22 amino-acid peptide derived from a precursor (MLN, P12872), which may also generate a
motilin-associated peptide (MLN, P12872). These receptors promote gastrointestinal motility and are suggested to be responsible for the gastrointestinal prokinetic effects of certain macrolide antibiotics
(often called motilides; e.g. erythromycin), although for many of these molecules the evidence is sparse.
Nomenclature motilin receptor
HGNC, UniProt MLNR, O43193
Endogenous agonists motilin (MLN, P12872) [386, 1286, 1287, 1288]
Agonists alemcinal [1947], erythromycin-A [533, 1947], azithromycin [225]
Selective agonists camicinal [105, 1712], mitemcinal [1023, 1918] – Rabbit
Selective antagonists MA-2029 (pA2 9.2) [1884], GM-109 (pIC50 8) [736] – Rabbit
Labelled ligands [125I]motilin (human) (Agonist) [533]
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Comments: In terms of structure, the motilin receptor has clos-
est homology with the ghrelin receptor. Thus, the human motilin
receptor shares 52% overall amino acid identity with the ghre-
lin receptor and 86% in the transmembrane regions [759, 1918,
1947]. However, differences between the N-terminus regions of
these receptors means that their cognate peptide ligands do not
readily activate each other [408, 1712]. In laboratory rodents, the
gene encoding the motilin percursor appears to be absent, while
the receptor appears to be a pseudogene [759, 1710]. Functions
of motilin (MLN, P12872) are not usually detected in rodents, al-
though brain and other responses to motilin and the macrolide
alemcinal have been reported and the mechanism of these ac-
tions is obscure [1311, 1462]. Notably, in some non-laboratory
rodents (e.g. the North American kangaroo rat (Dipodomys) and
mouse (Microdipodops) a functional form of motilin may exist but
the motilin receptor is non-functional [1159]. Marked differences
in ligand afﬁnities for the motilin receptor in dogs and humans
may be explained by signiﬁcant differences in receptor structure
[1711]. Note that for the complex macrolide structures, selectivity
of action has often not been rigorously examined and other ac-
tions are possible (e.g. P2X inhibition by erythromycin; [2216]).
Small molecule motilin receptor agonists are now described [1159,
1712, 2100]. The motilin receptor does not appear to have consti-
tutive activity [812]. Although not proven, the existence of biased
agonism at the receptor has been suggested [1288, 1348, 1709]. A
truncated 5-transmembrane structure has been identiﬁed but this
is without activity when transfected into a host cell [533]. Recep-
tor dimerisation has not been reported.
Further reading on Motilin receptor
De Smet B et al. (2009) Motilin and ghrelin as prokinetic drug targets. Pharmacol. Ther. 123: 207-23
[PMID:19427331]
Sanger GJ et al. (2016) Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.
Nat Rev Gastroenterol Hepatol 13: 38-48 [PMID:26392067]
Neuromedin U receptors
G protein-coupled receptors → Neuromedin U receptors
Overview: Neuromedin U receptors (provisional nomen-
clature as recommended by NC-IUPHAR [557]) are acti-
vated by the endogenous 25 amino acid peptide neuromedin U
(neuromedin U-25 (NMU, P48645), NmU-25), a peptide originally
isolated from pig spinal cord [1344]. In humans, NmU-25 appears
to be the sole product of a precursor gene (NMU, P48645) showing
a broad tissue distribution, but which is expressed at highest lev-
els in the upper gastrointestinal tract, CNS, bone marrow and fetal
liver. Much shorter versions of NmU are found in some species,
but not in human, and are derived at least in some instances from
the proteolytic cleavage of the longer NmU. Despite species differ-
ences in NmU structure, the C-terminal region (particularly the
C-terminal pentapeptide) is highly conserved and contains bio-
logical activity. Neuromedin S (neuromedin S-33 (NMS, Q5H8A3))
has also been identiﬁed as an endogenous agonist [1378]. NmS-
33 is, as its name suggests, a 33 amino-acid product of a precursor
protein derived from a single gene and contains an amidated C-
terminal heptapeptide identical to NmU. NmS-33 appears to acti-
vate NMU receptors with equivalent potency to NmU-25.
Nomenclature NMU1 receptor NMU2 receptor
HGNC, UniProt NMUR1, Q9HB89 NMUR2, Q9GZQ4
Antagonists – R-PSOP (pKB 7) [1193]
Comments: NMU1 and NMU2 couple predominantly to Gq/11 although there is evidence of good coupling to Gi/o [218, 825, 833]. NMU1 and NMU2 can be labelled with [125I]-NmU and [125I]-NmS
(of various species, e.g. [1319]), BODIPY® TMR-NMU or Cy3B-NMU-8 [218]. A range of radiolabelled (125I-), ﬂuorescently labelled (e.g. Cy3, Cy5, rhodamine and FAM) and biotin labelled versions of
neuromedin U-25 (NMU, P48645) and neuromedin S-33 (NMS, Q5H8A3) are now commercially available.
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Further reading on Neuromedin U receptors
Brighton PJ et al. (2004) Neuromedin U and its receptors: structure, function, and physiological
roles. Pharmacol. Rev. 56: 231-48 [PMID:15169928]
Budhiraja S et al. (2009) Neuromedin U: physiology, pharmacology and therapeutic potential. Fun-
dam Clin Pharmacol 23: 149-57 [PMID:19645813]
Mitchell JD et al. (2009) Emerging pharmacology and physiology of neuromedin U and the struc-
turally related peptide neuromedin S. Br. J. Pharmacol. 158: 87-103 [PMID:19519756]
Novak CM. (2009) Neuromedin S and U. Endocrinology 150: 2985-7 [PMID:19549882]
Neuropeptide FF/neuropeptide AF receptors
G protein-coupled receptors → Neuropeptide FF/neuropeptide AF receptors
Overview: The Neuropeptide FF receptor family contains
two subtypes, NPFF1 and NPFF2 (provisional nomenclature
[557]), which exhibit high afﬁnities for neuropeptide FF (NPFF,
O15130) and RFamide related peptides (RFRP: precursor gene sym-
bol NPVF, Q9HCQ7). NPFF1 is broadly distributed in the central
nervous system with the highest levels found in the limbic system
and the hypothalamus. NPFF2 is present in high density in the su-
perﬁcial layers of the mammalian spinal cord where it is involved
in nociception and modulation of opioid functions.
Nomenclature NPFF1 receptor NPFF2 receptor
HGNC, UniProt NPFFR1, Q9GZQ6 NPFFR2, Q9Y5X5
Potency order of endogenous ligands RFRP-1 (NPVF, Q9HCQ7) > RFRP-3 (NPVF, Q9HCQ7) > FMRFneuropeptide FF (NPFF,
O15130) > neuropeptide AF (NPFF, O15130) > neuropeptide SF (NPFF, O15130),
QRFP43 (QRFP, P83859), PrRP-31 (PRLH, P81277) [663]
neuropeptide AF (NPFF, O15130), neuropeptide FF (NPFF, O15130) >
PrRP-31 (PRLH, P81277) > FMRF, QRFP43 (QRFP, P83859) >
neuropeptide SF (NPFF, O15130) [663]
Endogenous agonists neuropeptide FF (NPFF, O15130) [663, 664, 1359], RFRP-3 (NPVF, Q9HCQ7) [664, 665,
1359]
neuropeptide FF (NPFF, O15130) [664, 1358]
Selective agonists – dNPA [1681], AC263093 [1092]
Antagonists RF9 (pKi 7.2) [1814] –
Selective antagonists AC262620 (pKi 7.7–8.1) [1092], AC262970 (pKi 7.4–8.1) [1092] –
Labelled ligands [125I]Y-RFRP-3 (Agonist) [664], [3H]NPVF (Agonist) [1928], [125I]NPFF (Agonist) [663] [125I]EYF (Agonist) [1359], [3H]EYF (Agonist) [1928], [125I]NPFF (Agonist)
[663]
Comments: An orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors. The antagonist RF9 is selective for NPFF receptors, but does not distinguish
between the NPFF1 and NPFF2 subtypes (pKi 7.1 and 7.2, respectively, [1814]).
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Further reading on Neuropeptide FF/neuropeptide AF receptors
Moulédous L et al. (2010) Opioid-modulating properties of the neuropeptide FF system. Biofactors
36: 423-9 [PMID:20803521]
Vyas N et al. (2006) Structure-activity relationships of neuropeptide FF and related peptidic and
non-peptidic derivatives. Peptides 27: 990-6 [PMID:16490282]
Yang HY et al. (2008) Modulatory role of neuropeptide FF system in nociception and opiate anal-
gesia. Neuropeptides 42: 1-18 [PMID:17854890]
Neuropeptide S receptor
G protein-coupled receptors → Neuropeptide S receptor
Overview: The neuropeptide S receptor (NPS, provisional nomenclature [557]) responds to the 20 amino-acid peptide neuropeptide S derived from a precursor (NPS, P0C0P6).
Nomenclature NPS receptor
HGNC, UniProt NPSR1, Q6W5P4
Endogenous agonists neuropeptide S (NPS, P0C0P6) [2159]
Selective agonists PWT1-NPS [1692] – Mouse
Selective antagonists NCGC 84 (pA2 9) [1957], SHA 68 (pA2 8.1) [1693] – Mouse, RTI-118 [2214]
Labelled ligands [125I]Tyr10NPS (human) (Agonist) [2159]
Comments: Multiple single-nucleotide polymorphisms (SNP)
and several splice variants have been identiﬁed in the human NPS
receptor. The most interesting of these is an Asn-Ile exchange at
position 107 (Asn107Ile). The human NPS receptor Asn107Ile dis-
played similar binding afﬁnity but higher NPS potency (by approx.
10-fold) than human NPS receptor Asn107 [1645]. Several epi-
demiological studies reported an association between Asn107Ile
receptor variant and susceptibility to panic disorders [458, 460,
1506, 1621]. The SNP Asn107Ile has also been linked to sleep
behavior [662], inﬂammatory bowel disease [402], schizophrenia
[1145], increased impulsivity and ADHD symptoms [1083]. Inter-
estingly, a carboxy-terminal splice variant of human NPS receptor
was found to be overexpressed in asthmatic patients [1091].
Further reading on Neuropeptide S receptor
Guerrini R et al. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S
and its receptor. Med Res Rev 30: 751-77 [PMID:19824051]
Xu YL et al. (2004) Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects.
Neuron 43: 487-497 [PMID:15312648]
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Neuropeptide W/neuropeptide B receptors
G protein-coupled receptors → Neuropeptide W/neuropeptide B receptors
Overview: The neuropeptide BW receptor 1 (NPBW1, pro-
visional nomenclature [557]) is activated by two 23-
amino-acid peptides, neuropeptide W (neuropeptide W-23
(NPW, Q8N729)) and neuropeptide B (neuropeptide B-23 (NPB,
Q8NG41)) [584, 1792]. C-terminally extended forms of the pep-
tides (neuropeptide W-30 (NPW, Q8N729) and neuropeptide B-29
(NPB, Q8NG41)) also activate NPBW1 [216]. Unique to both forms
of neuropeptide B is the N-terminal bromination of the ﬁrst tryp-
tophan residue, and it is from this post-translational modiﬁcation
that the nomenclature NPB is derived. These peptides were ﬁrst
identiﬁed from bovine hypothalamus and therefore are classed
as neuropeptides. Endogenous variants of the peptides with-
out the N-terminal bromination, des-Br-neuropeptide B-23 (NPB,
Q8NG41) and des-Br-neuropeptide B-29 (NPB, Q8NG41), were
not found to be major components of bovine hypothalamic tis-
sue extracts. The NPBW2 receptor is activated by the short and
C-terminal extended forms of neuropeptide W and neuropeptide
B [216].
Nomenclature NPBW1 receptor NPBW2 receptor
HGNC, UniProt NPBWR1, P48145 NPBWR2, P48146
Potency order of endogenous ligands neuropeptide B-29 (NPB, Q8NG41) > neuropeptide B-23 (NPB,
Q8NG41) > neuropeptide W-23 (NPW, Q8N729) > neuropeptide W-30
(NPW, Q8N729) [216]
neuropeptide W-23 (NPW, Q8N729) > neuropeptide W-30 (NPW, Q8N729) >
neuropeptide B-29 (NPB, Q8NG41) > neuropeptide B-23 (NPB, Q8NG41) [216]
Selective agonists Ava3 [945], Ava5 [945] –
Labelled ligands [125I]NPW-23 (human) (Agonist) [1816] [125I]NPW-23 (human) (Agonist) [1792]
Comments: Potency measurements were conducted with
heterologously-expressed receptors with a range of 0.14-0.57 nM
(NPBW1) and 0.98-21 nM (NPBW2). NPBW1-/- mice show
changes in social behavior, suggesting that the NPBW1 pathway
may have an important role in the emotional responses of social
interaction [1414]. For a review of the contribution of neuropep-
tideB/W to social dominance, see [2080]. It has been reported that
neuropeptideWmay have a key role in the gating of stressful stim-
uli whenmice are exposed to novel environments [1392]. Two an-
tagonists have been discovered and reported to have afﬁnity for
NPBW1, ML181 and ML250, the latter exhibiting improved selec-
tivity ( ∼ 100 fold) for NPBW1 compared to MCH1 receptors [694,
695]. Computational insights into the binding of antagonists to
this receptor have also been described [1541].
Further reading on Neuropeptide W/neuropeptide B receptors
Sakurai T. (2013) NPBWR1 and NPBWR2: Implications in Energy Homeostasis, Pain, and Emotion.
Front Endocrinol (Lausanne) 4: 23 [PMID:23515889]
Singh G et al. (2006) Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled
receptor system. Br. J. Pharmacol. 148: 1033-41 [PMID:16847439]
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Neuropeptide Y receptors
G protein-coupled receptors → Neuropeptide Y receptors
Overview: Neuropeptide Y (NPY) receptors (nomenclature as
agreed by the NC-IUPHAR Subcommittee on Neuropep-
tide Y Receptors [1330]) are activated by the endogenous
peptides neuropeptide Y (NPY, P01303), neuropeptide Y-(3-36),
peptide YY (PYY, P10082), PYY-(3-36) and pancreatic polypeptide
(PPY, P01298) (PP). The receptor originally identiﬁed as the Y3
receptor has been identiﬁed as the CXCR4 chemokine recepter
(originally named LESTR, [1201]). The y6 receptor is a func-
tional gene product in mouse, absent in rat, but contains a frame-
shift mutation in primates producing a truncated non-functional
gene [676]. Many of the agonists exhibit differing degrees of se-
lectivity dependent on the species examined. For example, the
potency of PP is greater at the rat Y4 receptor than at the hu-
man receptor [513]. In addition, many agonists lack selectiv-
ity for individual subtypes, but can exhibit comparable potency
against pairs of NPY receptor subtypes, or have not been exam-
ined for activity at all subtypes. [125I]-PYY or [125I]-NPY can be
used to label Y1, Y2, Y5 and y6 subtypes non-selectively, while
[125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP may be used
to label Y5 receptors preferentially (note that cPP denotes chicken
peptide sequence and hPP is the human sequence).
Nomenclature Y1 receptor Y2 receptor Y4 receptor Y5 receptor y6 receptor
HGNC, UniProt NPY1R, P25929 NPY2R, P49146 NPY4R, P50391 NPY5R, Q15761 NPY6R, Q99463
Potency order of endogenous
ligands
neuropeptide Y = peptide YY
 pancreatic polypeptide
peptide YY = peptide YY(3-36) = neuropeptide Y
= neuropeptide Y(3-36)  pancreatic
polypeptide
pancreatic polypeptide 
neuropeptide Y = peptide
YY
neuropeptide Y > peptide YY
> pancreatic polypeptide
neuropeptide Y =
peptide YY >
pancreatic
polypeptide
Endogenous agonists neuropeptide Y (NPY,
P01303), peptide YY (PYY,
P10082)
PYY-(3-36) (PYY, P10082) [619, 633],
neuropeptide Y (NPY, P01303),
neuropeptide Y-(3-36) (NPY, P01303),
peptide YY (PYY, P10082)
pancreatic polypeptide
(PPY, P01298) [98, 1217,
1978, 2165]
– –
Agonists [Leu31,Pro34]NPY [392],
[Leu31,Pro34]PYY (human),
[Pro34]NPY,
[Pro34]PYY (human)
– – – –
Selective agonists – – – [Ala31,Aib32]NPY (pig) [264] –
Selective antagonists BIBO3304 (pIC50 9.5)
[2110], BIBP3226 (pKi
8.1–9.3) [463, 2111]
BIIE0246 (pIC50 8.5) [461], JNJ-5207787 (pIC50
6.9–7.1) [182]
– L-152,804 (pKi 7.6) [944] –
Selective allosteric modulators – – niclosamide (Positive)
[1827]
– –
Labelled ligands [3H]BIBP3226 (Antagonist)
(pKd 8.7),
[125I][Leu31,Pro34]NPY
(Agonist)
[125I]PYY-(3-36) (human) (Agonist) [125I]PP (human)
(Agonist)
[125I][cPP(1-7), NPY(19-23),
Ala31, Aib32, Gln34]hPP
(Agonist) [481] – Rat
–
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(continued)
Nomenclature Y1 receptor Y2 receptor Y4 receptor Y5 receptor y6 receptor
Comments Note that Pro34-containing
NPY and PYY can also bind
Y4 and Y5 receptors, so
strictly speaking are not
selective, but are the
’preferred’ agonists.
– – – –
Comments: The Y1 agonists indicated are selective relative to Y2 receptors. BIBP3226 is selective relative to Y2, Y4 and Y5 receptors [632]. NPY-(13-36) is Y2 selective relative to Y1 and Y5 receptors.
PYY-(3-36) is Y2 selective relative to Y1 receptors. Note that Pro34-containing NPY and PYY can also bind Y4 and Y5, thus they are selective only relative to Y2. The y6 receptor is a pseudogene in humans,
but is functional in mouse, rabbit and some other mammals.
Further reading on Neuropeptide Y receptors
Bowers ME et al. (2012) Neuropeptide regulation of fear and anxiety: Implications of chole-
cystokinin, endogenous opioids, and neuropeptide Y. Physiol. Behav. 107: 699-710
[PMID:22429904]
Michel MC et al. (1998) XVI. International Union of Pharmacology recommendations for the
nomenclature of neuropeptide Y, peptide YY and pancreatic polypeptide receptors. Pharma-
col. Rev. 50: 143-150 [PMID:9549761]
Pedragosa-Badia X et al. (2013) Neuropeptide Y receptors: how to get subtype selectivity. Front
Endocrinol (Lausanne) 4: 5 [PMID:23382728]
Zhang L et al. (2011) The neuropeptide Y system: pathophysiological and therapeutic implications
in obesity and cancer. Pharmacol. Ther. 131: 91-113 [PMID:21439311]
Neurotensin receptors
G protein-coupled receptors → Neurotensin receptors
Overview: Neurotensin receptors (nomenclature as recommended by NC-IUPHAR [557]) are activated by the endogenous tridecapeptide neurotensin (pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-
Tyr-Ile-Leu) derived from a precursor (NTS, 30990), which also generates neuromedin N, an agonist at the NTS2 receptor. [
3H]neurotensin (human, mouse, rat) and [125I]neurotensin (human, mouse, rat)
may be used to label NTS1 and NTS2 receptors at 0.1-0.3 and 3-5 nM concentrations respectively.
Nomenclature NTS1 receptor NTS2 receptor
HGNC, UniProt NTSR1, P30989 NTSR2, O95665
Potency order of endogenous ligands neurotensin (NTS, P30990) > neuromedin N {Mouse, Rat} [776] neurotensin (NTS, P30990) = neuromedin N {Mouse, Rat} [1297]
Selective agonists JMV449 [1822] – Rat levocabastine [1297, 1657]
Selective antagonists meclinertant (pIC50 7.5–8.2) [699] –
Labelled ligands [3H]meclinertant (Antagonist) (pKd 8.5) [1085] – Rat –
Searchable database: http://www.guidetopharmacology.org/index.jsp Neurotensin receptors S94
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.13878/full
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129
Comments: neurotensin (NTS, P30990) appears to be a low-
efﬁcacy agonist at the NTS2 receptor [2039], while the NTS1 recep-
tor antagonist meclinertant is an agonist at NTS2 receptors [2039].
An additional protein, provisionally termed NTS3 (also known as
NTR3, gp95 and sortilin; ENSG00000134243), has been suggested
to bind lipoprotein lipase and mediate its degradation [1460]. It
has been reported to interact with the NTS1 receptor [1273] and
the NTS2 receptor [260], and has been implicated in hormone traf-
ﬁcking and/or neurotensin uptake. A splice variant of the NTS2
receptor bearing 5 transmembrane domains has been identiﬁed
in mouse [195] and later in rat [1561].
Further reading on Neurotensin receptors
Boules M et al. (2013) Diverse roles of neurotensin agonists in the central nervous system. Front
Endocrinol (Lausanne) 4: 36 [PMID:23526754]
Mazella J et al. (2012) Neurotensin and its receptors in the control of glucose homeostasis. Front
Endocrinol (Lausanne) 3: 143 [PMID:23230428]
Myers RM et al. (2009) Cancer, chemistry, and the cell: molecules that interact with the neurotensin
receptors. ACS Chem. Biol. 4: 503-25 [PMID:19462983]
Tanganelli S et al. (2012) Relevance of dopamine D(2)/neurotensin NTS1 and NMDA/neurotensin
NTS1 receptor interaction in psychiatric and neurodegenerative disorders. Curr. Med. Chem.
19: 304-16 [PMID:22335510]
Opioid receptors
G protein-coupled receptors → Opioid receptors
Overview: Opioid and opioid-like receptors are activated by
a variety of endogenous peptides including [Met]enkephalin
(PENK, P01210) (met), [Leu]enkephalin (PENK, P01210) (leu),
β-endorphin (POMC, P01189) (β-end), α-neodynorphin (PDYN,
P01213), dynorphin A (PDYN, P01213) (dynA), dynorphin B
(PDYN, P01213) (dynB), big dynorphin (PDYN, P01213) (Big
dyn), nociceptin/orphanin FQ (PNOC, Q13519) (N/OFQ);
endomorphin-1 and endomorphin-2 are also potential endoge-
nous peptides. The Greek letter nomenclature for the opioid
receptors, μ, δ and κ , is well established, and NC-IUPHAR con-
siders this nomenclature appropriate, along with the symbols
spelled out (mu, delta, and kappa), and the acronyms, MOP,
DOP, and KOP. [390, 441, 557]. The human N/OFQ receptor,
NOP, is considered ’opioid-related’ rather than opioid because,
while it exhibits a high degree of structural homology with the
conventional opioid receptors [1361], it displays a distinct phar-
macology. Currently there are numerous clinically used drugs,
such as morphine and many other opioid analgesics, as well as
antagonists such as naloxone, however only for the μ receptor.
Nomenclature δ receptor κ receptor μ receptor NOP receptor
HGNC, UniProt OPRD1, P41143 OPRK1, P41145 OPRM1, P35372 OPRL1, P41146
Principal endogenous agonists β-endorphin (POMC, P01189), [Leu]enkephalin
(PENK, P01210), [Met]enkephalin (PENK, P01210)
big dynorphin (PDYN, P01213), dynorphin A
(PDYN, P01213)
β-endorphin (POMC, P01189),
[Met]enkephalin (PENK, P01210),
[Leu]enkephalin (PENK, P01210)
nociceptin/orphanin FQ (PNOC,
Q13519) [11, 153, 1507]
Potential endogenous agonists – – endomorphin-1, endomorphin-2 –
Agonists DADLE [1972], etorphine [1972],
ethylketocyclazocine [1972]
– levorphanol [727],
hydromorphone [2094], fentanyl
[1972], buprenorphine (Partial
agonist) [1972], methadone
[1595], codeine [1972],
tapentadol [1992], pethidine
[1595]
–
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(continued)
Nomenclature δ receptor κ receptor μ receptor NOP receptor
Sub/family-selective agonists BU08028 (Partial agonist) [979] BU08028 [979] BU08028 (Partial agonist) [979] cebranopadol [1182], BU08028
(Partial agonist) [979]
Selective agonists UFP-512 [2033], BW373U86 [1115], ADL5859
[1115], DPDPE [1391, 1972],
[D-Ala2]deltorphin II [515], ADL5747 [1116],
SNC80 [268, 1620]
U50488 [313, 1545, 1813, 1972, 2046,
2222, 2224], enadoline [848, 1447], U69593
[1089, 1972], salvinorin A [259, 1677]
sufentanil [2041], DAMGO [726,
1972], loperamide [323],
morphine [653, 1972], PL017
[304, 1972]
N/OFQ-(1-13)-NH2 [153, 696,
1304, 1507], Ac-RYYRWK-NH2
(Partial agonist) [464, 1304],
SCH221510 [2030], Ro64-6198
[898, 2108]
Antagonists naltrexone (pKi 8) [1972], naloxone (pKi 7.2)
[1972]
buprenorphine (pKi 9.1–10.2) [1972, 2224],
nalmefene (pKi 9.5) [1972], naltrexone (pKi
8.4–9.4) [1545, 1813, 1972], naloxone (pKi
7.6–8.6) [1545, 1813, 1972, 2222, 2224]
naltrexone (pKi 9.1–9.7) [965,
1972], nalmefene (pKi 9.5)
[1972], nalorphine (pKi 8.9)
[1972], naloxone (pKi 8.9) [1972],
methylnaltrexone (pKi 8.7) [2094]
–
Sub/family-selective antagonists AT-076 (pKi 7.7) [1972, 2201] AT-076 (pKi 8.9) [1972, 2202] AT-076 (pKi 8.8) [1972, 2202] AT-076 (pKi 8.8) [2202]
Selective antagonists naltriben (pKi 10) [1841, 1972], naltrindole (pKi
9.7) [1594, 1972], TIPPψ (Inverse agonist) (pKi
9) [1735, 1972]
nor-binaltorphimine (pKi 8.9–11) [1545,
1593, 1813, 1972, 2222, 2224],
5’-guanidinonaltrindole (pKi 9.7–9.9) [924,
1545, 1868], JDTic (pKi 9–9.4) [1400, 1951,
2202]
alvimopan (pKi 9.3) [1114],
levallorphan (pKi 8.8–9.3) [1250],
CTAP (pKi 8.6) [304, 1972]
UFP-101 (pKi 10.2) [269],
LY2940094 (pKi 10) [1971],
compound 24 (pKi 9.6) [549],
SB 612111 (pKi 9.2–9.5) [1856,
2200], J-113397 (pIC50 8.3)
[962]
Allosteric modulators – – BMS-986123 (Neutral) (pKB 6)
[247], BMS-986121 (Positive)
(pKB 5.7) [247], BMS-986124
(Neutral) (pKB 5.7) [247],
BMS-986122 (Positive) (pKB 5.3)
[247]
–
Labelled ligands [3H]naltrindole (Antagonist) (pKd 10.4) [2161] –
Rat, [3H][D-Ala2]deltorphin I (Selective Agonist)
[1865], [3H]diprenorphine (Agonist) [52, 1972],
[3H]DPDPE (Agonist) [26], [3H]deltorphin II
(Agonist) [261], [3H]naltriben (Antagonist) [1154]
[3H]diprenorphine (Antagonist) (pKd 9.1)
[52, 1813], [3H]U69593 (Agonist) [1089,
1545, 1813], [3H]enadoline (Agonist) [1815]
[3H]diprenorphine (Antagonist)
(pKd 10.1) [1638] – Mouse,
[3H]DAMGO (Agonist) [1638] –
Rat, [3H]PL017 (Agonist) [751] –
Rat
[3H]N/OFQ (Agonist) [464,
1360]
Comments: Three naloxone-sensitive opioid receptor genes have
been identiﬁed in humans, and while the μ-receptor in particu-
lar may be subject to extensive alternative splicing [1535], these
putative isoforms have not been correlated with any of the sub-
types of receptor proposed in years past. Opioid receptors may
heterodimerize with each other or with other 7TM receptors [926],
and give rise to complexes with a unique pharmacology, however,
evidence for such heterodimers in native cells is equivocal and the
consequences of this heterodimerization for signalling remains
largely unknown. For μ-opioid receptors at least, dimerization
does not seem to be required for signalling [1078]. A distinct met-
enkephalin receptor lacking structural resemblance to the opioid
receptors listed has been identiﬁed (OGFR, 9NZT2) and termed an
opioid growth factor receptor [2198].
Endomorphin-1 and endomorphin-2 have been identiﬁed as
highly selective, putative endogenous agonists for the μ-opioid
receptor. At present, however, the mechanisms for endomorphin
synthesis in vivo have not been established, and there is no gene
identiﬁed that encodes for either. Thus, the status of these pep-
tides as endogenous ligands remains unproven.
Two areas of increasing importance in deﬁning opioid recep-
tor function are the presence of functionally relevant single nu-
cleotide polymorphisms in human μ-receptors [1490] and the
identiﬁcation of biased signalling by opioid receptor ligands, in
particular, compounds previously characterized as antagonists
[236]. Pathway bias for agonists makes general rank orders of po-
tency and efﬁcacy somewhat obsolete, so these do not appear in
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the table. As ever, the mechanisms underlying the acute and long
term regulation of opiod receptor function are the subject of in-
tense investigation and debate.
The richness of opioid receptor pharmacology has been enhanced
with the recent discovery of allosteric modulators of μ and δ re-
ceptors, notably the positive allosteric modulators and silent al-
losteric "antagonists" outlined in [247, 248]. Negative allosteric
modulation of opioid receptors has been previously suggested
[953], whether all compounds are acting at a similar site remains
to be established.
Further reading on Opioid receptors
Butelman ER et al. (2012) κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic
implications for addiction. Trends Neurosci. 35: 587-96 [PMID:22709632]
Cox BM et al. (2015) Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br. J. Phar-
macol. 172: 317-23 [PMID:24528283]
Pradhan AA et al. (2011) The delta opioid receptor: an evolving target for the treatment of brain
disorders. Trends Pharmacol. Sci. 32: 581-90 [PMID:21925742]
Williams JT et al. (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, inter-
nalization, and tolerance. Pharmacol. Rev. 65: 223-54 [PMID:23321159]
Orexin receptors
G protein-coupled receptors → Orexin receptors
Overview: Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [557]) are activated by the endogenous polypeptides orexin-A (HCRT, O43612)
and orexin-B (HCRT, O43612) (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage [1703].
Nomenclature OX1 receptor OX2 receptor
HGNC, UniProt HCRTR1, O43613 HCRTR2, O43614
Potency order of endogenous ligands orexin-A (HCRT, O43612) > orexin-B (HCRT, O43612) orexin-A (HCRT, O43612) = orexin-B (HCRT, O43612)
Selective agonists – [Ala11, D-Leu15]orexin-B [66, 1612]
Selective antagonists suvorexant (pKi 9.3) [391], SB-649868 (pKi 9.1) [442], SB-674042 (pKi
8.7–9.1) [1098, 1253, 1255], ﬁlorexant (pKi 8.6) [2124], almorexant (pIC50
7.9) [221], SB-408124 (pKi 7.2–7.6) [1098, 1253], SB-334867 (pKi 7.4–7.5)
[1253, 1591]
ﬁlorexant (pKi 9.5) [2124], suvorexant (pKi 9.5) [391], EMPA (pKi 9) [1252],
SB-649868 (pKi 8.9) [442], JNJ-10397049 (pKi 8–8.6) [1300], almorexant (pIC50
8.1) [221], TCS-OX2-29 (pKi 7.4) [798]
Labelled ligands – [3H]-almorexant (Selective Antagonist) (pKd 8.9–9.8) [1253, 1255], [
3H]Cp-1
(Selective Antagonist) (pKd 9.2–9.4) [1253], [
3H]EMPA (Selective Antagonist) (pKd
8.6–9) [1252, 1255], [125I]-orexin-A (Agonist) [1066, 1611, 1703]
Comments: The primary coupling of orexin receptors to Gq/11
proteins is rather speculative and based on the strong activation
of phospholipase C, though recent studies in recombinant CHO
cells also stress the importance of Gq/11 [1065]. Coupling of both
receptors to Gi/o and Gs has also been reported [951, 1068, 1146,
1629] for most cellular responses observed, the G protein path-
way is unknown. The potency order of endogenous ligands may
depend on the cellular signal transduction machinery. Most of
the OX2 receptor selective antagonists listed are weakly selective
(≤10-fold), or selectivitymay be less than 100-fold or not unequiv-
ocally determined. [Ala11, D-Leu15]orexin-B may show poor OX2
receptor selectivity [1612].
Orexin receptors have been reported to be able to form com-
plexes with each other and some other GPCRs as well as
CRF receptors [1067, 1426], which might affect the signaling and
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pharmacology. Recently a promising synthetic orexin receptor lig-
and (compound 26) has been reported but not thoroughly charac-
terized [1412]. Loss-of-function mutations in the gene encoding
the OX2 receptor underlie canine hereditary narcolepsy [1177].
Antagonists of the orexin receptors are the focus of major drug
discovery effort for their potential to treat insomnia and other dis-
orders of wakefulness [1668], while agonists would likely be useful
in human narcolepsy.
Further reading on Orexin receptors
Baimel C et al. (2015) Orexin/hypocretin role in reward: implications for opioid and other addic-
tions. Br. J. Pharmacol. 172: 334-48 [PMID:24641197]
Kukkonen JP. (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am. J.
Physiol., Cell Physiol. 304: C2-32 [PMID:23034387]
Li SB et al. (2016) Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders. Curr Psychi-
atry Rep 18: 7 [PMID:26733323]
Mahler SV et al. (2014) Motivational activation: a unifying hypothesis of orexin/hypocretin func-
tion. Nat. Neurosci. 17: 1298-303 [PMID:25254979]
Oxoglutarate receptor
G protein-coupled receptors → Oxoglutarate receptor
Overview: Nomenclature as recommended by NC-IUPHAR [414].
Nomenclature oxoglutarate receptor
HGNC, UniProt OXGR1, Q96P68
Endogenous agonists α-ketoglutaric acid [762, 1854]
P2Y receptors
G protein-coupled receptors → P2Y receptors
Overview: P2Y receptors (nomenclature as agreed by
the NC-IUPHAR Subcommittee on P2Y Receptors [1,
2]) are activated by the endogenous ligands ATP, ADP,
uridine triphosphate, uridine diphosphate and UDP-glucose. The
relationship of many of the cloned receptors to endogenously ex-
pressed receptors is not yet established and so it might be appro-
priate to use wording such as ’uridine triphosphate-preferring (or
ATP-, etc.) P2Y receptor’ or ’P2Y1-like’, etc., until further, as yet
undeﬁned, corroborative criteria can be applied [251, 514, 878,
2044, 2089].
Clinically used drugs acting on these receptors include the dinu-
cleoside polyphosphate diquafosol, agonist of the P2Y2 receptor
subtype, approved in Japan for the management of dry eye disease
[1101], and the P2Y12 receptor antagonists prasugrel, ticagrelor
and cangrelor, all approved as antiplatelet drugs [273, 1602].
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Nomenclature P2Y1 receptor P2Y2 receptor P2Y4 receptor P2Y6 receptor
HGNC, UniProt P2RY1, P47900 P2RY2, P41231 P2RY4, P51582 P2RY6, Q15077
Potency order of endogenous ligands ADP>ATP uridine triphosphate > ATP [1112] uridine triphosphate>ATP (at rat
recombinant receptors, UTP =
ATP)
uridine diphosphate 
uridine triphosphate > ADP
Endogenous agonists – uridine triphosphate [989, 1112] – –
Agonists ADPβS [1921], 2MeSADP [1729, 2054] – – –
Sub/family-selective agonists – diquafosol [1554], denufosol [1113,
1554, 2181], UTPγS [1112]
diquafosol [240], denufosol
[2181], UTPγS [1113]
–
Selective agonists MRS2365 [329], 2-Cl-ADP(α-BH3) [76] MRS2698 [874], 2-thioUTP [498],
PSB1114 (EC50 value determined using
an IP3 functional assay) [498, 499, 873]
MRS4062 [1276], MRS2927
[1276], (N)methanocarba-UTP
[989]
Rp-5-OMe-UDPαB [644, 702],
MRS2957 [1275], MRS2693 [146]
Antagonists suramin (pKi 5.3) [2054], PPADS (pKi 5.2)
[2054]
– ATP (pKd 6.2) [970] –
Sub/family-selective antagonists – reactive blue-2 (pIC50 6) [892], suramin
(pIC50 4.3) [892, 1729]
PPADS (pEC50 2–5) [881],
reactive blue-2 (pIC50 4.7) [171]
– Rat
reactive blue-2 (pKB 6) [2045],
PPADS (pKB 4) [2045], suramin
(pKB 4) [2045]
Selective antagonists MRS2500 (pKi 8.8–9.1) [286, 988],
MRS2279 (pKi 7.9) [2054], MRS2179 (pKi
7–7.1) [203, 2054]
AR-C118925XX (pIC50 ∼6) [968],
AR-C126313 (pEC50 6) [874], PSB-416
(pIC50 4.7) [792]
ATP (pKd 6.2) [970] MRS2578 (pIC50 7.4) [1257],
MRS2567 (pIC50 6.9) [1257]
Allosteric modulators 2,2’-pyridylisatogen tosylate (Negative)
(pIC50 7.8) [601]
– – –
Selective allosteric modulators BMS compound 16 (Negative) (pKi 6.9)
[2206]
– – –
Labelled ligands [3H]MRS2279 (Antagonist) (pKd 8.1) [2054],
[3H]2MeSADP (Agonist) [1921], [35S]ADPβS
(Agonist)
– – MRS4162 (Selective Antagonist)
(pEC50 7.6) [897]
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Nomenclature P2Y11 receptor P2Y12 receptor P2Y13 receptor P2Y14 receptor
HGNC, UniProt P2RY11, Q96G91 P2RY12, Q9H244 P2RY13, Q9BPV8 P2RY14, Q15391
Potency order of endogenous ligands ATP ADP [775] ADPATP uridine diphosphate [281]
Sub/family-selective agonists – 2MeSADP [775], ADPβS [1921] 2MeSADP [1271], 2MeSATP [1271], ADPβS [1271] –
Selective agonists AR-C67085 [93, 372], NF546
[1317], ATPγS [372]
– – α.β-methylene-2-thio-UDP
[407], MRS2905 [879],
2-thio-UDP [407]
Antagonists – PSB-0739 (pKi 7.6) [97] – –
Sub/family-selective antagonists suramin (pIC50 4.8–6) [372],
reactive blue-2 (pIC50 5)
[372]
cangrelor (pIC50 9.4) [882], Ap4A (pIC50
6) [1271], 2MeSAMP (pIC50 5.4) [1921]
cangrelor (pIC50 8.3) [1271], Ap4A (pIC50 6.7)
[1271], 2MeSAMP (pIC50 5.6) [1271]
–
Selective antagonists NF157 (pKi 7.3) [1999],
NF340 (pIC50 6.4–7.1)
[1317]
AZD1283 (pKi 8) [79, 2207], ARL66096
(pIC50 7.9) [846, 847], ticagrelor (pKi
7.8) [2203]
MRS2603 (pIC50 6.2) [996], MRS2211 (pIC50 6)
[996]
PPTN (pKi 10.1) [102]
Labelled ligands – [3H]2MeSADP (Agonist) [1921],
[3H]PSB-0413 (Antagonist) (pKd 8.3–8.5)
[497, 1497]
[33P]2MeSADP (Agonist) [1271] MRS4174 (Selective
Antagonist) (pKi 10.1) [1006],
MRS4183 (Selective Agonist)
[1005]
Comments: A series of 4-alkyloxyimino derivatives of uridine-
5’-triphosphate which could be useful for derivatization as ﬂuores-
cent P2Y2/4/6 receptor probes has been recently synthesized [897].
Single nucleotide polymorphisms of the P2YR1 gene are associ-
ated with different platelet reactivity to ADP ADP [784]. Three fre-
quent nonsynonymous P2Y2 receptor polymorphisms have been
identiﬁed, one of which was signiﬁcantly more common in cys-
tic ﬁbrosis patients. This polymorphism is linked to increases
in Ca2+ inﬂux in transfected cells, and might therefore play a
role in disease development [263]. Although uridine triphosphate
(UTP) was also shown to be a biased agonist at P2Y11, this is still
under debate [1388, 2104]. A group of single nucleotide poly-
morphisms in the P2Y12 gene, forming the so called P2Y12 H2
haplotype, has been associated with increased platelet responsive-
ness to ADP, increased risk of peripheral arterial disease and with
coronary artery disease [291]. The platelet-type bleeding disorder
due to P2Y12 receptor defects is an autosomal recessive condition
characterized by mild to moderate mucocutaneous bleeding and
excessive bleeding after surgery or trauma. The defect is due to the
inability of ADP to induce platelet aggregation [287]. The P2Y13
receptor Met-158-Thr polymorphism, which is in linkage disequi-
librium with the P2Y12 locus, is not associated with acute my-
ocardial infarction, diabetes mellitus or related risk factors [44].
The P2Y14 receptor was previously considered to exclusively bind
sugar nucleotides such as UDP-glucose and UDP-galactose [299].
However, more recent evidence with several cell lines has demon-
strated that uridine diphosphate (UDP) is 5-fold more potent than
UDP-glucose [281]. UDP was also shown to competitively antago-
nise the UDP-glucose response at the human recombinant P2Y14
receptor [578].
Further reading on P2Y receptors
Abbracchio MP et al. (2006) International Union of Pharmacology LVIII: update on the P2Y G
protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to
therapy. Pharmacol. Rev. 58: 281-341 [PMID:16968944]
Jacobson KA et al. (2015) Nucleotides Acting at P2Y Receptors: Connecting Structure and Function.
Mol. Pharmacol. 88: 220-30 [PMID:25837834]
von Kügelgen I et al. (2016) Pharmacology and structure of P2Y receptors. Neuropharmacology 104:
50-61 [PMID:26519900]
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Parathyroid hormone receptors
G protein-coupled receptors → Parathyroid hormone receptors
Overview: The parathyroid hormone receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Parathyroid Hormone Receptors [606]) are family B G protein-coupled
receptors. The parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH1 receptor) is activated by precursor-derived peptides: PTH (PTH, P01270) (84 amino acids), and
PTHrP (PTHLH, P12272) (141 amino-acids) and related peptides (PTH-(1-34), PTHrP-(1-36) (PTHLH, P12272)). The parathyroid hormone 2 receptor (PTH2 receptor) is activated by the precursor-derived
peptide TIP39 (PTH2, Q96A98) (39 amino acids). [125I]PTH may be used to label both PTH1 and PTH2 receptors.
Nomenclature PTH1 receptor PTH2 receptor
HGNC, UniProt PTH1R, Q03431 PTH2R, P49190
Potency order of endogenous ligands PTH (PTH, P01270) = PTHrP (PTHLH, P12272) TIP39 (PTH2, Q96A98), PTH (PTH, P01270)  PTHrP (PTHLH, P12272)
Agonists teriparatide [604] TIP39 (PTH2, Q96A98) [661, 804]
Selective agonists PTHrP-(1-34) (human) [605] – Rat –
Comments: The parathyroid hormone type 1 receptor (PTHR) is the canonical GPCR for PTH and PTHrP. It is coupled to Gs and Gq and regulates the development of bone, heart, mammary glands and
other tissues in response to PTHrP, and blood concentrations of calcium and phosphate ions, as well as vitamin D, in response to PTH. Another important action of the PTH/PTHR system is to stimulate
bone formation when the hormone is intermittently administrated (daily injection). Although PTH (PTH, P01270) is an agonist at human PTH2 receptors, it fails to activate the rodent orthologues. TIP39
(PTH2, Q96A98) is a weak antagonist at PTH1 receptors [925].
Further reading on Parathyroid hormone receptors
Cheloha RW et al. (2015) PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.
Nat Rev Endocrinol [PMID:26303600]
Gardella TJ et al. (2015) International Union of Basic and Clinical Pharmacology. XCIII. The
Parathyroid Hormone Receptors-Family B G Protein-Coupled Receptors. Pharmacol. Rev. 67:
310-37 [PMID:25713287]
Vilardaga JP et al. (2014) Endosomal generation of cAMP in GPCR signaling. Nat. Chem. Biol. 10:
700-6 [PMID:25271346]
Platelet-activating factor receptor
G protein-coupled receptors → Platelet-activating factor receptor
Overview: Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is an ether phospholipid mediator associated with platelet coagulation, but also subserves inﬂammatory roles.
The PAF receptor (provisional nomenclature recommended by NC-IUPHAR [557]) is activated by PAF and other suggested endogenous ligands are oxidized phosphatidylcholine [1265] and
lysophosphatidylcholine [1492]. It may also be activated by bacterial lipopolysaccharide [1417].
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Nomenclature PAF receptor
HGNC, UniProt PTAFR, P25105
Selective agonists methylcarbamyl PAF
Selective antagonists foropafant (pKi 10.3) [774], ABT-491 (pKi 9.2) [30], CV-6209 (pIC50 8.1–8.3) [652, 1416], L659989 (pKi 7.8) [851], apafant (pKi 5.2–7.5) [1529, 1904]
Labelled ligands [3H]PAF (Agonist) [585, 1416]
Comments: Note that a previously recommended radioligand ([3H]apafant; Kd 44.6 nM) is currently unavailable.
Further reading on Platelet-activating factor receptor
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Ishii S et al. (2000) Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor
mutant mice. Prog. Lipid Res. 39: 41-82 [PMID:10729607]
Prescott SM et al. (2000) Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem.
69: 419-45 [PMID:10966465]
Prokineticin receptors
G protein-coupled receptors → Prokineticin receptors
Overview: Prokineticin receptors, PKR1 and PKR2 (provi-
sional nomenclature as recommended by NC-IUPHAR
[557]) respond to the cysteine-rich 81-86 amino-acid peptides
prokineticin-1 (PROK1, Q9HC23) (also known as endocrine gland-
derived vascular endothelial growth factor, mambakine) and
prokineticin-2 (PROK2, Q9HC23) (protein Bv8 homologue). An
orthologue of PROK1 from black mamba (Dendroaspis polylepis)
venom, mamba intestinal toxin 1 (MIT1, [1749]) is a potent, non-
selective agonist at prokineticin receptors [1279], while Bv8, an
orthologue of PROK2 from amphibians (Bombina sp., [1357]), is
equipotent at recombinant PKR1 and PKR2 [1435], and has high
potency inmacrophage chemotaxis assays, which are lost in PKR1-
null mice.
Nomenclature PKR1 PKR2
HGNC, UniProt PROKR1, Q8TCW9 PROKR2, Q8NFJ6
Potency order of endogenous ligands prokineticin-2 (PROK2, Q9HC23) > prokineticin-1 (PROK1, Q9HC23) >
prokineticin-2β (PROK2) [1175, 1279, 1843]
prokineticin-2 (PROK2, Q9HC23) > prokineticin-1 (PROK1, Q9HC23) >
prokineticin-2β (PROK2) [1175, 1279, 1843]
Endogenous agonists prokineticin-2 (PROK2, Q9HC23) [316, 1279], prokineticin-1 (PROK1, Q9HC23)
[316, 1279], prokineticin-2β (PROK2) [316]
prokineticin-2 (PROK2, Q9HC23) [316, 1279], prokineticin-1 (PROK1, Q9HC23)
[316, 1279], prokineticin-2β (PROK2) [316]
Agonists MIT1 [1279] MIT1 [1279]
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Nomenclature PKR1 PKR2
Selective agonists IS20 [612], IS1 [612] –
Labelled ligands [125I]BH-MIT1 (Agonist) [1279] [125I]BH-MIT1 (Agonist) [1279]
Comments: Genetic mutations in PROKR1 are associated with Hirschsprung’s disease [1688], while genetic mutations in PROKR2 are associated with hypogonadotropic hypogonadism with anosmia
[455], hypopituitarism with pituitary stalk interruption [1649] and Hirschsprung’s disease [1688].
Further reading on Prokineticin receptors
Boulberdaa M et al. (2011) Prokineticin receptor 1 (PKR1) signalling in cardiovascular and kidney
functions. Cardiovasc. Res. 92: 191-8 [PMID:21856786]
Negri L et al. (2012) Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr
Opin Pharmacol 12: 62-6 [PMID:22136937]
Negri L et al. (2007) Bv8/Prokineticin proteins and their receptors. Life Sci. 81: 1103-16
[PMID:17881008]
Ngan ES et al. (2008) Prokineticin-signaling pathway. Int. J. Biochem. Cell Biol. 40: 1679-84
[PMID:18440852]
Prolactin-releasing peptide receptor
G protein-coupled receptors → Prolactin-releasing peptide receptor
Overview: The precursor (PRLH, P81277) for PrRP generates 31
and 20-amino-acid versions. QRFP43 (QRFP, P83859) (named
after a pyroglutamylated arginine-phenylalanine-amide peptide)
is a 43 amino acid peptide derived from QRFP (P83859) and is
also known as P518 or 26RFa. RFRP is an RF amide-related pep-
tide [794] derived from a FMRFamide-related peptide precursor
(NPVF, Q9HCQ7), which is cleaved to generate neuropeptide SF
(NPFF, O15130), neuropeptide RFRP-1 (NPVF, Q9HCQ7), neu-
ropeptide RFRP-2 (NPVF, Q9HCQ7) and neuropeptide RFRP-3
(NPVF, Q9HCQ7) (neuropeptide NPVF).
Nomenclature PrRP receptor
HGNC, UniProt PRLHR, P49683
Potency order of endogenous ligands PrRP-20 (PRLH, P81277) = PrRP-31 (PRLH, P81277) [1099]
Endogenous agonists PrRP-20 (PRLH, P81277) [509, 1099], PrRP-31 (PRLH, P81277) [509, 1099]
Endogenous antagonists neuropeptide Y (NPY, P01303) (pKi 5.4) [1087]
Labelled ligands [125I]PrRP-20 (human) (Agonist) [1099], [125I]PrRP31 (Agonist) [501]
Comments: The orphan receptor GPR83 (Q9NYM4) shows sequence similarities with NPFF1, NPFF2, PrRP and QRFP receptors.
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Further reading on Prolactin-releasing peptide receptor
SamsonWK et al. (2006) Prolactin releasing peptide (PrRP): an endogenous regulator of cell growth.
Peptides 27: 1099-103 [PMID:16500730]
Takayanagi Y et al. (2010) Roles of prolactin-releasing peptide and RFamide related peptides in the
control of stress and food intake. FEBS J. 277: 4998-5005 [PMID:21126313]
Prostanoid receptors
G protein-coupled receptors → Prostanoid receptors
Overview: Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [2132]) are activated by the endogenous ligands prostaglandins PGD2,
PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Measurement of the potency of PGI2 and thromboxane A2 is hampered by their instability in physiological salt solution; they are
often replaced by cicaprost and U46619, respectively, in receptor characterization studies.
Nomenclature DP1 receptor DP2 receptor
HGNC, UniProt PTGDR, Q13258 PTGDR2, Q9Y5Y4
Potency order of endogenous ligands PGD2 > PGE1  PGE2 > PGF2α > PGI2, thromboxane A2 PGD2  PGF2α, PGE2 > PGI2, thromboxane A2
Selective agonists BW 245C [173, 2133, 2134], L-644,698 [2133, 2134] 15(R)-15-methyl-PGD2 [747, 1366, 1889]
Antagonists – fevipiprant (pKd 9) [1908, 1909], ramatroban (pKi 7.4) [1889]
Selective antagonists laropiprant (pKi 10.1) [1882], BWA868C (pKi 8.6–9.3) [173, 640, 2133],
ONO-AE3-237 (pKi 7.7) [796, 1974, 1976]
CAY 10471 (pIC50 8.9) [1684, 2003]
Labelled ligands [3H]PGD2 (Agonist) [2119, 2133] [3H]PGD2 (Agonist) [1280, 1790]
Nomenclature EP1 receptor EP2 receptor EP3 receptor EP4 receptor
HGNC, UniProt PTGER1, P34995 PTGER2, P43116 PTGER3, P43115 PTGER4, P35408
Potency order of endogenous
ligands
PGE2 > PGE1 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 = PGE1 > PGF2α, PGI2 >
PGD2, thromboxane A2
PGE2, PGE1 > PGF2α, PGI2 > PGD2,
thromboxane A2
PGE2 = PGE1 > PGF2α, PGI2 >
PGD2, thromboxane A2
Endogenous agonists – PGE2 [7, 1871, 2119] PGE2 (EP3-III isoform) [7] –
Agonists 17-phenyl-ω-trinor-PGE2 [1783] PGE1 [111] misoprostol (methyl ester) (EP3-III isoform) [7] –
Selective agonists ONO-DI-004 [1899] – Mouse ONO-AE1-259 [1899] – Mouse,
butaprost (free acid form) [7, 1871]
sulprostone (EP3-III isoform) [7], ONO-AE-248
[562, 1206]
L902688 [563, 1129],
ONO-AE1-329 [562, 563]
Antagonists – – – EP4A (pKi 7.6–8.5) [1229, 2195]
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Nomenclature EP1 receptor EP2 receptor EP3 receptor EP4 receptor
Selective antagonists ONO-8711 (pKi 9.2) [2079], SC-51322
(pKi 7.9) [7]
PF-04418948 (PF-04418948 has
weaker afﬁnity at the EP2-receptor in
guinea-pigs) (pKB 8.3) [14, 157],
TG6-129 (pKB 8.1) [598]
L-826266 (EP3-III isoform (pKi=8.04 in the
presence of HSA)) (pKi 9.1) [933],
ONO-AE3-240 (pIC50 8.8) [38] – Mouse,
DG-041 (pKi 8.4) [931]
ONO-AE3-208 (pKi 8.5),
GW 627368 (pKi 7–7.1) [2119,
2120]
Labelled ligands [3H]PGE2 (Agonist) [7, 1783, 2119] [3H]PGE2 (Agonist) [7, 2119] [3H]PGE2 (Agonist) [7, 2119] [3H]PGE2 (Agonist) [7, 420,
2107, 2119]
Nomenclature FP receptor IP receptor TP receptor
HGNC, UniProt PTGFR, P43088 PTGIR, P43119 TBXA2R, P21731
Potency order of endogenous ligands PGF2α > PGD2 > PGE2 > PGI2, thromboxane A2 PGI2  PGE1 > PGD2, PGF2α > thromboxane A2 thromboxane A2 = PGH2  PGD2, PGE2, PGF2α,
PGI2
Endogenous agonists – PGI2 [1804], PGE1 [1277, 1873] –
Agonists – iloprost [7, 2119], treprostinil [2107] –
Selective agonists ﬂuprostenol [7], latanoprost (free acid form) [7] cicaprost [7] U46619 [7]
Antagonists – – ramatroban (pKi 8) [1944]
Selective antagonists AS604872 (pKi 7.5) [361] RO1138452 (pKi 8.7) [162], RO3244794 (pA2 8.5)
[162]
vapiprost (pKi 8.3–9.4) [63, 1216], SQ-29548 (pKi
8.1–9.1) [7, 1907, 2119]
Labelled ligands [3H]PGF2α (Agonist) [7, 8, 2119],
[3H](+)-ﬂuprostenol (Agonist)
[3H]iloprost (Agonist) [7, 172, 2107, 2119] [125I]SAP (Antagonist) (pKd 7.7–9.3) [1415],
[125I]BOP (Agonist) [1381], [3H]SQ-29548
(Antagonist) (pKd 7.4–8.2) [7, 2119]
Comments: Whilst cicaprost is selective for IP receptors, it does
exhibit moderate agonist potency at EP4 receptors [7]. Apart
from IP receptors, iloprost also binds to EP1 receptors. The IP
receptor agonist treprostinil binds also to human EP2 and DP1 re-
ceptors with high afﬁnity (pKi 8.44 and 8.36, respectively) [2107].
The EP1 agonist 17-phenyl-ω-trinor-PGE2 also shows agonist
activity at EP3 receptors. Butaprost and SC46275 may require de-
esteriﬁcation within tissues to attain full agonist potency. There
is evidence for subtypes of FP [1171] and TP receptors [1050,
1637]. mRNA for the EP3 receptor undergoes alternative splicing
to produce variants which can interfere with signalling [1509]
or generate complex patterns of G-protein (Gi/o, Gq/11, Gs and
G12,13) coupling (e.g. [1042, 1433]). The number of EP3 receptor
(protein) variants are variable depending on species, with ﬁve in
human, three in rat and three in mouse. Putative receptor(s) for
prostamide F (which as yet lack molecular correlates) and which
preferentially recognize PGF2-1-ethanolamide and its analogues
(e.g. Bimatoprost) have been identiﬁed, together with moderate-
potency antagonists (e.g. AGN 211334) [2131]. The free acid form
of AL-12182, AL12180, used in in vitro studies, has a EC50 of 15nM
which is the concentration of the compound giving half-maximal
stimulation of inositol phosphate turnover in HEK-293 cells
expressing the human FP receptor [1784]. References given along-
side the TP receptor agonists I-BOP [1295] and STA2 [63] use hu-
man platelets as the source of TP receptors for competition radio-
ligand binding assays to determine the indicated activity values.
Pharmacological evidence for a second IP receptor, denoted IP2,
in the central nervous system [1924, 2082] and in the BEAS-2B
human airway epithelial cell line [2122] is available.
This receptor is selectively activated by 15R-17,18,19,
20-tetranor-16-m-tolyl-isocarbacyclin (15R-TIC) and 15R-Deoxy
17,18,19,20-tetranor-16-m-tolyl-isocarbacyclin (15-deoxy-TIC).
However, molecular biological evidence for an IP2 subtype is
currently lacking.
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Further reading on Prostanoid receptors
Woodward DF et al. (2011) International union of basic and clinical pharmacology. LXXXIII: classiﬁcation of prostanoid receptors, updating 15 years of progress. Pharmacol. Rev. 63: 471-538
[PMID:21752876]
Proteinase-activated receptors
G protein-coupled receptors → Proteinase-activated receptors
Overview: Proteinase-activated receptors (PARs, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on
Proteinase-activated Receptors [809]) are unique members
of the GPCR superfamily activated by proteolytic cleavage of their
amino terminal exodomains. Agonist proteinase-induced hydrol-
ysis unmasks a tethered ligand (TL) at the exposed amino termi-
nus, which acts intramolecularly at the binding site in the body of
the receptor to effect transmembrane signalling. TL sequences at
human PAR1-4 are SFLLRN-NH2, SLIGKV-NH2, TFRGAP-NH2 and
GYPGQV-NH2, respectively. With the exception of PAR3, these
synthetic peptide sequences (as carboxyl terminal amides) are able
to act as agonists at their respective receptors. Several proteinases,
including neutrophil elastase, cathepsin G and chymotrypsin can
have inhibitory effects at PAR1 and PAR2 such that they cleave the
exodomain of the receptor without inducing activation of Gαq-
coupled calcium signalling, thereby preventing activation by acti-
vating proteinases but not by agonist peptides. Neutrophil elastase
(NE) cleavage of PAR1 and PAR2 can however activate MAP kinase
signaling by exposing a TL that is different from the one revealed
by trypsin [1624]. PAR2 ectivation by NE regulates inﬂammation
and pain responses [1397, 2217] and triggersmucin secretion from
airway epithelial cells [2220].
Nomenclature PAR1 PAR2 PAR3 PAR4
HGNC, UniProt F2R, P25116 F2RL1, P55085 F2RL2, O00254 F2RL3, Q96RI0
Agonist proteases thrombin (F2, P00734), activated
protein C (PROC, P04070),
matrix metalloproteinase 1 (MMP1,
P45452), matrix metalloproteinase 13
(MMP13, P45452) [73]
Trypsin, tryptase, TF/VIIa, Xa thrombin (F2, P00734) thrombin (F2, P00734),
trypsin, cathepsin G (CTSG,
P08311)
Agonists F16357 – – –
Selective agonists TFLLR-NH2 [355] AC264613 [1767], AY77 [2178], AC-55541 [1767], GB110 [104],
2-furoyl-LIGRLO-amide [1305], SLIGKV-NH2 [1134], SLIGRL-NH2 [1134]
– AYPGKF-NH2, GYPGKF-NH2,
GYPGQV-NH2
Selective antagonists vorapaxar (pKi 8.1) [295], atopaxar
(pIC50 7.7) [1024], RWJ-56110 (pIC50
6.4) [49]
GB88 (pIC50 5.7) [1886], P2pal18s [1776] – YD-3 (pIC50 6.9) [2091],
ML354 (pIC50 6.8) [2091]
Labelled ligands [3H]haTRAP (Agonist) [17] 2-furoyl-LIGRL[N-(Alexa Fluor 594)-O]-NH2 (Agonist) [810],
2-furoyl-LIGRL[N[3H]propionyl]-O-NH2 (Agonist) [810],
[3H]2-furoyl-LIGRL-NH2 (Selective Agonist) [946],
trans-cinnamoyl-LIGRLO [N-[3H]propionyl]-NH2 (Agonist) [28]
– –
Comments TFLLR-NH2 is selective relative to the
PAR2 receptor [159, 958].
2-Furoyl-LIGRLO-NH2 activity was measured via calcium mobilisation in HEK
293 cells which constitutively coexpress human PAR1 and PAR2.
– –
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Comments: Endogenous serine proteases (EC 3.4.21.) ac-
tive at the proteinase-activated receptors include: thrombin (F2,
P00734), generated by the action of Factor X (F10, P00742) on
liver-derived prothrombin (F2, P00734); trypsin, generated by the
action of enterokinase (TMPRSS15, P98073) on pancreatic-derived
trypsinogen (PRSS1, P07477); tryptase, a family of enzymes (α/β1
TPSAB1, Q15661 ; γ1TPSG1, Q9NRR2; δ1TPSD1, Q9BZJ3) secreted
from mast cells; cathepsin G (CTSG, P08311) generated from
leukocytes; liver-derived protein C (PROC, P04070) generated in
plasma by thrombin (F2, P00734) and matrix metalloproteinase 1
(MMP1, P45452).
Further reading on Proteinase-activated receptors
Adams MN et al. (2011) Structure, function and pathophysiology of protease activated receptors.
Pharmacol. Ther. 130: 248-82 [PMID:21277892]
Canto I et al. (2012) Allosteric modulation of protease-activated receptor signaling. Mini Rev Med
Chem 12: 804-11 [PMID:22681248]
García PS et al. (2010) The role of thrombin and protease-activated receptors in pain mechanisms.
Thromb. Haemost. 103: 1145-51 [PMID:20431855]
Hollenberg MD et al. (2002) International Union of Pharmacology. XXVIII. Proteinase-activated
receptors. Pharmacol. Rev. 54: 203-17 [PMID:12037136]
Ramachandran R et al. (2012) Targeting proteinase-activated receptors: therapeutic potential and
challenges. Nat Rev Drug Discov 11: 69-86 [PMID:22212680]
Soh UJ et al. (2010) Signal transduction by protease-activated receptors. Br. J. Pharmacol. 160:
191-203 [PMID:20423334]
QRFP receptor
G protein-coupled receptors → QRFP receptor
Overview: The human gene encoding the QRFP receptor (QRFPR, also known as the peptide P518 receptor), previously designated as an orphan GPCR receptor was identiﬁed in 2001 by Lee et al.
from a hypothalamus cDNA library [1131]. However, the reported cDNA (AF411117) is a chimera with bases 1-127 derived from chromosome 1 and bases 155-1368 derived from chromosome 4. When
corrected, QRFPR (also referred to as SP9155 or AQ27) encodes a 431 amino acid protein that shares sequence similarities in the transmembrane spanning regions with other peptide receptors. These
include neuropeptide FF2 (38%), neuropeptide Y2 (37%) and galanin Gal1 (35%) receptors.
Nomenclature QRFP receptor
HGNC, UniProt QRFPR, Q96P65
Endogenous agonists QRFP43 (QRFP, P83859) [311, 587, 1923] – Rat, QRFP26 (QRFP) [311, 910]
Agonists LV-2172 [1448]
Selective antagonists compound 25e (pIC50 7.3) [628, 629]
Labelled ligands [125I]QRFP43 (human) (Agonist) [587, 1063, 1923]
Comments: The orphan receptor GPR83 (9NYM4) shows sequence similarities with the QRFP receptor, as well as with the NPFF1, NPFF2, and PrRP receptors.
Further reading on QRFP receptor
Fukusumi S et al. (2006) Recent advances in mammalian RFamide peptides: the discovery and functional analyses of PrRP, RFRPs and QRFP. Peptides 27: 1073-86 [PMID:16500002]
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Relaxin family peptide receptors
G protein-coupled receptors → Relaxin family peptide receptors
Overview: Relaxin family peptide receptors (RXFP, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on Re-
laxin family peptide receptors [112, 713]) may be divided
into two pairs, RXFP1/2 and RXFP3/4. Endogenous agonists
at these receptors are a number of heterodimeric peptide hor-
mones structurally related to insulin: relaxin-1 (RLN1, P04808),
relaxin (RLN2, P04090), relaxin-3 (RLN3, Q8WXF3) (also known
as INSL7), insulin-like peptide 3 (INSL3 (INSL3, P51460)) and
INSL5 (INSL5, Q9Y5Q6).
Species homologues of relaxin have distinct pharmacology –
relaxin (RLN2, P04090) interacts with RXFP1, RXFP2 and RXFP3,
whereas mouse and rat relaxin selectively bind to and activate
RXFP1 [1755] and porcine relaxin may have a higher efﬁcacy than
human relaxin (RLN2, P04090) [714]. Relaxin-3 (RLN3, Q8WXF3)
has differential afﬁnity for RXFP2 between species; mouse and
rat RXFP2 have a higher afﬁnity for relaxin-3 (RLN3, Q8WXF3)
[1754]. At least two binding sites have been identiﬁed on RXFP1
and RXFP2: a high-afﬁnity site in the leucine-rich repeat region
of the ectodomain and a somewhat lower-afﬁnity site located in
the surface loops of the transmembrane domain [714, 1885]. The
unique N-terminal LDLa module of RXFP1 and RXFP2 is essential
for receptor signalling [1756].
Nomenclature RXFP1 RXFP2 RXFP3 RXFP4
HGNC, UniProt RXFP1, Q9HBX9 RXFP2, Q8WXD0 RXFP3, Q9NSD7 RXFP4, Q8TDU9
Potency order of endogenous ligands relaxin (RLN2, P04090) =
relaxin-1 (RLN1, P04808)
> relaxin-3 (RLN3,
Q8WXF3) [1885]
INSL3 (INSL3, P51460) > relaxin (RLN2, P04090) 
relaxin-3 (RLN3, Q8WXF3) [1072, 1885]
relaxin-3 (RLN3, Q8WXF3) >
relaxin-3 (B chain) (RLN3,
Q8WXF3) > relaxin (RLN2,
P04090) [1186]
INSL5 (INSL5, Q9Y5Q6) = relaxin-3
(RLN3, Q8WXF3) > relaxin-3 (B chain)
(RLN3, Q8WXF3) [1184, 1185]
Endogenous antagonists – – INSL5 (INSL5, Q9Y5Q6) (pKi 7)
[2223]
–
Antagonists B-R13/17K H2 relaxin
(pEC50 5.7–6.7) [827,
1446]
–
R3(B23-27)R/I5 chimeric peptide
(pIC50 9.2) [1064]
R3(B23-27)R/I5 chimeric peptide
(pIC50 8–8.6) [749, 1064]
Selective antagonists – A(9-26)INSL3 (pKi 9.1) [826], A(10-24)INSL3 (pKi
8.7) [826], A(C10/15S)INSL3 (pKi 8.6) [2210],
INSL3 B chain dimer analogue 8 (pKi 8.5) [1781],
A(10/15C)INSL3 (pKi 8.3) [2210],
cyclic INSL3 B-chain analogue 6 (pKi 6.7) [1779],
INSL3 B-chain analogue (pKi 5.1) [434],
(des 1-8) A-chain INSL3 analogue [262]
minimised relaxin-3 analogue 3
(pKi 7.6) [1777], R3-B1-22R (pKi
7.4) [749]
minimised relaxin-3 analogue 3 (pIC50
6.6) [1777]
Allosteric modulators ML290 (Agonist) (pEC50
7) [2146, 2149]
– – –
Labelled ligands [33P]relaxin (human)
(Agonist) [714, 1885],
europium-labelled relaxin
(Agonist) [1778],
[125I]relaxin (human)
(Agonist)
[125I]INSL3 (human) (Agonist) [1395],
[33P]relaxin (human) (Agonist) [714, 1885]
[125I]relaxin-3 (human) (Agonist)
[1186],
[125I]relaxin-3-B/INSL5 A chimera
(Agonist) [1184],
europium-labelled
relaxin-3-B/INSL5 A chimera
(Agonist) [749]
[125I]relaxin-3 (human) (Agonist) [1185],
[125I]relaxin-3-B/INSL5 A chimera
(Agonist) [1184],
europium-labelled mouse INSL5
(Agonist) [126],
europium-labelled relaxin-3-B/INSL5
A chimera (Agonist) [749],
europium-labelled INSL5 (pKd 8.3) [749]
Comments – europium-labelled INSL3 is a ﬂuorescent ligand for
this receptor (Kd=1nM) [1780].
– –
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Comments: Relaxin is the cognate peptide ligand for RXFP1
and is in extended Phase III clinical trials for the treatment of
acute heart failure [1322]. Relaxin has vasodilatory, anti-ﬁbrotic,
angiogenic, anti-apoptotic and anti-inﬂammatory effects. Small
molecule allosteric agonists such as ML290 have been developed
[1787, 2149]. The antiﬁbrotic actions of relaxin are dependent on
the angiotensin receptor AT2 [344]. RXFP2 and its cognate ligand
INSL3 have a more specialized role with mutations reported in
patients with cryptorchidism [538]. cAMP elevation is the major
signalling pathway for RXFP1 and RXFP2 [834, 835], but RXFP1
also activates MAP kinases, nitric oxide signalling, tyrosine kinase
phosphorylation and relaxin can interact with glucocorticoid re-
ceptors [716]. RXFP1 signalling involves lipid rafts, residues in the
C-terminus of the receptor and activation of phosphatidylinositol-
3-kinase [717] and pre-assembled protein complexes [715].
Receptor expression proﬁles suggest that RXFP3 is a brain neu-
ropeptide receptor and RXFP4 a gut hormone receptor with
the relaxin-3/RXFP3 system modulating feeding [596, 597, 749,
1777, 1830], anxiety [1694, 2204], and reward and motivated
goal-directed behaviours [821, 1694, 2055]. Relaxin-3 (RLN3,
Q8WXF3) is an agonist at RXFP3 and RXFP4 whereas INSL5
(INSL5, Q9Y5Q6) is an agonist at RXFP4 and a weak antagonist
at RXFP3. Unlike RXFP1 and RXFP2, both RXFP3 and RXFP4
are encoded by a single exon. INSL5 is secreted from enteroen-
docrine L cells and the INSL5/RXFP4 system controls food intake
and glucose homeostasis [685]. RXFP3 and RXFP4 couple to Gi/o
and inhibit adenylyl cyclase [1186, 2014], and also cause Erk1/2
phosphorylation [2014]. RXFP4 also causes phosphorylation of
p38MAPK, Akt and S6RP [51]. There is evidence that at RXFP3,
relaxin (RLN2, P04090) is a biased ligand compared to the cognate
ligand relaxin-3.
Further reading on Relaxin family peptide receptors
Bathgate RA et al. (2013) Relaxin family peptides and their receptors. Physiol. Rev. 93: 405-80
[PMID:23303914]
Du XJ et al. (2010) Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev
Cardiol 7: 48-58 [PMID:19935741]
Halls ML et al. (2015) International Union of Basic and Clinical Pharmacology. XCV. Recent ad-
vances in the understanding of the pharmacology and biological roles of relaxin family pep-
tide receptors 1-4, the receptors for relaxin family peptides. Pharmacol. Rev. 67: 389-440
[PMID:25761609]
Ivell R et al. (2011) Relaxin family peptides in the male reproductive system–a critical appraisal.
Mol. Hum. Reprod. 17: 71-84 [PMID:20952422]
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Somatostatin receptors
G protein-coupled receptors → Somatostatin receptors
Overview: Somatostatin (somatotropin release inhibiting factor) is an abundant neuropeptide, which acts on ﬁve subtypes of somatostatin receptor (SST1-SST5; nomenclature as agreed by the
NC-IUPHAR Subcommittee on Somatostatin Receptors [829]). Activation of these receptors produces a wide range of physiological effects throughout the body including the inhibition of
secretion of many hormones. Endogenous ligands for these receptors are somatostatin-14 (SRIF-14 (SST, P61278)) and somatostatin-28 (SRIF-28 (SST, P61278)). Cortistatin-14 {Mouse, Rat} has also been
suggested to be an endogenous ligand for somatostatin receptors [427].
Nomenclature SST1 receptor SST2 receptor SST3 receptor SST4 receptor SST5 receptor
HGNC, UniProt SSTR1, P30872 SSTR2, P30874 SSTR3, P32745 SSTR4, P31391 SSTR5, P35346
Agonists pasireotide [1740] pasireotide [1740] pasireotide [1740],
vapreotide [238, 1540,
1807]
NNC269100 [1197] pasireotide [1740]
Selective agonists L-797,591 [1669],
Des-Ala1,2,5-[D-Trp8,IAmp9]SRIF [512]
L-054,522 [2172], BIM 23027 [283],
octreotide [238, 1540, 1805, 1806, 1807,
2172]
L-796,778 [1669] L-803,087 [1669] BIM 23052 [1325, 1805, 1806,
1807], L-817,818 [1669]
Selective antagonists SRA880 (pKd 8–8.1) [831] [D-Tyr
8]CYN 154806 (pKd 8.1–8.9)
[1478]
NVP ACQ090 (pKi 7.9)
[832]
– –
Labelled ligands – [125I]Tyr3 SMS 201-995 (Agonist) [1805,
1806], [125I]BIM23027 (Agonist) [811] –
Rat
– – [125I]Tyr3 SMS 201-995 (Agonist)
[1805, 1806]
Comments: [125I]Tyr11-SRIF-14, [125I]LTT-SRIF-28, [125I]CGP 23996 and [125I]Tyr10-CST14may be used to label somatostatin receptors nonselectively. A number of nonpeptide subtype-selective agonists
have been synthesised [1669]. Octreotide and lanreotide are being used in the treatment of SST2-expressing neuroendocrine tumors and pasireotide for SST5-expressing neuroendocrine tumors. A novel
peptide somatostatin analogue, veldoreotide (somatoprim), has afﬁnity for SST2, SST4 and SST5 receptors and is a potent inhibitor of GH secretion [1586, 1793].
Further reading on Somatostatin receptors
Colao A et al. (2011) Resistance to somatostatin analogs in acromegaly. Endocr. Rev. 32: 247-71
[PMID:21123741]
Hoyer D et al. (2000) Somatostatin receptors. In The IUPHAR Compendium of Receptor Characterization
and Classiﬁcation, 2nd edn. Edited by Watson SP, Girdlestone D: IUPHAR Media: 354-364
Schulz S et al. (2014) Fine-tuning somatostatin receptor signalling by agonist-selective phosphoryla-
tion and dephosphorylation: IUPHAR Review 5. Br. J. Pharmacol. 171: 1591-9 [PMID:24328848]
Weckbecker G et al. (2003) Opportunities in somatostatin research: biological, chemical and thera-
peutic aspects. Nat Rev Drug Discov 2: 999-1017 [PMID:14654798]
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Succinate receptor
G protein-coupled receptors → Succinate receptor
Overview: Nomenclature as recommended by NC-IUPHAR [414]. The Succinate receptor has been identiﬁed as being activated by physiological levels of the Krebs’ cycle intermediate succinate
and other dicarboxylic acids such as maleate in 2004. Since its pairing with its endogenous ligand, the receptor has been the focus of intensive research and its role has been evidenced in various
(patho)physiological processes such as regulation of renin production, retinal angiogenesis or immune response.
Nomenclature succinate receptor
HGNC, UniProt SUCNR1, Q9BXA5
Endogenous agonists succinic acid [762, 1854]
Comments: In humans, there is the possibility of two open-reading frames (ORFs) for SUCNR1, allowing the generation of 330 or 334 amino acid proteins Wittenberger et al.[2127] noted that the 330-AA
protein was more likely to be expressed given the Kozak sequence surrounding the second ATG. Some databases report SUCNR1 as being 334-AA long.
Further reading on Succinate receptor
Ariza AC et al. (2012) The succinate receptor as a novel therapeutic target for oxidative and
metabolic stress-related conditions. Front Endocrinol (Lausanne) 3: 22. [PMID:22649411]
de Castro Fonseca M et al. (2016) GPR91: expanding the frontiers of Krebs cycle intermediates. Cell
Commun. Signal 14: 3 [PMID:26759054]
Gilissen J et al. (2016) Insight into SUCNR1 (GPR91) structure and function. Pharmacol. Ther. 159:
56-65 [PMID:26808164]
Peti-Peterdi J. (2010) High glucose and renin release: the role of succinate and GPR91. Kidney Int.
78 (12): 1214-7. [PMID:20861827]
Tachykinin receptors
G protein-coupled receptors → Tachykinin receptors
Overview: Tachykinin receptors (provisional nomencla-
ture as recommended by NC-IUPHAR [557]) are activated
by the endogenous peptides substance P (TAC1, P20366) (SP),
neurokinin A (TAC1, P20366) (NKA; previously known as sub-
stance K, neurokinin α, neuromedin L), neurokinin B (TAC3,
Q9UHF0) (NKB; previously known as neurokinin β, neuromedin
K), neuropeptide K (TAC1, P20366) and neuropeptide γ (TAC1,
P20366) (N-terminally extended forms of neurokinin A). The neu-
rokinins (A and B) are mammalian members of the tachykinin
family, which includes peptides of mammalian and nonmam-
malian origin containing the consensus sequence: Phe-x-Gly-Leu-
Met. Marked species differences in in vitro pharmacology exist for
all three receptors, in the context of nonpeptide ligands. Antago-
nists such as aprepitant and fosaprepitant were approved by FDA
and EMA, in combination with other antiemetic agents, for the
prevention of nausea and vomiting associated with emetogenic
cancer chemotherapy.
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Nomenclature NK1 receptor NK2 receptor NK3 receptor
HGNC, UniProt TACR1, P25103 TACR2, P21452 TACR3, P29371
Potency order of endogenous
ligands
substance P (TAC1, P20366) > neurokinin A (TAC1,
P20366) > neurokinin B (TAC3, Q9UHF0)
neurokinin A (TAC1, P20366) > neurokinin B (TAC3,
Q9UHF0)  substance P (TAC1, P20366)
neurokinin B (TAC3, Q9UHF0) > neurokinin A
(TAC1, P20366) > substance P (TAC1, P20366)
Agonists substance P-OMe [1960] – –
Selective agonists [Sar9,Met(O2)11]SP [1960], septide [130, 746],
[Pro9]SP [1975] – Rat
[Lys5,Me-Leu9,Nle10]NKA-(4-10) [1292] – Rat, GR64349
[432] – Rat, [βAla8]neurokinin A-(4-10) [505]
[Phe(Me)7]neurokinin B [1717, 1718], senktide
[1717, 1718, 1960]
Selective antagonists aprepitant (pKi 10.1) [709, 710], CP 99994 (pKi
9.3–9.7) [53, 1718], RP67580 (pIC50 7.7) [555]
GR94800 (pKi 9.8) [206], saredutant (pKi 9.4–9.7) [53,
505, 1718], GR 159897 (pKd 7.8–9.5) [137, 505, 1837],
MEN10627 (pKi 9.2) [638], nepadutant (pKi 8.5–8.7) [284,
358]
osanetant (pKi 8.4–9.7) [53, 116, 357, 504, 941,
1518, 1717, 1718, 1960], talnetant (pKi 7.4–9)
[133, 639, 1717, 1718], PD157672 (pIC50
7.8–7.9) [168, 1960]
Labelled ligands [125I]L703,606 (Antagonist) (pKd 9.5) [566],
[125I]BH-[Sar9,Met(O2)11]SP (Agonist) [1979] –
Rat, [3H]SP (human, mouse, rat) (Agonist) [84],
[125I]SP (human, mouse, rat) (Agonist),
[18F]SPA-RQ (Antagonist) [332]
[3H]saredutant (Antagonist) (pKd 9.7) [683] – Rat,
[125I]NKA (human, mouse, rat) (Agonist) [2077],
[3H]GR100679 (Antagonist) (pKd 9.2) [705]
[3H]osanetant (Antagonist) (pKd 9.9), [
3H]senktide
(Agonist) [693] – Guinea pig, [125I][MePhe7]NKB
(Agonist)
Comments: The NK1 receptor has also been described to couple to G proteins other than Gq/11 [1680]. The hexapeptide agonist septide appears to bind to an overlapping but non-identical site to
substance P (TAC1, P20366) on the NK1 receptor. There are suggestions for additional subtypes of tachykinin receptor; an orphan receptor (SwissProt P30098) with structural similarities to the NK3
receptor was found to respond to NKB when expressed in Xenopus oocytes or Chinese hamster ovary cells [459, 1049].
Further reading on Tachykinin receptors
Douglas SD et al. (2011) Neurokinin-1 receptor: functional signiﬁcance in the immune system
in reference to selected infections and inﬂammation. Ann. N. Y. Acad. Sci. 1217: 83-95
[PMID:21091716]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Jones S et al. (2008) The neurokinin 1 receptor: a potential new target for anti-platelet therapy?
Curr Opin Pharmacol 8: 114-9 [PMID:18296119]
Rance NE et al. (2010) Neurokinin B and the hypothalamic regulation of reproduction. Brain Res.
1364: 116-28 [PMID:20800582]
Rojas C et al. (2012) Pharmacological mechanisms of 5-HT_3 and tachykinin NK_1 receptor an-
tagonism to prevent chemotherapy-induced nausea and vomiting. Eur. J. Pharmacol. 684: 1-7
[PMID:22425650]
Steinhoff MS et al. (2014) Tachykinins and their receptors: contributions to physiological control
and the mechanisms of disease. Physiol. Rev. 94: 265-301 [PMID:24382888]
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Thyrotropin-releasing hormone receptors
G protein-coupled receptors → Thyrotropin-releasing hormone receptors
Overview: Thyrotropin-releasing hormone (TRH) receptors (provisional nomenclature as recommended by NC-IUPHAR [557]) are activated by the endogenous tripeptide TRH (TRH, P20396)
(pGlu-His-ProNH2). TRH (TRH, P20396) and TRH analogues fail to distinguish TRH1 and TRH2 receptors [1896]. [
3H]TRH (human, mouse, rat) is able to label both TRH1 and TRH2 receptors with Kd
values of 13 and 9 nM respectively. Synthesis and biology of ring-modiﬁed L-Histidine containing TRH analogues has been reported [1316].
Nomenclature TRH1 receptor TRH2 receptor
HGNC, UniProt TRHR, P34981 –
Antagonists diazepam (pKi 5.2) [471] – Rat –
Selective antagonists midazolam (pKi 5.5) [471] – Rat, chlordiazepoxide (pKi 4.8) [471] – Rat, chlordiazepoxide (pKi 4.7) [1878] – Mouse –
Comments – A class A G protein-coupled receptor: not present
in man
Further reading on Thyrotropin-releasing hormone receptors
Bílek R et al. (2011) TRH-like peptides. Physiol Res 60: 207-15 [PMID:21114375]
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Nillni EA. (2010) Regulation of the hypothalamic thyrotropin releasing hormone (TRH) neuron by
neuronal and peripheral inputs. Front Neuroendocrinol 31: 134-56 [PMID:20074584]
Trace amine receptor
G protein-coupled receptors → Trace amine receptor
Overview: Trace amine-associated receptors were discovered
from a search for novel 5-HT receptors [189], where 15 mam-
malian orthologues were identiﬁed and divided into two fam-
ilies. The TA1 receptor (nomenclature as agreed by the
NC-IUPHAR Subcommittee for the Trace amine receptor
[1244]) has afﬁnity for the endogenous trace amines tyramine,
β-phenylethylamine and octopamine in addition to the classi-
cal amine dopamine [189]. Emerging evidence suggests that TA1
is a modulator of monoaminergic activity in the brain [2151]
with TA1 and dopamine D2 receptors shown to form constitu-
tive heterodimers when co-expressed [519]. In addition to trace
amines, receptors can be activated by amphetamine-like psychos-
timulants, and endogenous thyronamines.
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Nomenclature TA1 receptor
HGNC, UniProt TAAR1, Q96RJ0
Potency order of endogenous ligands tyramine > β-phenylethylamine > octopamine = dopamine [189]
Agonists RO5166017 [1648]
Antagonists EPPTB (Inverse agonist) (pIC50 5.1) [205]
Labelled ligands [3H]tyramine (Agonist) [189]
Comments: In addition to TA1, in man there are up to 5 func-
tional TAAR genes (TAAR2,5,6,8,9). See [189] for detailed discus-
sion. The product of the gene TAAR2 (also known as GPR58)
appears to respond to β-phenylethylamine> tyramine and to cou-
ple through Gs [189]. TAAR3, in some individuals, and TAAR4
are pseudogenes in man, although functional in rodents. The sig-
nalling characteristics and pharmacology of TAAR5 (PNR, Putative
Neurotransmitter Receptor: TAAR5, O14804), TAAR6 (Trace amine
receptor 4, TaR-4: TAAR6, 96RI8), TAAR8 (Trace amine receptor
5, GPR102: TAAR8, Q969N4 ) and TAAR9 (trace amine associated
receptor 9: TAAR9, 96RI9) are lacking. The thyronamines, en-
dogenous derivatives of thyroid hormone, have afﬁnity for rodent
cloned trace amine receptors, including TA1 [1728]. An antagonist
EPPTB has recently been described with a pKi of 9.1 at the mouse
TA1 but >5.3 for human TA1 [1863].
Further reading on Trace amine receptor
Maguire JJ et al. (2009) International Union of Pharmacology. LXXII. Recommendations for trace
amine receptor nomenclature. Pharmacol. Rev. 61: 1-8 [PMID:19325074]
Pei Y et al. (2016) Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neuro-
chemistry, and Clinical Implications. Front Neurosci 10: 148 [PMID:27092049]
Urotensin receptor
G protein-coupled receptors → Urotensin receptor
Overview: The urotensin-II (U-II) receptor (UT, nomencla-
ture as agreed by the NC-IUPHAR Subcommittee on the
Urotensin receptor [466, 557, 2032]) is activated by the en-
dogenous dodecapeptide urotensin-II (UTS2, O95399), originally
isolated from the urophysis, the endocrine organ of the caudal
neurosecretory system of teleost ﬁsh [138]. Several structural
forms of U-II exist in ﬁsh and amphibians. The goby orthologue
was used to identify U-II as the cognate ligand for the predicted
receptor encoded by the rat gene gpr14 [389, 1195, 1379, 1476].
Human urotensin-II (UTS2, O95399), an 11-amino-acid peptide
[389], retains the cyclohexapeptide sequence of goby U-II that
is thought to be important in ligand binding [224, 1003]. This
sequence is also conserved in the deduced amino-acid sequence
of rat urotensin-II {Rat} (14 amino-acids) and mouse urotensin-II
{Mouse} (14 amino-acids), although the N-terminal is more di-
vergent from the human sequence [388]. A second endogenous
ligand for the UT has been discovered in rat [1890]. This is the
urotensin II-related peptide (UTS2B, Q765I0), an octapeptide that
is derived from a different gene, but shares the C-terminal se-
quence (CFWKYCV) common to U-II from other species. Identical
sequences to rat urotensin II-related peptide (UTS2B, Q765I0) are
predicted for themature mouse and human peptides [472]. UT ex-
hibits relatively high sequence identity with somatostatin, opioid
and galanin receptors [2032].
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Nomenclature UT receptor
HGNC, UniProt UTS2R, Q9UKP6
Endogenous agonists urotensin II-related peptide (UTS2B, Q765I0) [472, 1243], urotensin-II (UTS2, O95399) [467, 503, 681]
Selective agonists [Pen5]U-(4-11) (human) [681], U-II-(4-11) (human) [681], [3-iodo-Tyr6]U-II-(4-11) (human) [1084], Urolinin [95], FL104 [1139, 1141], AC-7954 [398, 1140]
Selective antagonists JNJ-39319202 (pKi 8.4) [1106], urantide (pKi 8.3) [1536], SB-706375 (pKi 8) [467], [Orn
5]URP (pKi 7.2) [445] – Rat, palosuran (pIC50 7.1) [366], SB-436811 (pKi 6.7) [912] – Rat,
SB-611812 (pKi 6.6) [1622], S6716 (Inverse agonist) (pIC50 6.4) [554], [Cha
6]U-II-(4-11) (pKi 6.4) [312] – Rat
Labelled ligands [125I]U-II (human) (Agonist) [42, 198, 312, 1243], [125I]N-biotin-[Ahx0, Bpa3]U-II (human) [454]
Comments: In the human vasculature, human urotensin-II (UTS2, O95399) elicits both vasoconstrictor (pD2 9.3-10.1, [1243]) and vasodilator (pIC50 10.3-10.4, [1872]) responses.
Further reading on Urotensin receptor
Foord SM et al. (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list.
Pharmacol Rev 57: 279-288 [PMID:15914470]
Hunt BD et al. (2010) A rat brain atlas of urotensin-II receptor expression and a review of central
urotensin-II effects. Naunyn Schmiedebergs Arch. Pharmacol. 382: 1-31 [PMID:20422157]
Maryanoff BE et al. (2010) Urotensin-II receptor modulators as potential drugs. J. Med. Chem. 53:
2695-708 [PMID:20043680]
Ross B et al. (2010) Role of urotensin II in health and disease. Am. J. Physiol. Regul. Integr. Comp.
Physiol. 298: R1156-72 [PMID:20421634]
Vasopressin and oxytocin receptors
G protein-coupled receptors → Vasopressin and oxytocin receptors
Overview: Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC-IUPHAR [557]) are activated by the endogenous cyclic nonapeptides vasopressin (AVP, P01185)
and oxytocin (OXT, P01178). These peptides are derived from precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin).
Nomenclature V1A receptor V1B receptor
HGNC, UniProt AVPR1A, P37288 AVPR1B, P47901
Potency order of endogenous ligands vasopressin (AVP, P01185) > oxytocin (OXT, P01178) vasopressin (AVP, P01185) > oxytocin (OXT, P01178)
Endogenous agonists vasopressin (AVP, P01185) [24, 326, 383, 439, 1418, 1571, 1702, 1913, 1914, 1945, 1946, 2162] vasopressin (AVP, P01185) [24, 326, 439, 682, 1418,
1702, 1913, 1914, 1946, 2162]
Selective agonists F180 [50, 383] d[Leu4]LVP [1553], d[Cha4]AVP [439, 682]
Antagonists conivaptan (pKi 8.2–8.4) [1913, 1914] nelivaptan (pKi 8.4–9.3) [678, 682, 1773]
Selective antagonists relcovaptan (pKi 8.1–9.3) [24, 383, 682, 1571, 1771, 1913, 1945, 1946, 1986],
d(CH2)5[Tyr(Me)2,Arg8]VP (pKi 9)
–
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(continued)
Nomenclature V1A receptor V1B receptor
Labelled ligands [125I]OH-LVA (Antagonist) (pKd 10.3–10.4) [334, 383, 1571], [
3H]AVP (human, mouse, rat) (Agonist)
[214, 334, 383, 384, 1418, 1571, 1702, 1913, 1914, 1945, 1946, 1986, 2162],
[3H]d(CH2)5[Tyr(Me)2]AVP (Antagonist) (pKd 9)
[3H]AVP (human, mouse, rat) (Agonist) [214, 334, 383,
384, 1418, 1571, 1702, 1913, 1914, 1945, 1946, 1986,
2162]
Nomenclature V2 receptor OT receptor
HGNC, UniProt AVPR2, P30518 OXTR, P30559
Potency order of endogenous ligands vasopressin (AVP, P01185) > oxytocin (OXT, P01178) oxytocin (OXT, P01178) > vasopressin (AVP, P01185)
Endogenous agonists vasopressin (AVP, P01185) [24, 326, 334, 439, 1418, 1702, 1771, 1913, 1914, 1946, 2162] oxytocin (OXT, P01178) [24, 334, 335, 360, 682, 895]
Selective agonists VNA932 [527], OPC-51803 [1418], d[Val4,DArg8]VP [Thr4,Gly7]OT [335, 500, 895]
Antagonists – L-371,257 (pKi 8.8) [682]
Selective antagonists conivaptan (pKi 9.4) [397], tolvaptan (pKi 9.4) [2162], satavaptan (pKi 8.4–9.3) [24, 383, 384,
1770, 1771, 1913, 1986], lixivaptan (Inverse agonist) (pKi 8.9–9.2) [33, 1771],
d(CH2)5[D-Ile2,Ile4]AVP (pKi 6.9–8.4) [1771], mozavaptan (Inverse agonist) (pKi 7.4–8.1) [384,
1771, 1913, 1946, 2162, 2163]
SSR126768A (pKi 8.8–9.1) [1772],
desGlyNH2-d(CH2)5[Tyr(Me)2,Thr4,Orn8]OT (pKi 8.5),
L-372662 (pKi 8.4) [127]
Labelled ligands [3H]AVP (human, mouse, rat) (Agonist) [334, 383, 384, 1418, 1702, 1913, 1914, 1946, 1986,
2162], [3H]dDAVP (Agonist) [334, 384, 1946], [3H]desGly-NH2[D-Ile2,Ile4]VP (pKd 8.6)
[125I]d(CH2)5[Tyr(Me)2,Thr4,Orn8,Tyr-NH29]OVT (Antagonist)
(pKd 10), [
3H]OT (human, mouse, rat) (Agonist) [334, 583,
895, 998], [111In]DOTA-dLVT (pKd 8.3) [333]
Comments: The V2 receptor exhibits marked species differences, such that many ligands (d(CH2)5[D-Ile2,Ile4]AVP and [3H]desGly-NH2[D-Ile2,Ile4]VP) exhibit low afﬁnity at human V2 receptors [29].
Similarly, [3H]d[D-Arg8]VP is V2 selective in the rat, not in the human [1702]. The gene encoding the V2 receptor is polymorphic in man, underlying nephrogenic diabetes insipidus [152]. D[Cha
4]AVP
is selective only for the human and bovine V1B receptors [439], while d[Leu
4]LVP has high afﬁnity for the rat V1B receptor [1553].
Further reading on Vasopressin and oxytocin receptors
Bartz JA et al. (2011) Social effects of oxytocin in humans: context and person matter. Trends Cogn.
Sci. (Regul. Ed.) 15: 301-9 [PMID:21696997]
Knepper MA. (2012) Systems biology in physiology: the vasopressin signaling network in kidney.
Am. J. Physiol., Cell Physiol. 303: C1115-24 [PMID:22932685]
Koshimizu TA et al. (2012) Vasopressin V1a and V1b receptors: from molecules to physiological
systems. Physiol. Rev. 92: 1813-64 [PMID:23073632]
Manning M et al. (2012) Oxytocin and vasopressin agonists and antagonists as research tools and
potential therapeutics. J. Neuroendocrinol. 24: 609-28 [PMID:22375852]
Meyer-Lindenberg A et al. (2011) Oxytocin and vasopressin in the human brain: social neuropep-
tides for translational medicine. Nat. Rev. Neurosci. 12: 524-38 [PMID:21852800]
Neumann ID et al. (2012) Balance of brain oxytocin and vasopressin: implications for anxiety,
depression, and social behaviors. Trends Neurosci. 35: 649-59 [PMID:22974560]
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VIP and PACAP receptors
G protein-coupled receptors → VIP and PACAP receptors
Overview: Vasoactive intestinal peptide (VIP) and pituitary
adenylate cyclase-activating peptide (PACAP) receptors (nomen-
clature as agreed by the NC-IUPHAR Subcommittee on
Vasoactive Intestinal Peptide Receptors [739, 740]) are ac-
tivated by the endogenous peptides VIP (VIP, P01282), PACAP-38
(ADCYAP1, P18509), PACAP-27 (ADCYAP1, P18509), peptide his-
tidine isoleucineamide (PHI {Mouse, Rat}), peptide histidine me-
thionineamide (PHM (VIP, P01282)) and peptide histidine va-
line (PHV (VIP, P01282)). VPAC1 and VPAC2 receptors dis-
play comparable afﬁnity for the PACAP peptides, PACAP-27
(ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509), and
VIP (VIP, P01282), whereas PACAP-27 (ADCYAP1, P18509) and
PACAP-38 (ADCYAP1, P18509) are >100 fold more potent than
VIP (VIP, P01282) as agonists of most isoforms of the PAC1 re-
ceptor. However, one splice variant of the human PAC1 receptor
has been reported to respond to PACAP-38 (ADCYAP1, P18509),
PACAP-27 (ADCYAP1, P18509) and VIP (VIP, P01282) with com-
parable afﬁnity [411]. PG 99-465 [1374] has been used as a selec-
tive VPAC2 receptor antagonist in a number of physiological stud-
ies, but has been reported to have signiﬁcant activity at VPAC1
and PAC1 receptors [446]. The selective PAC1 receptor agonist
maxadilan, was extracted from the salivary glands of sand ﬂies
(Lutzomyia longipalpis) and has no sequence homology to VIP (VIP,
P01282) or the PACAP peptides [1383]. Two deletion variants of
maxadilan, M65 [1994] and Max.d.4 [1384] have been reported to
be PAC1 receptor antagonists, but these peptides have not been
extensively characterised.
Nomenclature PAC1 receptor VPAC1 receptor VPAC2 receptor
HGNC, UniProt ADCYAP1R1, P41586 VIPR1, P32241 VIPR2, P41587
Potency order of endogenous ligands PACAP-27 (ADCYAP1, P18509),
PACAP-38 (ADCYAP1, P18509)  VIP
(VIP, P01282)
VIP (VIP, P01282), PACAP-27 (ADCYAP1, P18509), PACAP-38
(ADCYAP1, P18509)  GHRH (GHRH, P01286), PHI {Pig},
secretin (SCT, P09683)
VIP (VIP, P01282), PACAP-38 (ADCYAP1, P18509), PACAP-27
(ADCYAP1, P18509) > PHI {Pig}  GHRH (GHRH, P01286),
secretin (SCT, P09683)
Selective agonists maxadilan [446], maxadilan [446] [Lys15,Arg16,Leu27]VIP-(1-7)/GRF-(8-27)-NH2 [1369],
[Ala11,22,28]VIP [1458]
Ro 25-1553 [669, 930, 1369], Ro 25-1392 [2144]
Selective antagonists – PG 97-269 (pIC50 8.7) [668, 930] –
Labelled ligands [125I]PACAP-27 (Agonist) [1581] [125I]VIP (human, mouse, rat) (Agonist) [1458],
[125I]PACAP-27 (Agonist)
[125I]VIP (human, mouse, rat) (Agonist) [1458],
[125I]PACAP-27 (Agonist)
Comments: Subtypes of PAC1 receptors have been proposed based on tissue differences in the potencies of PACAP-27 (ADCYAP1, P18509) and PACAP-38 (ADCYAP1, P18509); these might result from
differences in G protein coupling and second messenger mechanisms [2018], or from alternative splicing of PAC1 receptor mRNA [1859].
Further reading on VIP and PACAP receptors
Harmar AJ et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for
vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol
Rev 50: 265-270 [PMID:9647867]
Harmar AJ et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide
and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br. J. Pharmacol. 166:
4-17 [PMID:22289055]
Reglodi D et al. (2012) Effects of pituitary adenylate cyclase activating polypeptide in the urinary
system, with special emphasis on its protective effects in the kidney. Neuropeptides 46: 61-70
[PMID:21621841]
Smith CB et al. (2012) Is PACAP the major neurotransmitter for stress transduction at the
adrenomedullary synapse? J. Mol. Neurosci. 48: 403-12 [PMID:22610912]
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